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ABSTRACT 
 
 
 Over the past two decades, there has been an increase in the research and 
development and therapeutic application of monoclonal antibodies (mAbs).  An 
application of pharmacokinetic (PK) and pharmacodynamic concepts that has likely 
contributed to the success of the pre-clinical and clinical drug development of therapeutic 
mAbs is population PK, which attempts to quantify the typical disposition characteristics 
and sources of PK variability (such as between-subject, within-subject, and inter-occasion 
variability) within study populations.  Population PK also attempts to identify and 
quantify the impact of covariates on systemic drug exposure and assess their potential 
implications for clinical dosing.  The general theme of my dissertation research was 
population PK modeling of therapeutic mAbs, which focused on the population PK 
modeling of cetuximab, and the evaluation of different estimation methods for population 
PK modeling of therapeutic mAbs with nonlinear PK characteristics. 
 
 Cetuximab is a therapeutic mAb directed against the epidermal growth factor 
receptor and is indicated in the treatment of squamous cell carcinoma of the head and 
neck (SCCHN).  I performed a population PK analysis of cetuximab using nonlinear 
mixed effects modeling and the software NONMEM.  A total of 912 cetuximab 
concentrations were available from 143 patients with recurrent and/or metastatic SCCHN 
enrolled in two phase I/II studies.  The PK of cetuximab was best described by a two-
compartment model with Michaelis-Menten type saturable elimination.  Mean population 
estimates (between-subject variability, %CV) of the PK parameters were: Vmax 4.38 
mg/hr (15.4%), Km 74 μg/ml, V1 2.83 L (18.6%), V2 2.43 L (56.4%), and Q 0.103 L/hr 
(97.2%).  Ideal body weight and white blood cell count were identified as predictors of 
Vmax, and total body weight as a predictor of V1.  My findings suggested that clinical dose 
adjustments beyond the approved body surface area-based dosing of cetuximab may be 
warranted in patients with extreme deviations of their actual body weight from ideal body 
weight.  Agreement between simulated and measured concentrations for up to 43 weeks 
of therapy indicated that the final population PK model was able to adequately describe 
the nonlinear PK of cetuximab in patients with SCCHN at the currently approved dosage 
regimen, and that the cetuximab PK parameters remained constant during prolonged 
therapy. 
 
 Nonlinear eliminaton is a common characteristic of the PK of therapeutic mAbs.  
Accordingly, PK models with nonlinear elimination are commonly used in population PK 
analyses of mAbs, but difficulties detecting and characterizing this nonlinear PK have 
been reported in a number of studies.  The challenge with detecting and characterizing 
the nonlinear elimination of therapeutic mAbs may not only be dependent on the clinical 
study design, but also on the estimation method used for the population PK analysis.  
However, little work has been done so far evaluating population estimation methods 
using PK models that are representative of the typical disposition characteristics of 
therapeutic mAbs.  In order to address this question, I conducted a simulation study to 
compare the parameter estimation performance of the first-order (FO), first-order 
conditional estimation with interaction (FOCE-I), and Laplacian estimation with 
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interaction (LAP-I) methods in NONMEM and a Bayesian Markov Chain Monte Carlo 
(MCMC) method in WinBUGS when applied to population PK modeling of therapeutic 
mAbs with nonlinear PK.  The Bayesian MCMC method was evaluated with both vague 
and informative priors.  Published findings of population PK analyses of therapeutic 
mAbs were used to define the informative priors.  Simulations were performed with 
uncertainty included simultaneously on all parameters in the population PK model in 
order to evaluate the sensitivity of estimation performance to uncertainty in the 
simulation model parameters.  The impact of study design on estimation performance 
was explored by evaluating the methods under a dose-ranging design (‘informative 
design’) and four different single dose level designs at different dose levels 
(‘uninformative designs’). 
 
 Under all study designs, the FO method generally produced larger bias and lower 
precision for all model parameters compared to the other estimation methods.  
Comparison between the methods in NONMEM and WinBUGS was limited to the 
informative and uninformative 600 mg dose level study designs due to prolonged run 
times with WinBUGS.  Under the informative study design, bias and precision for all 
model parameters was less than ±25% and 52%, respectively, for FOCE-I, LAP-I, and 
Bayesian MCMC with both sets of priors.  Under the uninformative 600 mg dose level 
design, the estimation performance of FOCE-I and LAP-I decreased as bias and precision 
for many of the model parameters, in particular those related to nonlinear elimination, 
significantly increased to ±40-173% and 53-173%, respectively, while Bayesian MCMC 
with informative priors provided a clear performance advantage producing results that 
were comparable to those under the informative design.  Under both informative and 
uninformative 600 mg dose level designs, the estimation performance of FOCE-I, LAP-I, 
and Bayesian MCMC showed sensitivity to uncertainty in the simulation parameter 
values for one or more parameters.  This was especially evident when informative 
Bayesian priors were used under the uninformative 600 mg dose level design, which was 
expected given the relative uninformativeness of the data under this particular design. 
 
The findings from this work should be of value to pharmacometricians involved 
in population PK modeling of therapeutic mAbs.  When sufficient concentration-time 
data are available to characterize the nonlinear elimination of the mAb, then FOCE-I, 
LAP-I, or Bayesian MCMC would likely be suitable for the populatin PK analysis.  In 
situations where insufficient data are available to characterize the nonlinear elimination 
of the mAb, and relevant prior information is readily available, the use of a Bayesian 
MCMC method with informative priors should be considered. 
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CHAPTER 1.  POPULATION PHARMACOKINETICS OF THERAPEUTIC 
MONOCLONAL ANTIBODIES* 
 
 
Introduction 
 
Over the past two decades there has been an increase in the research and 
development and therapeutic application of monoclonal antibodies (mAbs).  Currently, 
there are over 20 mAb products (i.e. antibodies, antibody fragments, or antibody-
conjugates) approved by the U.S. Food and Drug Administration (FDA) for therapeutic 
use in areas such as oncology, immunology, ophthalmology, cardiovascular disease, and 
infectious disease.  As most approved therapeutic mAb products are intact and 
unconjugated, this review will focus on this class. 
 
It is estimated that half of all current projects in new drug development are 
biologics, with mAbs being the predominant class of biologics under clinical study (1).  
In 2008, it was reported that there were over 200 mAbs undergoing clinical study (2).  
One likely reason for the continued success of the clinical development of mAbs is the 
application and integration of pharmacokinetic (PK) and pharmacodynamic (PD) 
concepts in all stages of pre-clinical and clinical drug development (3, 4).  Such 
implementation of PK/PD modeling and simulation in drug product development 
provides a rational, scientifically based framework for efficient decision making 
regarding the selection of potential drug candidates, for maximum information gain from 
the performed experiments and studies, and for conducting fewer, more focused clinical 
trials with improved efficiency and cost effectiveness (5).  One application of PK/PD 
concepts in drug development is population PK, which attempts to quantify the typical 
disposition characteristics and sources of PK variability (such as between-subject, within-
subject, and inter-occasion) within study populations.  Population PK also attempts to 
identify and quantify the impact of covariates on systemic drug exposure, and assess their 
potential implications for clinical dosing.  Findings from population PK analyses are 
included in the drug labeling of over half of the approved therapeutic mAb products, and 
several mAb population PK studies have also been published in the scientific literature.  
The aim of this report is to review the population PK of therapeutic intact mAbs, while 
highlighting important similarities/dissimilarities across different mAbs with respect to 
their drug disposition characteristics.  The report will be supplemented with discussions 
on the general PK behavior of mAbs and their structural properties, which have partially 
been reviewed elsewhere in different context (6-9). 
 
 
Antibody Structure 
 
The basic structure of human antibodies or immunoglobulins (Ig) consists of two  
 
*This chapter adapted with permission.  Dirks NL, Meibohm B. Population 
pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 
2010;49(10) In press. 
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identical heavy chains and two identical light chains joined together by a number of 
disulfide bridges.  There are five classes (isotypes) of antibodies termed IgG, IgA, IgM, 
IgE, and IgD, which share the same basic structure, but differ with regards to their heavy 
chains γ, α, μ, ε, δ, respectively (10).  In addition to the different heavy chain structures, 
there are also two types of light chains (κ and λ).   IgG is the most predominant of the 
five isotypes with a serum concentration of approximately 12 mg/ml, representing about 
70-80% of total serum Ig (10).  The IgG class can be further subdivided into four 
subclasses (or subisotypes), IgG1, IgG2, IgG3, and IgG4, based on structural differences 
in the γ heavy chain.  This review focuses on IgG, as all of the population PK analyses 
included in the discussion were of therapeutic mAbs of the IgG type.  All of the approved 
therapeutic intact mAbs are also of the IgG isotype. 
 
The structure of IgG is depicted in Figure 1-1A.  The heavy and light chains of 
IgG are made up of variable and constant domains based on sequence similarities 
between different IgG molecules.  The IgG molecule is comprised of three basic units: 
two identical antigen binding fragments (Fabs) and the crystallizable fragment (Fc).  The 
variable heavy, constant heavy 1, variable light, and constant light domains make up the 
Fab, and the Fc is made up of the constant heavy 2 and constant heavy 3 domains.  The 
whole IgG molecule has a molecular weight of 150 kDa, and intact mAbs of the same 
isotype have an approximately similar molecular weight.  Within the variable regions of 
both the heavy chain and light chain, there are three sections called complementarity 
determining regions (CDRs).  These hypervariable regions are associated with the mAb’s 
affinity and specificity for a given antigen.  The structural diversity of the Fab allows 
different IgG molecules to recognize a wide variety of antigens, while the ability to 
trigger immune effector functions through interaction with Fcγ receptors and 
complement, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC), are conferred upon by consistency in the Fc structure.  
The Fc region of the mAb also interacts with another important Fc receptor for IgG, the 
neonatal Fc receptor (FcRn), which acts in part as a salvage receptor protecting IgG from 
intracellular catabolism.  As will become evident later in the review, the Fab and Fc 
regions are not only important to antibody function, but can significantly influence the 
PK behavior of mAbs. 
 
Muromonab-CD3 (Orthoclone OKT3), a murine IgG2a antibody against CD3 
indicated for the treatment of acute organ rejection, became the first mAb approved for 
therapeutic use in 1986.  However, the use of mAbs of murine origin in the clinic has 
been limited due to several factors including their short elimination half-lives and high 
immunogenic potential.  To overcome these limitations with murine mAbs, advances in 
biotechnology such as recombinant engineering have facilitated the development of 
chimeric, humanized, and fully human antibodies, which contain a larger content of 
human protein sequence (11).  These three structural classes of mAbs are depicted in 
Figure 1-1B.  In chimeric mAbs, the antibody is constructed by transferring murine 
variable regions to constant regions of human origin.  This reduces the murine content in 
chimeric mAbs to about one-third.  In humanized or CDR-grafted mAbs, the CDRs (and 
possibly parts of the framework regions surrounding the CDRs) are of murine origin, 
which makes up about 5-10% of the mAb.  Although the immunogenic potential of a 
 3
 
 
 
Figure 1-1. Linear representation of the structure of immunoglobulin G (A) and the 
different classes of therapeutic monoclonal antibodies (B).  CDR = complementarity 
determining region; CH1D, CH2D, and CH3D = constant heavy chain domains; CLD = 
constant light chain domain; Fab = antigen binding fragment; Fc = crystallizable 
fragment; VHD = variable heavy chain domain; VLD = variable light chain domain. 
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mAb is expected to decrease with decreasing murine content 
(murine>chimeric>humanized>human), all classes of therapeutic mAbs have the 
potential to trigger the formation of human antibodies against the mAb (6).  Such anti-
mAb antibodies can have a significant effect on both the PK and PD of the therapeutic 
mAb (7, 9).  As will be discussed later in the review, the PK effect of the presence of 
antibodies to the therapeutic mAb can be assessed by including this as a covariate in the 
population model.  Currently, most approved therapeutic mAbs are of the humanized 
type.  Fully human mAbs that have been approved by the FDA include adalimumab, 
golimumab, panitumumab, and ustekinumab. 
 
 
Population Pharmacokinetics 
 
While a number of concepts related to population analysis are mentioned in this 
review (e.g., between-subject variability and residual variability), a discussion of the 
basic concepts and principles of population PK modeling is beyond the scope of this 
report.  For readers that are not familiar with population PK modeling, there are a number 
of papers and books in the literature that provide an excellent review of the topic (12-16).  
Results from the population PK analyses of therapeutic mAbs are summarized and split 
into Tables 1-1 through 1-6.  In some cases a population PK/PD analysis was performed, 
and these are noted in Table 1-1.  The only non-therapeutic mAb included in the tables is 
HuCC49∆CH2, which was investigated in patients undergoing radioimmunoguided 
surgery (17).  The structural characteristics and pharmacologic target of the different 
mAbs are listed in Table 1-1, as well as the patient population the study was conducted 
in, and the model used to describe the PK of the mAb.  Population parameter estimates 
related to mAb absorption, distribution, elimination, and identified covariate effects are 
presented in Tables 1-2 through 1-6.  Of note is the fact that all of the population PK 
analyses were of chimeric, humanized, or fully human antibodies, except for the murine 
antibodies inolimomab and mabF19 (Table 1-1).  Differences in the population PK of 
murine mAbs and the other mAb types were observed and will be discussed later in the 
review.  While the patient populations in the studies cover a wide variety of clinical 
indications, all of the studies were conducted in adult patients.  A few population PK 
analyses of mAbs have been conducted in pediatric patients including daclizumab (18) 
and SB 209763 (19), but these studies were not included in this review for comparative 
purposes.  In the majority of the population PK studies, the nonlinear mixed effects 
modeling was performed using NONMEM (Icon Development Solutions, Ellicott City, 
MD) and the first-order conditional estimation method (FOCE) with or without the η-ε 
interaction option (20).  Other software and methods used in a couple of studies (21, 22) 
included a conditional first-order method implemented in Winnonmix (Pharsight 
corporation, Mountain View, NC), and the Monte Carlo parametric expectation 
maximization (MCPEM) method implemented in an augmented version of ADAPT II 
(Biomedical Simulations Resource, University of Southern California, Los Angeles, CA). 
 
 5
Table 1-1. Therapeutic monoclonal antibodies with published population pharmacokinetic analyses. 
 
Antibody Structure/Isotype Target Patient population PK model 
Alemtuzumab (23)† CDR-grafted rat/human IgG1 CD52 B-cell chronic lymphocytic leukaemia 2C NL 
AMG 162 (denosumab) (24)† Human IgG2 RANKL Healthy postmenopausal women 2C NL+L 
ATM-027 (25)† Humanized IgG1 Vβ 5.2/5.3 TCR Multiple sclerosis 2C L 
Basiliximab (26) Chimeric mouse/human IgG1 CD25 Renal transplant  2C L 
Basiliximab (27) Chimeric mouse/human IgG1 CD25 Liver transplant 2C L 
Bevacizumab (28) CDR-grafted mouse/human IgG1 VEGF Various solid tumors and colorectal, 2C L 
      non-small cell lung, and breast cancer  
Cetuximab (29) Chimeric mouse/human IgG1 EGFR Head and neck cancer 2C NL 
Clenoliximab (30)† Chimeric macaque/human IgG4 CD4 Rheumatoid arthritis 2C NL 
CP-751, 871 (31) Human IgG2 IGF-IR Multiple myeloma and solid tumors 2C NL+L* 
Denosumab (32)† Human IgG2 RANKL Healthy postmenopausal women and  2C NL+L 
   breast cancer  
Efalizumab (21)† CDR-grafted mouse/human IgG1 CD11a Psoriasis 2C NL+L 
Efalizumab (33) CDR-grafted mouse/human IgG1 CD11a Psoriasis 1C L 
Golimumab (34) Human IgG1 TNF-α Rheumatoid arthritis 2C L 
hu1124 (efalizumab) (35)† CDR-grafted mouse/human IgG1 CD11a Psoriasis 2C NL+L 
    RMC 
HuCC49∆CH2 (17) CDR-grafted mouse/human TAG-72 Colorectal cancer 2C L 
  IgG1-CH2 domain deletion      
Infliximab (36) Chimeric mouse/human IgG1 TNF-α Ankylosing spondylitis 2C L 
Infliximab (37) Chimeric mouse/human IgG1 TNF-α Ulcerative colitis 2C L 
Inolimomab (38)† Mouse IgG1 CD25 Acute graft-versus-host disease 2C L 
mAbF19 (39) Mouse IgG FAP Colorectal cancer and soft tissue  2C L 
   sarcoma  
Matuzumab (40) CDR-grafted mouse/human IgG1 EGFR Pancreatic and various cancers  2C NL+L 
   (primarily colorectal)  
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Table 1-1 continued. 
 
Antibody Structure/Isotype Target Patient population PK model 
Omalizumab (41)† CDR-grafted mouse/human IgG1 IgE Asthma, allergic rhinitis, and healthy  TMDD 
   atopic subjects  
Panitumumab (42) Human IgG2 EGFR Various solid tumors and colorectal, 2C NL+L 
   non-small cell lung, and renal cancer  
Pertuzumab (43) CDR-grafted mouse/human IgG1 HER2 Breast cancer, ovarian cancer, and  2C L 
   solid malignancies  
Rituximab (44) Chimeric mouse/human IgG1 CD20 Rheumatoid arthritis 2C L 
Sibrotuzumab (45) CDR-grafted mouse/human IgG1 FAP Colorectal and non-small cell lung  2C NL+L 
   cancer  
Trastuzumab (46) CDR-grafted mouse/human IgG1 HER2 Breast cancer and solid tumors 2C L 
Ustekinumab (47) Human IgG1 IL-12 and IL-23 Psoriasis 1C L 
 
1C or 2C = one- or two-compartment model; CDR = complementarity determining region; EGFR = epidermal growth factor 
receptor; FAP = fibroblast activation protein; HER2 = human epidermal growth factor receptor 2; IGF-IR = insulin-like 
growth factor I receptor; L = model with linear elimination from the central compartment; NL = model with nonlinear 
elimination from the central compartment; NL+L = model with parallel linear and nonlinear elimination pathways from the 
central compartment; NL+L* = model with nonlinear and linear elimination pathways from the central and peripheral 
compartments, respectively; RANKL = receptor activator of nuclear factor-κB ligand; RMC = receptor-mediated clearance 
model; TAG-72 = tumor-associated glycoprotein-72; TCR = T-cell receptor; TMDD = target-mediated drug disposition 
model; TNF-α = tumor necrosis factor alpha; VEGF = vascular endothelial growth factor. 
† Population pharmacokinetic/pharmacodynamic analysis. 
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Table 1-2. Population estimates and their between-subject variability [%RSE or confidence interval *,^] of absorption 
related parameters.** 
 
Antibody F †  F BSV (%CV)  Ka† (day-1)  Ka BSV (%CV)  
Efalizumab (21) 0.564 [5.3] 51 [13] 0.242 [9.4] 44 [12] 
Denosumab (24) 0.747a    0.132 [4.9] NE  
Denosumab (32) 0.491b    0.174 [5.1] 53  
Omalizumab (41)     0.48 [5.7] 40  
Efalizumab (33)     0.191 [0.095-0.394^] NE  
Ustekinumab (47)     0.354 [0.277-0.499^] NE  
 
BSV = between-subject variability; F = absolute bioavailability; Ka = absorption rate constant; NE = not estimated; %RSE = 
percent relative standard error. 
* 90% or ^ 95% bootstrap confidence interval. 
** Not available or not applicable estimates are blank. 
† F and Ka were determined following subcutaneous administration. 
a. θF (theta estimate for calculation of bioavailability) (%RSE) was 2.96 (23); θF BSV was not estimated. 
b. θF (%RSE) and θF BSV were 0.964 (7.9) and 68 %CV, respectively. 
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Table 1-3. Population estimates and their between-subject variability [%RSE or confidence interval *,^] of distribution 
related parameters.** 
 
Antibody V1 (L)  V1 BSV (%CV)  V2 (L)  V2 BSV (%CV)  Vss (L) 
Sibrotuzumab (45) 4.13 [3.7] 20 [52] 3.19 [8.8] 20 [52] 7.32‡ 
Matuzumab (40) 3.72 [3.0] 22a [20] 1.84 [9.0] 62a [28] 5.56‡ 
Efalizumabi (35) 5.14b [8.6] 39 [33] 4.18‡       9.32‡ 
Efalizumab (21) 4.50c   [3.5] 52 [9.0] 2.26‡       6.76‡ 
Denosumab (24) 2.38 [7.4] 16   1.59‡       3.97‡ 
Denosumab (32) 2.42 [7.0] 37   1.27 [5.8] NE   3.69‡ 
CP-751, 871 (31) 4.02 [4.0] 22 [50] 6.82 [24] 92 [49] 10.84‡ 
Panitumumab (42) 3.95 [3.83-4.10*] 34k [28-39*] 2.59 [2.30-2.87*] 38 [27-49*] 6.54‡ 
Cetuximab (29) 2.83 [2.69-2.96*] 19 [13-22*] 2.43 [1.95-2.85*] 56 [18-73*] 5.26‡ 
Alemtuzumab (23) 11.3 [8.92-16.4^] 84 [21] 41.5 [21.3-73.2^] 179 [28] 52.8‡ 
Clenoliximab (30) 3.58 [8.5] 37   5.35‡       8.93‡ 
Golimumab (34) 3.07 [2.63-3.51^] 26 [28] 3.68 [2.71-4.75^] 45 [40] 6.75‡ 
Inolimomab (38) 2.76 [26] 68d [20] 2.25 [18] NE   5.01‡ 
mAbF19 (39) 3.13 [11] 37 [49] 1.74‡, j       4.87j 
HuCC49∆CH2 (17) 3.46 [3.09-3.84*] 23e [10-34*] 2.50 [1.52-3.69*] NE   5.96‡ 
Rituximab (44) 2.98 [2.88-3.08^] 12 [9.5-14^] 3.64‡       6.62‡ 
Trastuzumab (46) 2.95 [2.67-3.27^] 29 [21-38^] 4.79‡       7.74‡ 
Pertuzumab (43) 2.74 [2.64-2.84^] 16 [13-19^] 2.16‡       4.9‡ 
Bevacizumab (28) 2.66 [2.57-2.76^] 17 [14-20^] 2.76‡       5.42‡ 
Infliximab (36) 3.06 [2.96-3.16^] 18f [16-19^] 2.94 [2.63-3.24^] NE   6.0‡ 
Infliximab (37) 3.29 [3.02-3.58^] 22 [18-26^] 4.13 [3.65-4.57^] NE  7.42‡ 
Basiliximab (26) 3.72 [1.2] 41 [18] 4.08‡       7.8‡ 
Basiliximab (27) 5.47 [7.4] 31 [32] 1.78‡       7.25‡ 
ATM-027 (25) 2.8 [6.9] NE   3.1 [19] 25 [38] 5.9‡ 
Omalizumab (41) 5.9g [1.8] 13            
Efalizumab (33) 9.13g [3.9-11.7^] 29 [<10-3-44^]          
Ustekinumab (47) 15.7g, h [15.1-16.2^] 33 [28-38^]          
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Table 1-3 continued. 
 
Antibody Q (L/day)  
Q BSV 
(%CV)  
Sibrotuzumab (45) 0.902 [9.6] NE   
Matuzumab (40) 0.919 [7.6] NE   
Efalizumabi (35) 2.46‡       
Efalizumab (21) 0.437‡       
Denosumab (24) 0.533‡       
Denosumab (32) 0.629 [18] NE   
CP-751, 871 (31) 0.7 [14] 50 [56] 
Panitumumab (42) 0.390 [0.323-0.475*] NE  
Cetuximab (29) 2.47 [1.49-4.58*] 97 [40-133*] 
Alemtuzumab (23) 25.2 [10.6-51.1^] NE   
Clenoliximab (30) 0.877‡       
Golimumab (34) 0.42 [0.31-0.50^] 45 [52] 
Inolimomab (38) 53.3 [52] 43d [425] 
mAbF19 (39) 3.41 [18] NE   
HuCC49∆CH2 (17) 0.154 [0.122-0.191*] 39 [24-54*] 
Rituximab (44) 0.656‡       
Trastuzumab (46) 0.484‡       
Pertuzumab (43) 0.556‡       
Bevacizumab (28) 0.593‡       
Infliximab (36) 1.72 [1.14-2.6^] NE   
Infliximab (37) 7.14 [3.67-10.10^] NE  
Basiliximab (26) 4.17‡       
Basiliximab (27) 0.569‡       
ATM-027 (25) 2.18 [170] NE   
Omalizumab (41)         
Efalizumab (33)         
Ustekinumab (47)         
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Table 1-3 continued. 
 
Antibody K12 (day-1)  
K12 BSV 
(%CV)  K21 (day-1)  
K21 BSV 
(%CV)  
Sibrotuzumab (45) 0.218‡       0.283‡       
Matuzumab (40) 0.247‡       0.499‡       
Efalizumabi (35) 0.478 [24] 112 [53] 0.588 [11] NE   
Efalizumab (21) 0.097 [21] 168 [6.1] 0.193 [13] 96 [7.7] 
Denosumab (24) 0.224 [12] NE   0.336 [13] NE   
Denosumab (32) 0.260‡       0.495‡       
CP-751, 871 (31)                 
Panitumumab (42) 0.0987‡    0.151‡    
Cetuximab (29) 0.873‡       1.02‡       
Alemtuzumab (23) 2.23‡       0.607‡       
Clenoliximab (30) 0.245 [5.2] 12   0.164 [21] 28   
Golimumab (34) 0.137‡       0.114‡       
Inolimomab (38) 19.3‡       23.7‡       
mAbF19 (39) 1.09‡       1.96‡       
HuCC49∆CH2 (17) 0.0445‡       0.0616‡       
Rituximab (44) 0.22 [0.20-0.25^] NE   0.18 [0.17-0.19^] NE   
Trastuzumab (46) 0.164 [0.135-0.191^] 54 [43-62^] 0.101 [0.0826-0.122^] 67 [57-78^] 
Pertuzumab (43) 0.203 [0.159-0.416^] NE   0.258 [0.203-0.480^] 25 [11-34^] 
Bevacizumab (28) 0.223 [0.134-0.501^] NE   0.215 [0.138-0.416^] NE   
Infliximab (36) 0.562‡       0.585‡       
Infliximab (37) 2.170‡    1.729‡    
Basiliximab (26) 1.12 [14] NE   1.02 [31] 51 [29] 
Basiliximab (27) 0.104 [38] 68 [45] 0.319 [25] 94 [33] 
ATM-027 (25) 0.779‡       0.703‡       
Omalizumab (41)                 
Efalizumab (33)                 
Ustekinumab (47)                 
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Table 1-3 continued. 
 
BSV = between-subject variability; K12 and K21 = distribution rate constants from central to peripheral compartment and vice 
versa, respectively; NE = not estimated; Q = intercompartmental clearance; %RSE = percent relative standard error; V1 or V2 
= volume of the central or peripheral compartment, respectively; Vss = volume of distribution at steady state. 
* 90% or ^ 95% bootstrap confidence interval. 
** Not available or not applicable estimates are blank. 
‡ Parameter derived from population estimates using the following equations:  CLL or CLT = K10*V1; Q=K12*V1=K21*V2; 
Vss=V1+V2. 
a. Covariance of between-subject variability estimated; correlation coefficients: V1_V2 (0.777), V1_Vmax (0.875), V2_Vmax 
(0.875). 
b. Calculated for a 70 kg patient using V1 (73.4 ml/kg) and Vmax (39 μg/kg/day) population estimates. 
c. Calculated for a 70 kg patient using V1 (64.3 ml/kg) and Vmax (26.9 μg/kg/day) population estimates. 
d. Covariance of between-subject variability estimated; correlation coefficients: CL_V1 (-0.05), CL_Q (-0.76), V1_Q (-0.62). 
e. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.729; [0.335-0.910*]). 
f. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.342; [0.214-0.456^]). 
g. Apparent clearance or volume of distribution (i.e., CL/F or V/F). 
h. Covariance of between-subject variability estimated; correlation coefficient: CL/F_V/F (0.817). 
i. Results reported for 2C NL+L model; a receptor-mediated clearance model was also investigated. 
j. Vss (%RSE) and Vss BSV (%RSE) estimates were 4.87 L (9.2) and 31 %CV (45), respectively. 
k. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.662; [0.396-1.02*]). 
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Table 1-4. Population estimates and their between-subject variability [%RSE or confidence interval *,^] of clearance related 
parameters.** 
 
Antibody Vmax (mg/day)  
Vmax BSV 
(%CV)  Km (mg/L)  
Km BSV 
(%CV)  
CLint 
(L/day) 
Sibrotuzumab (45) 0.811 [25] 29 [50] 0.219 [57] NE   3.70‡ 
Matuzumab (40) 10.9 [14] 54a [38] 4.0 [30] NE   2.73‡ 
Efalizumab i  (35) 2.73b      [11] 42 [51] 0.0973 [27] 122 [74] 28.1‡ 
Efalizumab (21) 1.88c       [4.3] 65 [8.1] 0.033 [21] 124 [6.8] 57.0‡ 
Denosumab (24) 0.0878 [7.5] 32   0.164 [11] NE   0.54‡ 
Denosumab (32) 0.0895 [6.3] 46   0.192 [7.5] NE   0.47‡ 
CP-751, 871 (31) 2.42 [29] 34 [210] 1.22 [97] 69 [94] 1.98‡ 
Panitumumab (42) 12.1 [11.4-12.7*] 29j [24-33*] 0.426 [0.364-0.586*] 80j [59-100*] 28.4‡ 
Cetuximab (29) 105 [81.6-159*] 15 [12-19*] 74 [38.2-163*] NE   1.42‡ 
Alemtuzumab (23) 24.5 [15.6-44.2^] 32 [32] 0.338 [0.226-0.849^] 145 [37] 72.5‡ 
Clenoliximab (30) 35.8 [4.2] 47   1.29 [23] NE   27.8‡ 
Golimumab (34)          
Inolimomab (38)          
mAbF19 (39)          
HuCC49∆CH2 (17)          
Rituximab (44)          
Trastuzumab (46)          
Pertuzumab (43)          
Bevacizumab (28)          
Infliximab (36)          
Infliximab (37)          
Basiliximab (26)          
Basiliximab (27)          
ATM-027 (25)          
Omalizumab (41)          
Efalizumab (33)          
Ustekinumab (47)          
 13
Table 1-4 continued. 
 
Antibody CLL (L/day)  
CLL BSV 
(%CV)  
Sibrotuzumab (45) 0.530 [9.6] 57 [52] 
Matuzumab (40) 0.348 [4.1] 24 [21] 
Efalizumab i  (35) 0.535‡       
Efalizumab (21) 0.513‡       
Denosumab (24) 0.066 [7.2] 25   
Denosumab (32) 0.0710 [4.5] 32   
CP-751, 871 (31) 0.243 [8.3] 59 [34] 
Panitumumab (42) 0.273 [0.258-0.294*] 28k [19-37*] 
Cetuximab (29)         
Alemtuzumab (23)         
Clenoliximab (30)         
Golimumab (34)         
Inolimomab (38)         
mAbF19 (39)         
HuCC49∆CH2 (17)         
Rituximab (44)         
Trastuzumab (46)         
Pertuzumab (43)         
Bevacizumab (28)         
Infliximab (36)         
Infliximab (37)     
Basiliximab (26)         
Basiliximab (27)         
ATM-027 (25)         
Omalizumab (41)         
Efalizumab (33)         
Ustekinumab (47)         
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Table 1-4 continued. 
 
Antibody CLT (L/day) 
CLT BSV 
(%CV)    K10 (day-1) 
K10 BSV 
(%CV) 
Sibrotuzumab (45)         0.128‡       
Matuzumab (40)         0.0935‡       
Efalizumab i  (35)         0.104 [17] 21 [99] 
Efalizumab (21)         0.114 [5.8] 50 [9.5] 
Denosumab (24)         0.0277‡       
Denosumab (32)         0.0293‡       
CP-751, 871 (31)                 
Panitumumab (42)     0.0691‡    
Cetuximab (29)                 
Alemtuzumab (23)                 
Clenoliximab (30)                 
Golimumab (34) 0.40 [0.33-0.49^] 44 [19] 0.130‡       
Inolimomab (38) 1.85 [19] 43d [87] 0.670‡       
mAbF19 (39) 2.62 [15] 54 [31] 0.837‡       
HuCC49∆CH2 (17) 1.53 [1.36-1.71*] 28e [20-35*] 0.442‡       
Rituximab (44) 0.257 [0.246-0.271^] 28 [24-32^] 0.0862‡       
Trastuzumab (46) 0.225 [0.213-0.238^] 43 [39-47^] 0.0763‡       
Pertuzumab (43) 0.214 [0.201-0.228^] 31 [27-34^] 0.0781‡       
Bevacizumab (28) 0.207 [0.188-0.226^] 26 [23-31^] 0.0778‡       
Infliximab (36) 0.273 [0.259-0.288^] 34f [30-37^] 0.0892‡       
Infliximab (37) 0.407 [0.388-0.427^] 38 [35-41^] 0.124‡    
Basiliximab (26) 0.882‡       0.237 [19] 35 [26] 
Basiliximab (27) 1.33‡       0.243 [9.1] 42 [29] 
ATM-027 (25) 0.190 [6.7] 28 [24] 0.0679‡       
Omalizumab (41) 0.176g   [2.1] 20           
Efalizumab (33) 1.29g    [1.17-1.39^] 48 [45-51^]         
Ustekinumab (47) 0.465g, h  [0.448-0.480^] 41 [38-44^]         
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Table 1-4 continued. 
 
BSV = between-subject variability; CLT = clearance; CLL = clearance of linear elimination pathway; CLint = intrinsic 
clearance (calculated as Vmax/Km); K10 = elimination rate constant from central compartment; Km = concentration at half-
maximum elimination rate; NE = not estimated; %RSE = percent relative standard error; Vmax = maximum elimination rate; 
Vss = volume of distribution at steady state. 
* 90% or ^ 95% bootstrap confidence interval. 
** Not available or not applicable estimates are blank. 
‡ Parameter derived from population estimates using the following equations:  CLL or CLT = K10*V1; Q=K12*V1=K21*V2; 
Vss=V1+V2. 
a. Covariance of between-subject variability estimated; correlation coefficients: V1_V2 (0.777), V1_Vmax (0.875), V2_Vmax 
(0.875). 
b. Calculated for a 70 kg patient using V1 (73.4 ml/kg) and Vmax (39 μg/kg/day) population estimates. 
c. Calculated for a 70 kg patient using V1 (64.3 ml/kg) and Vmax (26.9 μg/kg/day) population estimates. 
d. Covariance of between-subject variability estimated; correlation coefficients: CL_V1 (-0.05), CL_Q (-0.76), V1_Q (-0.62). 
e. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.729; [0.335-0.910*]). 
f. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.342; [0.214-0.456^]). 
g. Apparent clearance or volume of distribution (i.e., CL/F or V/F). 
h. Covariance of between-subject variability estimated; correlation coefficient: CL/F_V/F (0.817). 
i. Results reported for 2C NL+L model; a receptor-mediated clearance model was also investigated. 
j. Covariance of between-subject variability estimated; correlation coefficient: Vmax_Km (0.461; [0.136-0.746*]). 
k. Covariance of between-subject variability estimated; correlation coefficient: CL_V1 (0.662; [0.396-1.02*]). 
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Table 1-5. Identified covariates and their estimated effects on pharmacokinetic parameters** [%RSE or confidence interval 
*,^]. 
 
Antibody  On Vmax   On CLL  Notes 
Sibrotuzumab (45) WGTa  0.00934 [49] WGTa   0.0182 [19]   
Matuzumab (40)       WGTa   0.0087 [28]   
Denosumab (24) WGTb   0.6 [27] WGTb   0.918 [28]   
CP-751, 871 (31) WGTb   1.11 [74]         
Panitumumab (42) WGTb 0.621 [0.488-0.725*] WGTb 0.411 [0.261-0.572*] CLL was 23% slower in females 
 AGEb -0.495 [-0.688, -0.297*] GDRf 0.769 [0.721-0.818*] Patients with colorectal or renal  
    LUNGf 0.861 [0.799-0.937*] cancer had a faster CLL than 
    RENALf 0.957 [0.873-1.03*] patients with non-small cell lung 
    OTHERf 0.870 [0.792-0.956*] cancer or other types of cancer 
Cetuximab (29) IBWa    0.0108 [0.0077-0.0139*]         
  WBCa   0.0216 [0.0169-0.0296*]         
Alemtuzumab (23) WBCb   0.194 [0.081-0.382^]         
     On CLT   
Golimumab (34)               
HuCC49∆CH2 (17)       WGTc    0.75 fixed    
Rituximab (44)       BSAb     1.02 [0.54-1.64^] CL was 39% faster in males 
        GDRe     0.39 [0.17-0.63^]  
Trastuzumab (46)       METe       0.221 [0.0611-0.429^] CL was 22% faster in patients  
    ECDb     0.041 [0.013-0.071^] with four or more metastatic  
       sites 
Pertuzumab (43)       WGTb   0.587 [0.372-0.826^]  
        ALBb     -1.01 [-1.42,-0.632^]  
        ALKPb   0.169 [0.067-0.258^]  
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Table 1-5 continued. 
 
Antibody  On Vmax   On CLT  Notes 
Bevacizumab (28)       WGTb   0.368 [0.088-0.650^] CL was  26% faster in males 
        GDRe    0.264 [0.132-0.398^] CL in concomitant bolus-IFL  
    ALBb    0.726 [0.472-1.02^] regimen was 17% slower 
        ALKPb 0.133 [0.070-0.206^] compared to other concomitant 
        ASTb   0.0715 [0.002-0.144^] chemotherapy regimens  
    CHEMe  0.174 [0.096-0.244^] combined 
Infliximab (36)       WBCd   0.0106 [0.0051-0.0162^] CL was  42% faster for patients  
    IRe       0.419 [0.215-0.662^] positive for antibodies against 
       infliximab 
Infliximab (37)    ALBb -1.54 [-1.94, -1.17^] CL was 47% faster for patients  
    IRe 0.471 [0.28-0.831^] positive for antibodies against 
    GDRe -0.236 [-0.291, -0.181^] infliximab 
       CL was 24% slower in females 
ATM-027 (25)              
Omalizumab (41)       WGTb  0.911 [15]  
Efalizumab  (33)       WGTb   0.754 [0.511-0.956^] Obese patients (BMI ≥30) had a  
    AGEb    0.218 [0.091-0.344^] 10% faster CL/F 
        LYMb    0.165 [0.065-0.274^] Subjects receiving 2 mg/kg had  
    PASIb    0.220 [0.132-0.312^] a 24% slower CL/F vs. the 
        OBSe    0.0997 [0.015-0.211^] 1 mg/kg group 
        DOSEe  -0.240 [-0.292,-0.174^]  
Ustekinumab (47)       WGTb    0.840 [0.731-0.956^] CL/F was 28.7% faster in  
    DMe       0.287 [0.189-0.377^] patients with diabetes 
        IRe        0.355 [0.172-0.540^] CL/F was 35.5% faster for  
    ALBb    -0.896 [-1.09, -0.673^] patients positive for antibodies 
        CRCLb    0.188 [0.128-0.251^] against ustekinumab 
        GDRe     0.059 [0.030-0.093^] CL/F was 5.9% faster for  
        ALKPb   0.113 [0.065-0.161^] females 
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Table 1-5 continued. 
 
Antibody  On V1   On V2   On Q Notes 
Sibrotuzumab (45) WGTa   0.0125 [21] WGTa  0.0105 [40]       
Matuzumab (40) WGTa   0.0044 [35]             
Denosumab (24) WGTb   0.783 [30]             
CP-751, 871 (31) WGTb   0.630 [25] WGTb  2.21 [20]       
Panitumumab (42) WGTb 0.526 [0.415-0.632*]      V1 was 17% smaller in  
 GDRf 0.831 [0.792-0.871*]      females 
Cetuximab (29) WGTa   0.0083 [0.0057-0.0115*]             
Alemtuzumab (23)                   
Golimumab (34) WGTb   0.86 [17]             
HuCC49∆CH2 (17) WGTc   1.0 fixed   WGTc  1.0 fixed   WGTc 0.75 fixed   
Rituximab (44) BSAb    0.73 [0.45-1.05^]           V1 was  17% larger in  
  GDRe     0.17 [0.08-0.26^]           males 
Trastuzumab (46) WGTb     0.556 [0.211-0.824^]            
  ECDb      0.105 [0.0726-0.146^]            
Pertuzumab (43) BSAb   1.16 [0.890-1.45^]             
Bevacizumab (28) WGTb  0.411 [0.284-0.490^]           V1 was 22% larger in  
  GDRe    0.221 [0.173-0.285^]           males 
  ALBb   -0.333 [-0.461,-0.242^]            
Infliximab (36) BSAb    0.744 [0.510-0.978^]           V1 was 10% larger in  
  GDRe   0.100 [0.052-0.146^]           males 
Infliximab (37) WGTb 0.538 [0.394-0.700^]      V1 was 14% smaller in  
 GDRe -0.137 [-0.197, -0.072^]      females 
ATM-027 (25) GDRe    0.250 [24]           V1 was 25% larger in  
         males 
Omalizumab (41) WGTb   0.658 [15]             
Efalizumab (33)                  
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Table 1-5 continued. 
 
Antibody  On V1   On V2   On Q Notes 
Ustekinumab (47) WGTb    0.807 [0.707-0.905^]           V/F was 13.2% larger  
 DMe        0.132 [0.045-0.223^]      in patients with  
  RACEe   -0.111 [-0.154, -0.070^]           diabetes 
               V/F was 11.1% smaller  
         for non-Caucasians 
                  vs. Caucasians 
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Table 1-5 continued. 
 
AGE = age; ALB = albumin; ALKP = alkaline phosphatase; AST = aspartate aminotransferase; BMI = body mass index; 
BSA = body surface area; CHEM = concomitant chemotherapies; CLT = total clearance; CLL = clearance of linear 
elimination pathway; CL/F = apparent clearance; COVref = reference/typical covariate value; CRCL = creatinine clearance; 
DM = diabetes comorbidity; DOSE = dose group; ECD = serum level of shed HER2 receptor extracellular domain; F = 
female; GDR = gender; IBW = ideal body weight; IFL = irinotecan, 5-fluorouracil, leucovorin regimen; IR = immune 
response with development of antibodies to the therapeutic monoclonal antibody; LUNG = non-small cell lung cancer; LYM 
= lymphocyte count; M = male; MET = number of metastatic sites; OBS = obesity; OTHER = other cancer types (see 
referenced paper for details); PASI = psoriasis area and severity index score; Q = intercompartmental clearance; RENAL = 
renal cancer; %RSE = percent relative standard error; V1 or V2 = volume of the central or peripheral compartment, 
respectively; V/F = apparent volume of distribution; Vmax = maximum elimination rate; WBC = white blood cell count; WGT 
= body weight. 
* 90% or ^ 95% bootstrap confidence interval. 
** Not available or not applicable estimates are blank. 
Continuous covariate models: 
a. Linear proportional (covariate centered); P = θ1 * (1 + θCOV * (COV-COVref)). 
b. Power (covariate normalized); P = θ1 * (COV/COVref)**θCOV. 
c. Allometric (covariate normalized); θCOV in power model fixed to 0.75 or 1.0. 
d. Linear additive (covariate centered); P = θ1 + θCOV * (COV-COVref). 
Categorical covariate models: 
e. Linear proportional; P = θ1 * (1 + θCOV * COV) where COV is 0 or 1, for example. 
f. Power; P = θ1 * θCOV**COV where COV is 0 or 1, for example. 
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Table 1-6. Residual variability estimates** [%RSE or confidence interval *,^]. 
 
Antibody Proportional error (%CV)  Additive error (mg/L) 
Sibrotuzumab (45) 9.3 [6.8] 0.0491 [19] 
Matuzumab (40) 13.4 [1.5] 0.312 fixed   
Efalizumabb (35) 11.7 [21]     
Efalizumab (21) 35.9 [1.5]     
Denosumab (24) 35.9       
Denosumab (32)     2.66E-04   
CP-751, 871 (31) 26 [6.9]     
Panitumumab (42) 42.0 [36.3-48.4*] 0.03 [0.005-0.05*] 
Cetuximab (29) 14.6a [12.3-16.8*]     
  21.2a [18.8-23.7*]     
Alemtuzumab (23) 37.2 [31.0-40.0^] 0.0647 [0.0372-0.114^] 
Clenoliximab (30) 8.8 [29]     
Golimumab (34) 15.0 [23]     
Inolimomab (38) 30.2 [7]     
mAbF19 (39) 12.5 [31]     
HuCC49∆CH2 (17) 15.1 [12.5-17.6*] 19.1 dps/ml  [12.7-29.3*] 
Rituximab (44) 19.0 [17.2-21.3^] 0.54 [0.4-0.64^] 
Trastuzumab (46) 23 [21-24^]     
Pertuzumab (43) 19.2 [17.3-21.2^] 2.27 [0.002-4.16^] 
Bevacizumab (28) 17.2 [15.8-19.0^] 7.2 [0.093-10.3^] 
Infliximab (36) 22.9 [21.8-24.0^] 2.89 [2.48-3.22^] 
Infliximab (37) 40.3 [38.3-42.2^] 0.0413 [0.0368-0.0497^] 
Basiliximab (26) 29.8 [35] 0.371 [51] 
Basiliximab (27) 18.4 [18] 0.084 [23] 
ATM-027 (25) 26.0 [9.3] 0.0084 [15] 
Omalizumab (41) 16.7       
Efalizumab (33) 26.3 [22.2-29.8^] 1.58 [1.01-2.07^] 
Ustekinumab (47) 25.6   0.085 fixed   
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Table 1-6 continued. 
 
%RSE = relative standard error. 
* 90% or ^ 95% bootstrap confidence interval. 
** Not available or not applicable estimates are blank. 
a. Separate residual error models used per each clinical trial. 
b. Results reported for 2C NL+L model; a receptor-mediated clearance model was also investigated. 
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Antibody Absorption 
 
Most mAbs that are approved or in development are administered intravenously 
(IV), although other routes including subcutaneous (e.g., omalizumab, efalizumab, 
adalimumab) and intramuscular (e.g., palivizumab) administration are used.  Oral 
administration of mAbs has been limited due to their large molecular weight and polarity, 
as well as their susceptibility to denaturation and proteolytic degradation in the 
gastrointestinal tract. 
 
While the mechanism of absorption following subcutaneous (SC) or 
intramuscular administration (IM) is not completely understood, it has been suggested 
that mAbs are primarily absorbed via the lymphatic system.  This presumption is 
supported in part from a study in which the lymphatic absorption of 5-fluoro-2’-
deoxyuridine (molecular weight 0.246 kDa), inulin (5.2 kDa), cytochrome c (12.3 kDa), 
and human recombinant interferon alpha-2a (19 kDa), was investigated following SC 
administration in sheep (48).  A positive linear relationship was observed between the 
molecular weight of the compound and the proportion of the dose absorbed via the 
lymphatics. Molecules larger than 16 kDa predominantly underwent lymphatic 
absorption, while those under 1 kDa were primarily absorbed by the blood capillaries.  
The molecular weights of the investigated compounds are much smaller compared to that 
of IgG and intact therapeutic mAbs of the IgG type (~150 kDa), so extrapolation of the 
observed linear relationship to mAbs should be made with caution.  A sheep model was 
also used in another study to investigate the contribution of the lymphatics to the 
absorption and systemic availability of recombinant human erythropoietin alpha (30.4 
kDa) following SC administration (49).  This study reported an 84% and 75% recovery of 
the administered dose in the peripheral and central lymph, respectively.  Contrasting 
results to the above studies in sheep were reported in an investigation of lymphatic 
absorption of bovine insulin (5.6 kDa), bovine albumin (66 kDa), and recombinant 
human erythropoietin alpha (30.4 kDa), following SC administration in a rat model (50).  
The investigators found that for all three macromolecules, less than 3% of the 
administered SC dose was recovered in the lymph.  This study was conducted in rats 
which may not be a good model for human SC absorption, so extrapolation of the results 
to humans should be done with discretion.  Drawing any conclusions about the lymphatic 
absorption of IgG molecules based on the results of the aforementioned studies should by 
done with caution since IgG molecules were not specifically investigated.  There is still a 
great deal of uncertainty regarding the physiological mechanisms involved in the 
absorption of IgG following SC or IM administration, and in some aspects these 
mechanisms may differ from other macromolecules, for example the potential 
involvement of FcRn in this process (9). 
 
 Lymphatic absorption is believed to occur via convection, a process in which the 
mAb is “pulled” along by the flow of interstitial fluid into the highly permeable 
lymphatic capillaries where it is eventually returned back into the systemic circulation.  
Prior to reaching the systemic circulation, proteolytic degradation may occur at the 
injection site or during lymphatic transport, thereby reducing the bioavailable fraction of 
the antibody (9).  The flow of lymph through the lymphatic vessels is relatively slow, for 
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example, the lymph flow rate is approximately 1-2 ml/kg/hr for the thoracic duct (51).  
As a result, absorption of the mAb can take place over several days.  Typical values for 
time to reach maximal concentration following IM or SC administration range from 1-8 
days, and absolute bioavailabilities generally range from 50-100% (6, 7). 
 
The majority of the population PK studies were performed using concentration 
data following IV administration, but SC data was available in a small number of studies.  
These studies are listed in Table 1-2 along with population estimates and between-subject 
variabilities for absolute bioavailability (F) and absorption rate constant (Ka).  The 
median (range) population estimate for Ka was 0.217 day-1 (0.132-0.48).  Three different 
studies reported estimates for F which included values of 49.1, 56.4, and 74.7%.  These 
population estimates for F and Ka are in agreement with the general absorption 
characteristics of mAbs following IM or SC dosing.  Estimates of between-subject 
variability in F and Ka were large with values ranging from 40-53 %CV (Table 1-2), 
although variability in these two parameters was not often estimated. 
 
 
Antibody Distribution 
 
The ability of mAbs to cross cell membranes is significantly hindered by their 
large molecular weight and hydrophilicity/polarity.  Given this, mAbs often exhibit a 
small volume of distribution, and are believed to be largely confined to the vascular and 
interstitial spaces.  Other factors that influence the distribution characteristics of 
antibodies include the distribution and density of the antibody target and morphology of 
the vascular capillaries (i.e., continuous, fenestrated, and sinusoidal).  The movement of 
mAbs across or between cell membranes may occur via transcellular or paracellular 
mechanisms, respectively (7, 52, 53). 
 
The paracellular movement of mAbs occurs by means of convection, which is 
simply the transport of mAbs within the movement of fluid flow.  This fluid flow is set 
up by the natural physiological exchange of fluids between the capillaries, interstitial 
space, and lymphatics.  Convection is believed to be the primary mechanism responsible 
for the movement of mAbs from the vasculature to the interstitial space (9).  Convection 
also plays a role in the distribution of mAbs within the interstitial fluid, and facilitates the 
transport of antibody out of the tissue as interstitial fluid enters the lymphatic capillaries.  
Given that the paracellular pores of the lymphatic capillaries are much larger than those 
in the vascular endothelium, it is assumed that the convective clearance of mAbs from the 
tissue is much more efficient than the process of convective extravasation, thereby 
maintaining relatively low mAb concentrations in the interstitial fluid (7, 9).  
 
The transcellular movement of mAbs can occur via passive diffusion or 
endocytosis.  However, given the physiochemical properties of mAbs, it is likely that 
passive diffusion does not play a significant role in their distribution.  Endocytosis of 
mAbs can take place through three main processes: phagocytosis, fluid-phase 
pinocytosis, and receptor-mediated endocytosis (6).  Virtually all cells in the body have 
the ability to take up proteins and other macromolecules including mAbs from the 
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surrounding fluid space via fluid-phase pinocytosis.  Receptor-mediated endocytosis may 
take place following binding of the mAb to a cell surface antigen or Fcγ receptors (7). 
 
Another potential mechanism for extravasation of mAbs is transcytosis by 
vascular endothelial cells (7, 52, 54, 55).  Following fluid-phase pinocytosis by 
endothelial cells, mAbs within the intracellular vesicle may bind to FcRn, which not only 
protects the mAb from degradation, but eventually the mAb is recycled back into 
systemic circulation or transcytosed into the interstitial space (54).  The FcRn-mediated 
transcytosis of IgG has been demonstrated in both endothelial and epithelial cells (56-62).  
However, the importance of FcRn-mediated transcytosis of IgG in the distribution of 
mAbs remains to be elucidated. 
 
Following IV administration, the concentration-time profile of mAbs often 
follows a bi-exponential decline, which can be best described using a two-compartment 
PK model (11, 63).  Accordingly, a two-compartment model was used in the majority of 
the mAb population PK analyses (Table 1-1).  In the few studies where a one-
compartment PK model was used, concentration data was only available following SC 
administration.  The distribution phase of the mAbs in these studies may have been 
masked by a slow absorption phase often observed for mAbs following SC 
administration.  An attempt was made in the population PK analyses of pertuzumab and 
inolimomab to fit a three-compartment model to the concentration data, but this resulted 
in an overparameterized model and did not show a significant improvement in fit versus a 
two-compartment model (38, 43). 
 
Population estimates and between-subject variabilities for distribution related PK 
parameters are summarized in Table 1-3.  Estimates for the volume of the central (V1) 
and peripheral (V2) compartments were quite similar for the different mAbs with the 
exception of alemtuzumab.  Compared to other mAbs, alemtuzumab not only had a much 
larger V1 and V2 (11.3 L and 41.5 L, respectively), but between-subject variability in both 
of these parameters was also larger (84 %CV and 179 %CV, respectively) (23).  It is 
uncertain as to why these population parameter estimates for alemtuzumab are in stark 
contrast to what was observed for many of the other therapeutic mAbs.  The median 
(range) estimate for V1 and V2 based on studies that used a two-compartment PK model 
(excluding alemtuzumab) was 3.1 L (2.4-5.5) and 2.8 L (1.3-6.8), respectively.  In 
general, the estimates for V1 were approximately equal to plasma volume.  Between-
subject variability was quantified for V1 in all but one of the population PK studies 
(Table 1-3).  The between-subject variability in V1 was usually moderate, as the median 
(range) across all of the studies was 26 %CV (12-84).  The values for volume of 
distribution at steady state (Vss=V1+V2) suggest an apparently limited distribution outside 
of the vascular space, and are consistent with the behavior of endogenous IgG.  Based on 
data from early IgG metabolism studies in humans (64), the mean serum IgG 
concentration and total body IgG pool were 12 g/L and 1.06 g/kg body weight, 
respectively, which for a 70 kg person equates to a volume of distribution of around 6.2 L 
for IgG.  Population estimates for intercompartmental clearance (Q) and the distribution 
rate constants (K12 and K21) appeared to be less homogenous across the different mAbs 
compared to V1 and V2.  In general, the estimates for Q, K12, and K21, suggested a slow 
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transfer of mAb between the central and peripheral compartments.  The median Q across 
all of the studies that used a two-compartment model was 0.79 L/day.  Between-subject 
variability in V2, Q, K12, and K21 was often not estimated in the population PK models.  
When estimated, between-subject variability in these parameters was usually moderate to 
high.  Volume of distribution corrected for SC bioavailability (V1/F) was estimated in the 
population PK analyses of omalizumab, efalizumab, and ustekinumab, which have a 
bioavailability F following SC dosing of around 62%, 50%, and 57%, respectively (33, 
41, 47).  After adjusting for F, the volume of distribution for omalizumab, efalizumab, 
and ustekinumab are approximately 3.7, 4.6, and 9.0 L, respectively, which is in line with 
the results for other mAbs. 
 
When estimating Vss using a noncompartmental analysis or by fitting a 
mammillary compartmental model to the data, the assumption is made that elimination of 
the drug occurs at a site(s) in rapid equilibrium with plasma or the central compartment 
(63, 65).  For some mAbs this assumption may be valid.  However, there may be 
instances when a mAb undergoes significant elimination in peripheral tissues (e.g., via 
receptor-mediated endocytosis).  In these cases, the aforementioned methods of analysis 
can lead to errors in estimating Vss (63, 65).  Therefore, volumes of distribution reported 
in the literature for mAbs should be interpreted with caution. 
 
 
Antibody Clearance 
 
The two general pathways by which drugs are eliminated from the body are 
metabolism (e.g., catabolism) and excretion.  However, the role of non-catabolic routes, 
such as renal and biliary excretion, in the clearance of mAbs is negligible.  The 
glomerular filtration of mAbs is largely limited by their size, as the molecular cut-off 
weight for filtration is approximately 70 kDa (66).  While biliary excretion has been 
reported for IgA, it does not appear to be a significant route for elimination of IgG (9, 
67).  The primary route by which antibodies are eliminated is cellular uptake followed by 
proteolytic degradation.  Therapeutic antibodies often exhibit two distinct catabolic 
pathways (8): 1) a non-specific, linear (first-order) clearance pathway mediated by 
interaction between the Fc region of the antibody and Fc receptors (i.e., FcRn and Fcγ 
receptors) and 2) a nonlinear (target-mediated) clearance pathway mediated by the 
specific interaction between the Fab region of the antibody and its pharmacologic target. 
 
 
Fc-Receptor-Mediated Elimination 
 
The previous use of non-specific with regards to the linear clearance pathway 
reflects the notion that Fc-mediated elimination is a common pathway shared by both 
endogenous IgG and therapeutic IgG mAbs with a functional human Fc domain.  
Virtually all cells in the body have the ability to take up proteins and other 
macromolecules from the surrounding fluid space via endocytosis (e.g., fluid-phase 
pinocytosis).  The formed endosome may subsequently be delivered to a lysosome, where 
its contents undergo enzymatic degradation.  However, unlike most other proteins in the 
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endosome, a significant portion of IgG can be salvaged from lysosomal catabolism by an 
FcRn-mediated mechanism in cells expressing FcRn (68-70). 
 
Following cellular uptake of IgG, the environment inside the early endosome 
becomes mildly acidic.  IgG binds to FcRn in a pH dependent manner, and the decrease 
in pH allows IgG to bind to FcRn expressed within the endosome.  IgG that is bound to 
FcRn is redirected to the cell surface, while unbound IgG is delivered to the lysosome for 
degradation.  This partitioning of IgG-FcRn complexes and unbound IgG into two 
different pathways appears to occur within the sorting endosome (70).  Once the IgG-
FcRn complex is transported to the cell surface, the affinity of IgG to FcRn decreases as 
the result of the physiological pH, and IgG is released into the extracellular fluid.  This 
salvage pathway helps to explain the much longer elimination half-life of IgG (~21 days) 
compared to that of the other immunoglobulin classes whose half-lives range from 2-10 
days (6).  While the IgG1, IgG2, and IgG4 subclasses exhibit a half-life of around 21 
days, the half-life for IgG3 is only 7 days.  The shorter half-life of IgG3 has been 
attributed to binding differences to FcRn compared to the other IgG subclasses (8).  As 
the number of FcRn receptors is limited, the salvage pathway can be expected to be 
capacity limited.  This is supported by findings from a study by Morell et al., in which 
shorter IgG half-lives were observed in patients with elevated serum IgG concentrations 
compared to those with normal IgG levels (71).  However, the doses commonly 
administered for therapeutic mAbs are not likely to cause significant enough increases in 
serum IgG concentrations that result in saturation of the FcRn receptor (72).  Therapeutic 
mAbs are commonly administered at doses <10 mg/kg, which would increase the total 
body IgG by <1-2%, as humans typically possess 50-100 g of endogenous IgG (9).  
Furthermore, as will be discussed later in the review, the estimates for total clearance in 
mAbs with linear elimination characteristics and for the clearance of the linear 
elimination pathway in mAbs with parallel linear and nonlinear elimination were quite 
similar to the clearance of endogenous IgG.  The FcRn receptor is expressed in a wide 
variety of cells and tissues throughout the body including the vascular endothelium, 
monocytes, macrophages, dendritic cells, hepatocytes, and epithelial cells of the intestine, 
renal proximal convoluted tubules and upper airways (73, 74). 
 
Another set of receptors that bind to the Fc portion of IgG are the Fcγ receptors.  
These receptors play a significant role in mediating various immune effector functions 
such as phagocytosis and antibody dependent cellular cytotoxicity (75).  There are three 
different classes of Fcγ receptors (i.e., FcγRI, II, III) and they differ with regards to their 
cellular distribution, specificity for the different IgG subclasses, and affinity for 
monomeric or immune-complexed IgG (10).  The Fcγ receptors are expressed on a wide 
variety of cells including monocytes, macrophages, dendritic cells, neutrophils, NK 
(natural killer) cells, B cells, and hepatocytes (10, 73).  Based on their innate roles in 
immune responses, Fcγ receptors may be involved in the clearance of soluble mAb-
antigen immune complexes or cells opsonized by the mAb.  However, the significance of 
Fcγ receptor-mediated catabolism of mAbs is not as well understood as the role of FcRn. 
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Target-Mediated Elimination 
 
The interaction between a mAb and its pharmacologic target can contribute to the 
elimination of the mAb.  A concept often applied to the PK of mAbs is target-mediated 
drug disposition in which the interaction between a drug and pharmacologic target 
influences its PK characteristics (76, 77).  Receptor-mediated endocytosis, an example of 
target-mediated drug disposition, involves binding of the mAb to a receptor on the cell 
surface, which triggers internalization and subsequent lysosomal degradation of the mAb-
receptor complex.  The number of receptors within the distribution space of the mAb is 
limited, and therefore, the receptors may become saturated at therapeutic doses of the 
mAb resulting in nonlinear clearance.  The nonlinear clearance observed with many 
mAbs is believed to be due to saturation of target-mediated clearance pathways (8).  The 
role that target-mediated clearance plays in the total clearance of the mAb is dependent 
on a number of factors including the concentration and distribution of the receptor, and 
rates of receptor internalization and turnover (8). 
 
 Therapeutic mAbs that bind to soluble antigens may also undergo target-mediated 
elimination.  One potential mechanism that has been suggested is in which the soluble 
mAb-antigen complex binds to Fcγ receptors on cells such as monocytes and 
macrophages, which subsequently triggers internalization and catabolism of the complex 
(9).  If this elimination mechanism was present for a given therapeutic mAb, then it 
would be reasonable to anticipate that the clearance of the soluble mAb-antigen complex 
would be greater compared to that for the unbound and free mAb.  In a population PK/PD 
analysis of omalizumab (an anti-IgE mAb), the apparent clearance of the omalizumab-
IgE complex was 0.32 L/day compared to 0.18 L/day for free omalizumab (41).  The 
nonlinear PK observed for mAbs, such as omalizumab and denosumab (24, 78, 79), 
which target soluble antigens, suggests that saturable target-mediated mechanisms of 
elimination are not only limited to mAbs with membrane bound antigens (9). 
 
 
Clearance Models 
 
The different PK models used in the population analyses are listed in Table 1-1.  
In most studies compartmental PK models with linear, nonlinear, or parallel linear and 
nonlinear elimination pathways were used to describe the PK of the mAb.  In the 
population PK/PD analyses of efalizumab (35) and omalizumab (41) more complex 
mechanistically based target-mediated elimination models were applied.  A commonly 
used PK model that can be related to the distinct physiologic elimination pathways is a 
two-compartment model with parallel linear and nonlinear elimination from the central 
compartment, which is depicted in Figure 1-2A.  In this PK model, the total clearance 
(CLT) of the mAb is comprised of clearance from the nonlinear pathway (CLNL) plus that 
of the linear pathway (CLL).  Physiologically, the nonlinear pathway is thought to be 
related to elimination of the mAb via saturable target-mediated mechanisms (e.g., 
receptor-mediated endocytosis), while the linear component represents elimination 
pathways not saturable at therapeutic mAb concentrations such as Fc-mediated 
elimination.  The relationship between the clearance components of the model (CLL, 
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Figure 1-2. Pharmacokinetic behavior of a monoclonal antibody with parallel linear 
and nonlinear elimination pathways.  Schematic of a representative structural 
pharmacokinetic model with parallel elimination pathways (A).  Plot of clearance 
dependence on serum concentrations (B).  Simulated serum concentration-time profiles 
(C) using the pharmacokinetic model in (A) after single IV bolus doses of 50, 100, 200, 
400, 800, and 1600 mg.  Parameter values of 18 mg/day (Vmax), 5 mg/L (Km), 0.4 L/day 
(CLL), 4 L (V1), 3 L (V2), and 1.2 L/day (Q) were used for the simulation as well as for 
the clearance versus concentration plot.  C1 = concentration in central compartment; CLL 
= clearance of the linear elimination pathway; CLNL = clearance of the nonlinear 
elimination pathway (calculated as Vmax/(Km+C1)); CLT = total clearance (calculated as 
CLNL+CLL); Km = concentration at which elimination is half maximum; Q = 
intercompartmental clearance; V1 = volume of central compartment; V2 = volume of 
peripheral compartment; Vmax = maximum elimination rate. 
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CLNL, and CLT) and mAb concentration is described in Figure 1-2B.  At low 
concentrations total clearance is relatively unaffected by the mAb concentration, and 
target-mediated elimination contributes a significant portion to the overall clearance of 
the mAb (CLNL is approximately 7 times larger than CLL).  With increasing 
concentrations, total clearance decreases dramatically as the target-mediated elimination 
pathway starts to become saturated.  The concentration range at which this significant 
decrease in total clearance occurs is dependent on the Kd (dissociation constant) and/or 
EC50 of the mAb-receptor interaction, and lies for many mAbs in the range of 0.1-100 
mg/L.  At high concentrations, the total clearance approaches that of the first-order 
process (CLL), while the contribution from the nonlinear pathway becomes negligible.  A 
biphasic clearance versus dose profile has been observed for several therapeutic mAbs 
including cetuximab, trastuzuamb, and efalizumab (35, 79-82).  Another characteristic of 
this model is an S-shaped curve in the concentration-time profile (Figure 1-2C).  This 
may be observed at higher doses if concentrations are sampled for a prolonged time 
period, and is due to an increase in total clearance coinciding with an increase in CLNL as 
concentrations decrease.  Given a two-compartment PK model with one linear and one 
nonlinear elimination pathway, there are different structural variations that can be 
conceived by varying the location (i.e., central or peripheral compartment) of the two 
elimination pathways.  Issues regarding identifiability and indistinguishability of these 
different models has been investigated by Godfrey and colleagues (83).  In most studies 
that used a parallel elimination model, the configuration was one where both the linear 
and nonlinear elimination pathways originated from the central compartment.  However, 
other structural variations were evaluated in the population PK analyses of matuzumab 
and CP-751, 971 (31, 40). 
 
The most frequent PK model used in the population analyses was a one- or two-
compartment model with linear elimination (Table 1-1), which is inconsistent with the 
observation that many therapeutic mAbs exhibit nonlinear clearance (6, 8).  One reason 
for this discrepancy may have been related to the doses (concentrations) studied in the 
population PK analysis.  Referring back to Figure 1-2B, the dose of the mAb may result 
in concentrations that are high enough to saturate the target-mediated elimination 
pathway.  A compartmental model with linear elimination may adequately describe the 
data at these high concentrations, as the nonsaturable Fc-mediated elimination pathway 
becomes the major determinant of mAb clearance.  Nonlinear clearance has been 
observed for efalizumab and trastuzumab, and this was attributed to saturation of target-
mediated clearance pathways via their respective targets, CD11a and HER-2 (33, 35, 79, 
82).  Contrary to these observations, two separate population PK analyses of efalizumab 
and trastuzumab found that their PK was adequately described using a compartmental 
model with linear elimination (33, 46).  Based on PK data from dose escalation studies of 
efalizumab (35) and trastuzumab (82), the doses of these mAbs investigated in the 
aforementioned population PK analyses may have resulted in steady-state concentrations 
where target-mediated clearance was saturated and thus the use of a PK model with linear 
elimination was warranted.  In a population PK analysis of bevacizumab in patients with 
solid tumors, concentration data was pooled from a number of different clinical trials 
where the dosing regimen for bevacizumab varied (28).  The data from 10 patients that 
received bevacizumab doses of 0.1 and 0.3 mg/kg were excluded from the analysis as 
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clearance at these doses was faster, and these doses were not evaluated in further clinical 
trials.  The excluded set of patients represented a small fraction of the 491 patients 
included in the population PK study.  The final population PK model for bevacizumab 
included a two-compartment model with linear elimination (28).  The use of a PK model 
with linear elimination rather than with nonlinear elimination seems reasonable in this 
case, since the population PK model was used to describe bevacizumab concentrations at 
clinically relevant doses which did not included the doses of 0.1 and 0.3 mg/kg excluded 
from the analysis.  The lowest dose group was also excluded in a population PK analysis 
of golimumab, an antibody against tumor necrosis factor alpha (TNF-α), in patients with 
rheumatoid arthritis (34).  The dataset used to build the population PK model included 21 
patients who received single IV doses of golimumab ranging from 0.3-10 mg/kg, while 3 
patients who received 0.1 mg/kg were excluded from the analysis.  The inclusion of data 
from the 0.1 mg/kg group resulted in convergence difficulties, and it was believed that 
this may be due to a significant influence of TNF-α mediated disposition at a very low 
dose.  The final population PK model for golimumab included a two-compartment model 
with linear elimination (34). 
 
 
Clearance Population Estimates 
 
Population estimates and their between-subject variability for clearance related 
PK parameters are summarized in Table 1-4.  The estimates for the maximum elimination 
rate (Vmax) and the mAb concentration at which elimination is at half maximum (Km) 
varied considerably among the different therapeutic mAbs.  As nonlinear clearance is 
often attributed to target-mediated mechanisms, it can be expected that Vmax and Km will 
be specific for a given mAb and its pharmacologic target.  The Michaelis-Menten type 
parameters (Vmax and Km) can be related to parameters of a full model of target-mediated 
drug disposition (84, 85).  While between-subject variability was always estimated for 
Vmax, it was often not estimated for Km thereby treating it as a fixed value across 
individuals.  Given that Vmax is related to the number of pharmacologic targets within the 
mAb distribution space and Km is related to the affinity of the mAb to its target, it is a 
reasonable approach to hypothesize that physiologically there is more variability in Vmax 
among individuals than in Km.  Between-subject variability in Vmax was typically 
moderate to high with a median (range) value of 34 %CV (15-65 %CV) across the 
studies.  When estimated, variability in Km tended to be quite large with most estimates 
being greater than 100 %CV.  For mAbs with population estimates of Vmax and Km, their 
intrinsic clearance (CLint) was calculated as Vmax/Km and is reported in Table 1-4.  All of 
the therapeutic mAbs in Table 1-4, for which CLint was calculated, bind to a cell surface 
antigen.  The pharmacologic target for denosumab, receptor activator of nuclear factor-
κB ligand (RANKL), is expressed not only in a membrane-bound form but also in a 
soluble form (86, 87).  An interesting observation was made regarding the relationship 
between CLint and the location (i.e., blood or tissue) of the cell membrane target.  
Sibrotuzumab, matuzumab, cetuximab, denosumab, and CP-751,871 all bind to cell 
membrane antigens primarily expressed in tissue, and their calculated CLint values ranged 
from 0.47-3.70 L/day.  On the other hand, efalizumab, alemtuzumab, and clenoliximab, 
target different CD antigens largely expressed on white blood cells, and their CLint was 
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much larger with values ranging from 27.8-57.0 L/day.  Mechanistically, the larger CLint 
observed for mAbs that target blood cells may be due to a larger number of antigens 
within their primary distribution space compared to mAbs with membrane bound targets 
in tissue.  Panitumumab, cetuximab, and matuzumab are all anti-EGFR (epidermal 
growth factor receptor) mAbs, but the CLint for panitumumab (28.4 L/day) was much 
larger compared to that for cetuximab (1.42 L/day) and matuzumab (2.73 L/day) (Table 
1-4).  It is uncertain as to why these differences in CLint exist between the anti-EGFR 
mAbs, but one could hypothesize that the larger CLint observed for panitumumab is in 
part due to its higher affinity for EGFR (Kd=5 x 10-11 M) compared to cetuximab (Kd=39 
x 10-11 M) and matuzumab (Kd=34 x 10-11 M) (88-90). 
 
Assuming a volume of distribution of 6.2 L and an elimination half-life of 21 days 
for IgG (64) (with the exception of the IgG3 subclass), the clearance for endogenous IgG 
is approximately 0.21 L/day.  The population estimates for CLL were relatively close to 
the clearance of endogenous IgG, as the median (range) CLL estimate was 0.31 L/day 
(0.066-0.535 L/day).  The discrepancy between CLL values and the clearance for 
endogenous IgG may be due in part to different affinities of the therapeutic mAbs to the 
FcRn receptor and Fcγ receptor subtypes compared to IgG.  The population clearance 
estimates for several of the mAbs were around 0.2 L/day, and thus quite close to the 
clearance for endogenous IgG.  This suggests that either these mAbs do no exhibit 
saturable target-mediated clearance or that clearance via this pathway was negligible at 
the concentrations studied in the population analysis. 
 
The population clearance estimates for inolimomab, mAbF19, HuCC49∆CH2, 
and basiliximab, were much larger than those for other mAbs.  In the case of the first 
three mAbs listed, their increased clearance may have been due to impaired binding to 
the FcRn receptor, which protects IgG from proteolytic degradation (55).  Both 
inolimomab and mAbF19 are murine IgG mAbs (38, 39).  The rapid elimination of 
murine mAbs in humans has been attributed to the lack of binding of murine IgG to the 
human FcRn receptor (91).  No indication was given in the population PK analyses of 
inolimomab and mAbF19 if antibodies against these therapeutic mAbs were measured 
and/or detected (38, 39).  Considering that inolimomab and mAbF19 are murine mAbs, 
an immune response and formation of antibodies against the mAbs could be another 
potential reason for the larger clearance estimates compared to other therapeutic mAbs.  
HuCC49∆CH2 is a humanized IgG1 mAb, but is different in that it has a deletion in the 
constant heavy 2 domain to minimize immunogenicity (17).  The authors suggested that 
the increased clearance in HuCC49∆CH2 may have been due to the constant heavy 2 
domain deletion, which could have affected binding to the FcRn receptor (17).  This 
appears to be a valid argument as the FcRn receptor binds to a site on IgG formed 
between the constant heavy 2 and constant heavy 3 domains (10). 
 
The population PK of basiliximab has been investigated in patients with kidney 
(26) and liver (27) transplants, and the clearance in liver recipients was found to be larger 
compared to kidney receipients.  One likely explanation for the larger clearance in liver 
transplant patients is the additional route of basiliximab clearance through drained ascites 
fluid (27, 92). 
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Apparent clearance (CL/F) was estimated in the population PK analyses of 
omalizumab, efalizumab, and ustekinumab (Table 1-4), which have an F following SC 
dosing of around 62%, 50%, and 57%, respectively (33, 41, 47).  After adjusting for F, 
the clearance of omalizumab, efalizumab, and ustekinumab, are approximately 0.11, 
0.65, and 0.27 L/day, respectively.  The between-subject variability in CLL and CLT, 
much like the variability in Vmax, was moderate to large with estimates ranging from 20-
59 %CV. 
 
 
Covariates 
 
Identified covariates in population analyses of therapeutic mAbs and their 
estimated effects on PK parameters are presented in Table 1-5.  Covariates were 
commonly identified for the PK parameters Vmax, CLL, CLT, and V1.  No covariates were 
found to influence Km, which is not unexpected.  As Km reflects the intrinsic affinity of 
the mAb to its target, commonly evaluated covariates such as those related to 
demographics, size measurements, and blood chemistry/hematology labs would not be 
expected to have an effect on Km.  Polymorphic expression of the target could 
theoretically have an effect on the Km, but this type of genetic information has not been 
incorporated into any population PK models published to date for therapeutic mAbs.  
Polymorphic expression in the gene that encodes the FcγIIIa receptor (FCGR3A) has 
been associated with better clinical and/or biological response in non-Hodgkin’s 
lymphoma patients treated with rituximab (93, 94), Crohn’s disease patients treated with 
infliximab (95), and patients with breast cancer receiving trastuzumab therapy (96). 
 
 
Demographic and Anthropometric Measurements 
 
Size covariates are probably the most frequently identified and clinically relevant 
covariates in population PK analyses, and are well established as predictors of systemic 
exposure for small-molecule drugs as well as therapeutic mAbs (13).  Based on the 
findings summarized in Table 1-5, measures of body size were clearly the most 
commonly identified covariates found to influence the PK of therapeutic mAbs.  This is 
not surprising since PK parameters such as clearance and volume are often functions of 
body size (97).  Measures of body size that were frequently evaluated as covariates 
include body weight (WGT), ideal body weight (IBW), and body surface area (BSA).  
Common practice in the mAb population PK analyses was to evaluate different size 
covariates during the covariate modeling process to identify which, if any, were the most 
influential and should remain in the model.  Of the different measures of body size, WGT 
was the most common size covariate included in the final population PK model (Table 
1-5).  In most studies, the effect of body size on a PK parameter was modeled using a 
power function and the exponent in the function was treated as an estimable parameter.  
However, in a population PK analysis of HuCC49∆CH2 in colorectal cancer patients, the 
exponent was fixed to commonly used allometirc values of 0.75 for clearance terms and 
1.0 for volume terms (17). 
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The use of fixed dosing versus body size-based dosing for therapeutic mAbs in 
adults was recently addressed by Wang et al. (98).  A simulation study was carried out 
using published population PK and/or PD models for 12 therapeutic mAbs, and the 
performance of the two dosing strategies in reducing PK and/or PD variability was 
investigated.  The two dosing approaches performed similarly across the 12 mAbs 
investigated with fixed dosing being better for some mAbs and body size-based dosing 
for others.  Based on the findings, the authors recommended using fixed dosing in first-
in-human studies, and once sufficient data is available to assess the effect of body size on 
the PK/PD of the mAb, these findings can be used in part to determine the appropriate 
dosing strategy for subsequent phase 3 studies (98). 
 
Other demographic variables besides body size that were often evaluated as 
covariates included age, gender, and race.  Even after adjusting for body size, gender was 
identified as a predictor of CLL, CLT, and V1 in a small number of studies (Table 1-5).  
The effect of gender on the PK of ustekinumab and infliximab was relatively small and 
not considered to be clinically relevant (36, 47).  In the population PK analyses of 
bevacizumab and rituximab, the evaluation of gender as a covariate found that males had 
a larger CLT and V1 (values ranged from 17%-39% larger) (28, 44).  However, based on 
the prescribing information for these two mAbs, no dose adjustments for gender are 
recommended based on similar efficacy and safety profiles in males and females (99, 
100).  Race was evaluated as a covariate in a number of population PK studies including 
bevacizumab (28), cetuximab (29), pertuzumab (43), and alemtuzumab (23), but was not 
found to influence the PK of any of these mAbs.  The percentage of non-Caucasian 
patients was small in many studies, and may have precluded the ability to identify any 
possible differences between race groups.  In population PK studies of infliximab (36) 
and golimumab (34) race was not investigated as a covariate because most patients were 
Caucasian.  The only study where race was identified as a covariate was a population PK 
analysis of ustekinumab in psoriasis patients (47).  The V1/F for ustekinumab was found 
to be 11.1% lower in non-Caucasian patients versus that for Caucasians, but this was not 
considered to be clinically relevant.  Age was identified as a covariate in only the 
population PK analyses of efalizumab and panitumumab (33, 42).  Age was found to 
have an opposite effect in the two studies, as age was positively correlated with CL/F in 
the efalizumab analysis, and in the panitumumab analysis age was negatively correlated 
with Vmax. 
 
 
Receptor Number and Disease-Related Factors 
 
As many therapeutic mAbs undergo receptor-mediated endocytosis following 
binding to their target, it can be expected that the number of receptors within the 
distribution space of the mAb would affect its clearance.  Covariates related to receptor 
number may include flow cytometry measurements (e.g., receptor density and receptor-
positive cell counts) and analysis of biopsy samples using immunohistochemistry or 
fluorescence in situ hybridization.  Patient status and disease severity could also be 
related to receptor number, as one could hypothesize that for some conditions a patient 
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with more severe disease would have a higher receptor expression.  Time or duration of 
treatment is another variable that may be related to receptor number if administration of 
the therapeutic mAb results in down modulation of its target over time. 
 
Omalizumab and efalizumab are excellent examples where the effect of target-
mediated elimination was accounted for using a more complex mechanistic-based 
population PK/PD model (35, 41).  Similarly, a population PK/PD analysis in patients 
with B-cell chronic lymphocytic leukemia found that alemtuzumab exhibited nonlinear 
clearance attributable to saturation of target-mediated clearance mechanisms (23).  The 
only covariate found to influence the PK of alemtuzumab was white blood cell (WBC) 
count, which was a strong positive predictor of Vmax.  This could be expected as 
alemtuzumab targets CD52, an antigen present on the cell surface of WBCs including 
lymphocytes and monocytes.  The WBC count for each patient was updated over time 
when possible, and WBC counts were shown to generally decrease following repeated 
administration of alemtuzumab.  Therefore, alemtuzumab exhibited both time- and 
concentration-dependent clearance (23).  An interesting use of time as a covariate was 
applied in a population PK analysis of rituximab in patients with non-Hodgkin’s 
lymphoma (101).  The authors hypothesized that an observed increase in rituximab half-
life over time was due to a decrease in clearance as B cell (CD19+) count and/or tumor 
burden also decreased.  The PK of rituximab was described using a two-compartment 
model with two clearance pathways, where the clearance of one pathway remained 
constant while the other clearance decreased over time as a first-order process.  A 
covariate analysis found that patients with higher CD19 counts or larger measurable 
tumor lesions at baseline had a larger initial time-varying clearance (101). 
 
Trastuzumab is a humanized IgG1 mAb that targets the human epidermal growth 
factor receptor 2 (HER2).  The extracellular domain (ECD) of HER2 can be shed from 
the cell surface into the systemic circulation (soluble antigen), thereby providing an 
additional site for trastuzumab binding (46).  In a population PK analysis of trastuzumab 
in patients with HER2 positive metastatic breast cancer, several variables were 
investigated as potential covariates including HER2 overexpression by 
immunohistochemistry (IHC), number of metastatic sites, and serum concentrations of 
the ECD of HER2 (46).  All of the covariates were baseline values, hence no time-
varying covariates were used.  The number of metastatic sites was identified as the most 
influential covariate on clearance, which was 22% higher in patients with four or more 
sites.  The baseline concentration of ECD was found to positively influence both CLT and 
V1.  Patients with ECD concentrations of 200 ng/ml or greater had a 14% and 40% larger 
CLT and V1, respectively, compared to patients with a median ECD concentration of 8.23 
ng/ml.  The impact of ECD levels on the CLT of trastuzumab is in line with nonclinical 
studies that suggested that the trastuzumab-ECD complex has a higher clearance than 
unbound trastuzumab (46).  Potential reasons why ECD had an effect on V1 were not 
addressed in the paper.  HER2 overexpression based on IHC was not retained in the final 
model as a significant covariate. 
 
According to the prescribing information for bevacizumab, a population PK 
analysis found that patients with a high tumor burden (at or above the median value of 
 37
tumor surface area) had a clearance of 0.249 L/day versus 0.199 L/day in patients with 
tumor burdens below the median (99).  Tumor burden could not be evaluated as a 
covariate in a recently published population PK analysis of bevacizumab, because data 
was not available in all of the clinical trials included in the analysis (28).  However, 
albumin and alkaline phosphatase were found to positively influence the clearance of 
bevacizumab, and both were correlated with tumor burden in this study.  Assessments of 
physical performance and disease severity using scoring systems such as the Karnofsky 
performance scale, Psoriasis Area and Severity index (PASI), and Bath Ankylosing 
Spondylitis Disease Activity index, are commonly evaluated as covariates in population 
PK studies of mAbs used in areas of oncology and immunology (29, 36, 40, 46).  The 
only study to identify one of these scoring systems as a covariate was a population PK 
analysis of efalizumab, where PASI was found to have a modest effect on CL/F (33). 
 
 
Pharmacokinetic Drug Interactions 
 
Pharmacokinetic drug-drug interactions between therapeutic mAbs and 
conventional small-molecule drugs are usually not expected, since mAbs are presumably 
not substrates for cytochrome P-450 enzymes or drug transporters such as P-glycoprotein.  
As such, many of the clinical PK drug interaction studies that have been conducted 
between therapeutic mAbs and small-molecule drugs did not identify any interaction 
(102).  However, there have been a small number of clinical studies where small-
molecule drugs were found to have an effect on the PK of the mAb or vice versa (102).  
Since therapeutic mAbs are often administered with other treatments, concomitant 
medication was evaluated as a potential covariate in several of the population PK 
analyses.  In all but one of the studies, concomitant medication was not found to 
influence the PK of the mAb.  Examples of mAbs where concomitant medication was not 
identified as a covariate in the population PK analysis include cetuximab (29), rituximab 
(44), trastuzumab (46), and infliximab (36).  Concomitant chemotherapy was identified 
as a covariate in a population PK analysis of bevacizumab (28).  The clearance of 
bevacizumab when administered with the bolus-IFL (irinotecan/5-
fluorouracil/leucovorin) regimen was 17% lower compared to all other concomitant 
chemotherapy regimens combined, however, bevacizumab clearance when administered 
as monotherapy did not differ from that when administered with the bolus-IFL regimen.  
The effect of the concomitant chemotherapy on the clearance of bevacizumab was 
minimal and does not likely necessitate any dosage adjustments. 
 
 
Dosage Level 
 
A therapeutic mAb may be known to exhibit nonlinear clearance based on prior 
PK studies, but the concentration data available in a current population PK analysis may 
not support a more complex PK model with nonlinear clearance.  However, if 
concentration data in the population analysis is available from multiple dose groups, the 
nonlinear clearance of the mAb could be accounted for in part by evaluating dose as a 
predictor of clearance.  Such an approach was taken in a population PK analysis of 
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efalizumab in psoriasis patients who received weekly SC doses of 1 mg/kg or 2 mg/kg 
(33).  Efalizumab has been shown to exhibit nonlinear clearance attributable to saturation 
of target-mediated elimination mechanisms (35), and accordingly, various one-
compartment models with linear, nonlinear, and parallel linear and nonlinear elimination 
pathways were evaluated in the study (33).  A one-compartment model with linear 
elimination was found to adequately describe the PK of efalizumab, as the limited 
concentration data did not support the PK models with nonlinear elimination.  Dose was 
investigated as a covariate on CL/F, and it was found that patients in the 2 mg/kg group 
had a 24% lower CL/F versus patients in the 1 mg/kg group.  Dose group was also found 
to be a predictor of clearance in a population analysis of the mAb ING-1 in patients with 
advanced adenocarcinomas (103).  The PK of ING-1 was investigated across four IV 
dose levels ranging from 0.03 to 1.0 mg/kg.  The clearance of ING-1 was noted to 
decrease as the dose was increased, but the data did not support a PK model with 
nonlinear elimination.  Therefore, a one-compartment model with linear elimination was 
selected with dose included as a covariate on clearance.  The clearance of ING-1 
decreased from 56.7 to 21.8 mL/kg/day in the 0.03 mg/kg and 1.0 mg/kg dose groups, 
respectively. 
 
For a therapeutic mAb that exhibits nonlinear PK due to saturable target-mediated 
mechanisms, the ability to detect and adequately characterize the nonlinearity in a 
population analysis is largely dependent on the availability of concentration-time data 
from a wide range of doses.  However, as often encountered in drug development, 
concentration-time data may only be available from clinical studies where the doses 
studied (which may be clinically and therapeutically relevant) are high enough to saturate 
the nonlinear target-mediated elimination of the therapeutic mAb, thereby making it 
difficult to detect and characterize the nonlinear PK.  In such a case, if the population PK 
model is to be used for describing/predicting concentrations at doses where the nonlinear 
elimination pathway is at or near saturation, then using a PK model with linear 
elimination would be a reasonable approach as the Fc-mediated elimination pathway 
becomes the major determinant of the mAb clearance (see Figure 1-2B).   
 
 
Immunogenicity 
 
As therapeutic mAbs are exogenous proteins, they can elicit an immune response 
resulting in the formation of endogenous antibodies against the mAb.  The 
immunogenicity of a therapeutic mAb can be influenced by several factors including the 
structure and murine content of the antibody, immune status of the patient (e.g., 
immunocompetent or immunosuppressed), dose level, dosing frequency, and dosing route 
(104).  The formation of antibodies as the result of an immune response can have a 
significant effect on the PK, efficacy, and safety of a therapeutic mAb (104, 105).  A 
population PK analysis of infliximab in patients with ankylosing spondylitis found that 
patients positive for antibodies against infliximab had a 42% higher clearance than the 
remaining patients (36).  However, when concentrations below the lower limit of 
quantification (LLOQ) were imputed as one-half of the LLOQ (originally these values 
were removed from the dataset), patients positive for antibodies against infliximab had a 
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77% higher clearance.  The influence of antibody formation on the clearance of 
infliximab was found to have a much more pronounced effect in a population analysis 
conducted in patients with inflammatory bowel disease (22).  In this study, patients with 
antibodies against infliximab had an approximately 170% higher clearance versus other 
patients.  Another population PK analysis of infliximab in patients with ulcerative colitis, 
found that patients who developed antibodies against infliximab had a 47% higher 
clearance than those who did not (37).  The formation of antibodies was also identified as 
an important covariate in a population PK analysis of ustekinumab, where psoriasis 
patients with a positive immune response had a 36% higher CL/F (47). 
 
 
Blood Chemistries 
 
Blood chemistry tests related to hepatic and renal function were often evaluated as 
potential covariates in the population PK analyses, but were rarely identified as 
covariates.  In the population PK analyses of pertuzumab (43), bevacizumab (28), and 
ustekinumab (47) blood chemistries were found to influence the PK of the mAb (Table 
1-5).  The effect of blood chemistries on CLT and V1 in these studies was in general 
minimal and not likely to be clinically relevant.  It should be noted that in many of the 
population PK analyses the effect of marked hepatic and renal impairment could not be 
sufficiently evaluated, because patients included in the studies typically had adequate 
hepatic and renal function.  A population PK analysis of infliximab in patients with 
ulcerative colitis found albumin to be a negative predictor of CLT (37).  Similar 
observations were made in population PK studies of pertuzumab and ustekinumab (43, 
47).  In addition to IgG, the FcRn also binds and protects albumin from intracellular 
catabolism, thereby playing an important role in the homeostasis of both IgG and albumin 
(72, 106).  The authors of the infliximab analysis suggested that a higher albumin 
concentration could be an indicator of an increased number of FcRn and a related 
reduction in the rate of infliximab elimination (37). 
 
 
Disease and Comorbidities 
 
Only a small number of population PK studies investigated the effect of disease or 
comorbidities on the PK of the mAb.  The potential effect of disease on the PK of 
infliximab was investigated in a population analysis of patients being treated for either 
Crohn’s disease or ulcerative colitis (22).  No difference in the PK of infliximab was 
observed between patients with Crohn’s disease (n=30) and ulcerative colitis (n=3), but 
the small number of patients with ulcerative colitis may have precluded the ability to 
detect a possible difference.  A number of comorbidities including diabetes, hypertension, 
and hyperlipidemia, were investigated as covariates in a population PK analysis of 
ustekinumab in psoriasis patients (47).  This study found that patients with diabetes had a 
28.7% and 13.2% higher CL/F and V/F for ustekinumab, respectively.  The reason 
behind the effect of diabetes on the PK of ustekinumab is uncertain, but the authors 
suggested that altered lymphatic flow and particle transport, altered capillary 
permeability, increased interstitial fluid volume, and accelerated clearance of the 
 40
antibody resulting from increased glycation could be potential mechanisms (47).  Based 
on efficacy and safety data, the authors did not recommend that dose adjustments be 
made for diabetes.  The potential effect of cancer type was investigated in a population 
PK analysis of panitumumab in cancer patients with various solid tumors (42).  Patients 
with non-small cell lung cancer or other types of cancer had a smaller CLL (~13-14%) 
compared to patients with colorectal or renal cancer (42).  The reason for the difference 
in CLL between the different types of cancer is uncertain and was not addressed by the 
authors. 
 
 
Residual and Interoccasion Variability 
 
 Residual variability in most of the population PK studies was modeled using 
either a proportional or a combined additive and proportional error model.  In a few 
studies, an exponential error model was used to describe residual variability (29, 31, 35).  
Estimates of residual variability from the mAb population PK studies are summarized in 
Table 1-6.  Residual variability in the population PK analyses tended to be small to 
moderate.  Based on the values in Table 1-6, the median (range) proportional residual 
error across all of the studies was 21.2 %CV (8.8-42).  The proportional residual errors 
were relatively comparable across the different studies, while the additive residual errors 
were notably different.  The additive component of a residual variance model often 
corresponds to the lower limit of quantification of an assay.  Therefore, the large 
differences in the additive residual errors may be due in part to the different analytical 
assays used for different mAbs. 
 
 Residual variability can be dependent on a number of patient or study related 
factors, and these can be incorporated into the residual variance model as covariates (13).  
In most of the mAb population PK analyses, a simple residual error model with no 
covariates was used.  However, in a population PK analysis of cetuximab, separate 
residual error models were used for the two clinical studies included in the analysis (29).  
This was done because of the unbalanced sampling design of the two studies (i.e., 
extensive versus sparse sampling), and their performance in different clinical settings. 
 
 In addition to between-subject and residual variability, another source of random 
variability that can be incorporated into the population PK model is interoccasion 
variability (IOV).  The inclusion of IOV on model parameters was investigated for only a 
few mAbs.  In a recent population PK analysis of matuzumab, IOV was included on CLL 
(40).  Each infusion of matuzumab (up to the eighth infusion) was defined as one 
occasion.  Interoccasion variability in CLL was 23 %CV; however, this was very close to 
the estimated between-subject variability in CLL of 24 %CV.  The incorporation of 
interoccasion variability was also found to improve the model in a population PK 
analysis of sibrotuzumab (45).  Although sibrotuzumab was administered as an IV 
infusion, IOV was found to be best included in the disposition on F1 or the 
“bioavailability” in the central compartment.  Interoccasion variability in F1 was 13 
%CV, and was lower than between-subject variability in the PK parameters which ranged 
from 20-52 %CV. 
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Conclusion 
 
A review of the literature has shown that the population PK of different 
therapeutic mAbs are quite similar despite differences in their pharmacologic targets and 
being studied in different patient populations and disease states.  A two-compartment 
model was used in the majority of the population analyses to describe the disposition of 
the mAb.  Population estimates for V1 and V2 were typically small with a median (range) 
of 3.1 L (2.4-5.5) and 2.8 L (1.3-6.8), respectively.  The estimated between-subject 
variability in V1 was usually moderate with a median (range) of 26 %CV (12-84).  
Between-subject variability in other distribution related parameters such as V2 and Q 
were often not estimated. Although the most frequent PK models used in the population 
analyses were models with linear elimination, other models with nonlinear or parallel 
linear and nonlinear elimination pathways were also applied as many therapeutic mAbs 
are eliminated via saturable target-mediated mechanisms.  Population estimates of Vmax 
and Km, the parameters characterizing Michaelis-Menten-type saturable elimination 
pathways, varied considerably among the different therapeutic mAbs.  However, 
estimates for CLT in mAbs with linear elimination characteristics and CLL in mAbs with 
parallel linear and nonlinear elimination were quite similar among the different mAbs and 
typically ranged from around 0.2-0.5 L/day, which is relatively close to the estimated 
clearance of endogenous IgG of 0.21 L/day.  The between-subject variability in Vmax, 
CLT, and CLL was moderate to large with estimates ranging from 15-65 %CV.  Measures 
of body size were the most commonly identified covariates found to influence the PK of 
therapeutic mAbs. 
 
The similarities in the population PK of therapeutic mAbs are likely in part due to 
general structural features that are shared among most therapeutic mAbs as IgG 
molecules such as a functional human Fc region.  One could hypothesize that target-
binding specific PK parameters such as Vmax and Km are likely to be influenced by the 
interaction between a given therapeutic mAb and its target and thus show high variability 
among different mAbs, while the differences among parameters such as CLL, V1, V2, and 
Q that are thought to be largely affected by the general structural features of mAbs are 
minimal.  In fact, the biggest differences observed in the population PK between the 
considered mAbs were for population estimates of Vmax and Km.  For the most part, no 
significant differences were observed in the population PK of murine, chimeric, 
humanized, and fully human therapeutic mAbs.  The most notable difference observed 
between the different classes of mAbs was the larger population clearance estimates for 
the murine mAbs. 
 
The PK characteristics of mAbs are very dissimilar compared to traditional small-
molecule drugs (11, 79), and tend to be more complex as mAbs often exhibit target-
mediated drug disposition and nonlinear PK (4), which is oftentimes species-dependent 
and substantially complicates extrapolation of mAb PK characteristics from animal 
models to humans.  When analyzing the population PK of a mAb it is therefore not only 
important to have a general understanding about the PK of mAbs, but to also understand 
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the biology and pharmacology of the system.  The complex PK characteristics of mAbs 
pose a significant challenge to a pharmacometrician performing a population PK analysis, 
as complex models are often evaluated to describe the mAb’s PK, and the use of such 
models may be further complicated by limited concentration data.  However, the similar 
population PK profiles of different therapeutic mAbs are an aspect of this class of 
biologics that can be used to the advantage of a more informed data analysis.  The results 
of the studies summarized herein should be of value as they provide a general concept of 
what to expect with regard to applicable structural PK models, commonly identified 
covariates, and plausible estimates for typical population estimates, covariate effects, 
between-subject variability, and residual variability, which could be used for example to 
aid in choosing initial estimates or setting parameter boundaries.  The compiled results 
from the population PK studies could also serve a more practical purpose and be used to 
construct informative priors for a Bayesian data analysis or for constructing parameter 
uncertainty distributions to simulate PK data for a prototypical therapeutic mAb.  The 
ability to include prior information could prove to be particularly useful for mAbs as they 
often exhibit complex PK, and the use of complex PK models (e.g., parallel linear and 
nonlinear elimination pathways) may not be fully supported by available concentration 
data in datasets with sparse sampling and/or a limited number of dosage groups. 
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CHAPTER 2.  RESEARCH HYPOTHESES 
 
 
 Cetuximab is a therapeutic mAb directed against EGFR and is indicated in the 
treatment of squamous cell carcinoma of the head and neck (SCCHN).  The PK of 
cetuximab has been well characterized in phase I studies indicating that it exhibits 
nonlinear elimination, but these studies have mainly been limited to noncompartmental 
analyses (80, 81, 107), and the population PK of cetuximab has not been published in the 
literature except in abstract format for an analysis conducted for regulatory purposes 
(108, 109).  I hypothesized that (I) nonlinear mixed effects modeling can be used to 
develop a population PK model that could adequately predict the systemic exposure of 
cetuximab in patients with SCCHN.  Furthermore, I hypothesized that (II) covariates can 
be identified that are significant predictors for cetuximab systemic exposure. To address 
these hypotheses, I obtained cetuximab concentration-time data from two clinical trials in 
patients with SCCHN (110, 111), and a population PK analysis of the data with covariate 
analysis was carried out in Chapter 3. 
 
 The population PK analysis found that the PK of cetuximab was best described 
using a two-compartment model with nonlinear elimination.  During the analysis, a 
number of issues and challenges were encountered which were likely the result of an 
attempt to describe this nonlinearity.  The difficulty characterizing the nonlinear 
elimination of cetuximab was likely due to limitations of the clinical study designs, but 
may also have been due to the use of the FOCE estimation method in NONMEM 
throughout the analysis.  It is known that FOCE, in addition to the first-order (FO) and 
Laplacian (LAP) estimation methods in NONMEM, can be inaccurate when dealing with 
highly nonlinear models such as the PK model with nonlinear elimination used to 
describe the PK of cetuximab (112).  These estimation methods in NONMEM linearize 
the nonlinear mixed effects model (e.g., a population PK model) with regards to the 
between-subject random effects and then parameter estimates are obtained based on the 
linear approximation to the nonlinear model (13, 113).  Therefore, I hypothesized that 
(III) other parameter estimation methods that do avoid linearization lead to more accurate 
parameter estimates and better characterization of the nonlinear PK encountered with 
monoclonal antibodies such as cetuximab. 
 
 One available method for parameter estimation without linearization is a full 
Bayesian analysis using Markov Chain Monte Carlo (MCMC) methods such as that 
implemented in the software package WinBUGS (114).  One advantage of Bayesian 
MCMC methods over the FO, FOCE, and LAP methods in NONMEM is that the 
Bayesian MCMC methods do not rely on analytical approximations of the nonlinear 
mixed effects model, but instead use Monte Carlo integration techniques to obtain 
parameter estimates for the exact model (115, 116).  Another advantage of Bayesian 
MCMC methods is the ability to include prior knowledge about the model parameters 
into the Bayesian model. 
 
 Nonlinear elimination is a common characteristic of the PK of therapeutic mAbs 
(6, 8), and accordingly, PK models with nonlinear elimination were used in almost half of 
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the population PK analyses of therapeutic mAbs published in the scientific literature 
(Table 1-1).  Therefore, the question of how well other population estimation methods 
perform in evaluating the nonlinear elimination of cetuximab is also relevant for other 
therapeutic mAbs.  This notion is supported by the fact that similar difficulties 
encountered during the cetuximab analysis were also reported in population PK analyses 
of other therapeutic mAbs (Chapter 1). 
 
 To address my third hypothesis, I conducted a simulation study comparing the 
parameter estimation performance of the FO, FOCE with interaction (FOCE-I), and LAP-
I methods in NONMEM and a Bayesian MCMC method in WinBUGS when applied to 
population PK modeling of therapeutic mAbs with nonlinear PK.  The Bayesian MCMC 
method was evaluated with uninformative and informative priors, which were obtained 
from population PK analyses of therapeutic mAbs in the literature.  I evaluated the 
estimation methods under a dose-ranging design (informative study design) and four 
different single dose level designs at different dose levels (uninformative study designs).  
I made the following three subhypotheses: (IIIa) Under all study designs the FO method 
is less accurate and precise compared to the other estimation methods; (IIIb) When 
sufficient data is available to characterize the nonlinear PK of the therapeutic mAb, as in 
the case of the informative design, the estimation performance of FOCE-I, LAP-I, and 
Bayesian MCMC (with both sets of priors) is adequate and comparable for all methods; 
(IIIc) Under the less-than-optimal (uninformative) study designs the estimation 
performance of the FOCE-I and LAP-I methods declines compared to the informative 
study design, while the formal inclusion of prior information with the Bayesian MCMC 
method provides a clear performance advantage over the other methods. 
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CHAPTER 3.  POPULATION PHARMACOKINETICS OF CETUXIMAB IN 
PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND 
NECK* 
 
 
Introduction 
 
Cetuximab is a recombinant, human/mouse chimeric IgG1 mAb that binds 
specifically to the extracellular domain of the human EGFR (also known as ErbB-
1/HER1) (117).  By binding to EGFR, cetuximab prevents the binding of endogenous 
ligands such as epidermal growth factor and transforming growth factor-α (118).  This 
blockade prevents EGFR signaling which is intricately involved in multiple processes 
involved in tumor growth and metastasis, such as cell proliferation, cell differentiation, 
cell survival, cell migration, tumor angiogenesis, and DNA repair (119, 120).  Cetuximab 
can also induce internalization and subsequent degradation of EGFR, leading to 
downregulation of cell surface EGFR and a reduction in EGFR signaling (121, 122).  
Cetuximab is currently indicated in SCCHN and EGFR-expressing metastatic colorectal 
cancer (108).  It is approved as a single agent in both cancers, and in combination therapy 
with radiation therapy for SCCHN and with irinotecan for colorectal cancer. 
 
In early phase I studies, attempts to characterize the PK of cetuximab indicated 
that it exhibits nonlinear or Michaelis-Menten type elimination (81, 123).  This 
nonlinearity was attributed to saturation of the EGFR-mediated endocytosis of 
cetuximab, a clearance pathway that entails internalization and degradation of the 
EGFR/cetuximab complex (80).  While this nonlinear elimination pathway seems to be 
largely saturated at therapeutic concentrations, a second, nonspecific elimination pathway 
that is not saturable at therapeutic concentrations seems to be the major determinant for 
cetuximab elimination during therapy with approved cetuximab doses (109).  The 
resulting elimination half-life estimates at therapeutic concentrations range between 66 
and 97 hr at the approved dosing regimen of 400 mg/m2 initial dose followed by weekly 
doses of 250 mg/m2, but increase from 33.3 to 119.4 hr after single cetuximab doses of 
20 to 500 mg/m2 (109). 
 
Although cetuximab concentrations have been correlated with antitumor activity 
(124), most reports on cetuximab PK have been limited to noncompartmental analyses, 
and the population PK of cetuximab has not been published in the literature except in 
abstract format for an analysis conducted for regulatory purposes (108, 109). 
 
Thus, this chapter describes a population PK analysis based on data from two 
clinical trials in patients with SCCHN.  The objectives of this analysis were 1) to 
determine the typical population PK parameters for cetuximab and their between-subject 
variability, and 2) to identify covariates that are significant predictors for cetuximab  
 
*This chapter adapted with permission.  Dirks NL, Nolting A, Kovar A, Meibohm B. 
Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of 
the head and neck. J Clin Pharmacol 2008;48(3):267-78. 
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systemic exposure and to assess their potential implications for clinical dosing. 
 
 
Methods 
 
 
Study Design and Patient Population 
 
Cetuximab serum concentration-time data were obtained from two studies, EMR 
62202-008 (study A) and EMR 62202-016 (study B), that are described elsewhere in 
detail (110, 111).  Both studies were conducted in compliance with the Declaration of 
Helsinki and the Guidelines for Good Clinical Practice.  Written informed consent was 
obtained from all subjects. 
 
Study A was a randomized, multi-center phase I/II study (n=53) to evaluate the 
safety and tolerability of cetuximab (Erbitux®) in combination with platinum and 5-
fluorouracil (5-FU) as first-line treatment in patients with recurrent and/or metastatic 
SCCHN, and to evaluate the PK of cetuximab under coadministration with platinum 
(110).  Main inclusion criteria were stage III/IV recurrent or metastatic disease not 
suitable for local therapy, Karnofsky performance status ≥70, and adequate hematologic, 
liver, and renal function.  Cetuximab was administered as an initial dose of 400 mg/m2 
infused over 2 hours, followed by weekly doses of 250 mg/m2 given over 1 hour.  
Patients were randomized to receive either cisplatin 100 mg/m2 on day 2 of the 
chemotherapy cycle or carboplatin AUC 5 (target area under the curve of 5 mg/mL*min) 
on day 1 of the cycle.  5-FU was administered as a continuous infusion on day 1 for the 
duration of 120 hours at the assigned dose levels of 600, 800, and 1000 mg/m2/day.  
Chemotherapy (5-FU and platinum) cycles were repeated every 3 weeks.  The primary 
treatment phase duration was 6 weeks (2 cycles), but patients were allowed to continue 
with treatment if they benefited from the initial treatment phase.  Of the 53 patients 
enrolled into the study, 38 completed the primary treatment phase.  Peak and trough 
cetuximab concentrations were obtained at weeks 2-4 of therapy.  In addition to the peak 
and trough obtained on week 4, a full concentration-time profile was obtained with 
sampling at 3, 6, 10, 24, 48, 72, 96 and 168 hours after the start of cetuximab 
administration. 
 
Study B was a multi-center phase II study (n=103) to evaluate the efficacy and 
toxicity of cetuximab (Erbitux®) monotherapy in patients with platinum-refractory 
recurrent and/or metastatic SCCHN, and to investigate the PK of cetuximab (111).  Main 
inclusion criteria were stage III/IV recurrent or metastatic disease, a Karnofsky 
performance status ≥60, progressive disease documented by CT or MRI on platinum-
based therapy, and adequate hematologic, liver, and renal function.  Patients were to 
receive cetuximab as an initial infusion of 400 mg/m2 followed by weekly infusions of 
250 mg/m2 for at least six weeks, if possible.  If they responded to treatment or had stable 
disease, treatment was continued until disease progression, clinical deterioration, or 
unacceptable side effects were observed.  On occurrence of disease progression or 
clinical deterioration salvage treatment was offered with cetuximab (250 mg/m2 weekly) 
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plus the same platinum regimen the patient was on prior to receiving cetuximab 
monotherapy.  Of the 103 patients treated with cetuximab monotherapy, 53 subsequently 
received combination therapy.  Cetuximab peaks and troughs were obtained at weeks 1, 
4, and 6 during monotherapy.  If the patient entered the combination therapy phase, 
cetuximab peaks and troughs were obtained again at weeks 1, 4, and 6 after switching to 
combination therapy.  A sample was also taken at the end-of-study visit, which was up to 
six weeks after the last dose of cetuximab was administered.  The total study period 
ranged from 0.1 to 56 weeks with a median of 14 weeks. 
 
 
Assay Methodology 
 
Cetuximab serum concentrations were determined using a validated sandwich 
enzyme-linked immunosorbent assay (ELISA).  In brief, serum samples were diluted by a 
factor of 500 and added to microtiter plates coated with the extracellular domain of 
EGFR, which served as the capture antigen.  After incubation, plates were washed with 
buffer and further incubated with rabbit anti-human IgG conjugated with horseradish 
peroxidase, which binds to the cetuximab immobilized in the microtiter plates. Unbound 
conjugate was removed, and tetramethylbenzidine, a substrate for horseradish peroxidase, 
was added. Tetramethylbenzidine was oxidized to a colored product, the absorbance of 
which, was measured by a plate reader at 450 nm. This absorbance was directly related to 
the cetuximab concentration in the serum sample. The lower and upper limits of 
quantification were 0.5 ng/mL and 15 ng/ml for the diluted cetuximab samples, 
corresponding to 0.25 and 7.5 µg/mL for undiluted samples. Serum samples with higher 
concentrations of cetuximab were further diluted to fit into the linear calibration range. 
Accuracy of the assay was between 98.5 to 104%, the precision ranged from 2.2 to 6.3%. 
 
 
Population Pharmacokinetic Analysis 
 
The population PK analysis was performed by nonlinear mixed effects modeling 
using a NMQual (Metrum Institute, Augusta, ME) installation of NONMEM (version V, 
level 1.1; Icon Development Solutions, Ellicott City, MD) under Compaq Visual Fortran 
(version 6.5; Compaq Corporation, Houston, TX).  Xpose (125), Census (126), and S-
Plus (version 7.0; Insightful Corporation, Seattle, WA) were used for data management 
and visualization.  The FOCE method within NONMEM was used throughout the model 
building process (20).  Across the two studies, the majority of the concentration 
measurements were within the first 8 weeks of cetuximab therapy.  Therefore, the 
database was split with concentration data obtained during the first 8 weeks used for 
model building (‘the model building dataset’), and the remaining data for model 
qualification (‘the model evaluation dataset’).  Sampling times in the model evaluation 
data set ranged from week 10 to 43.  The structural model was evaluated using only the 
densely sampled data from study A.  The covariate model was subsequently built using 
data from both studies.  All concentration data was log transformed prior to the analysis, 
and the residual variance model was modified accordingly (transform-both-sides 
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approach).  Log transformation of the data stabilized the convergence of the structural 
models and resulted in shorter run times. 
 
Six structural models including one- or two-compartmental models with linear, 
nonlinear, or parallel linear and nonlinear elimination pathways were evaluated based on 
minimization of the Akaike Information Criterion (AIC) value, precision and plausibility 
of parameter estimates, and a number of goodness-of-fit plots.  The AIC was defined in 
terms of the objective function value (OFV) and number of parameters (p) in the model: 
AIC=OFV+2p.  Prior information about the PK of cetuximab from phase I and phase II 
trials, such as the presence of nonlinear elimination, was also taken into account while 
building the structural model. 
 
Between-subject variability in cetuximab PK parameters was assumed to follow a 
lognormal distribution, and was modeled according to an exponential error model.  
During the model building procedure, between-subject variability for parameters was 
assumed to be uncorrelated, and only the diagonal elements of the variance-covariance 
matrix were estimated.  Once the final model was determined, the addition of covariance 
terms was evaluated.  Due to the unbalanced sampling design of the two studies and their 
performance in different clinical settings, separate residual error models were used per 
study.  Residual variability was modeled using a log transformed exponential error 
model. 
 
Twenty-one potential covariates were evaluated.  The covariates were comprised 
of 1) demographic and anthropometric measurements: gender, age, ethnicity, WGT, IBW 
(127), BSA, and clinical study; 2) blood chemistry and hematology measurements: blood 
urea nitrogen, serum creatinine, creatinine clearance, total bilirubin, albumin, aspartate 
and alanine aminotransferases, and WBC count; 3) concomitant therapy and disease 
related factors: EGFR expression, presence of human anti-chimeric antibodies, 
concomitant platinum and/or 5-FU therapy, Karnofsky function score, and duration of 
cetuximab therapy.  Covariates were updated over time in the observation records for 
each patient when the respective data were available.  Before building the covariate 
model, all potential covariates were plotted against each other to identify any high 
intercorrelation, as to avoid simultaneous inclusion of correlated predictors (128). 
 
The covariate model was built using a stepwise forward addition/backward 
deletion modeling approach (129).  Inclusion of a covariate-parameter relationship was 
based on the likelihood ratio test.  The criteria for including a covariate in the model 
during the forward addition steps was a decrease in the OFV of 3.84 (p<0.05).  During 
the backward deletion steps, an OFV change of 10.83 (p<0.001) was required for a 
covariate to remain in the model.  A more stringent criterion was used during the 
backward deletion steps because of the multiple comparisons made during the forward 
portion of stepwise covariate modeling.  Covariate modeling was also guided by 
goodness-of-fit plots and changes in between-subject variability. 
 
A stratified approach to the univariate analysis was taken during the forward 
addition step of the covariate modeling, in that size covariates (IBW, WGT, BSA) were 
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first evaluated and included in the model.  Once the effect of size on cetuximab PK had 
been accounted for, the remaining covariates were evaluated in the model.  The stratified 
approach was taken as correlation often exists between size covariates and non-size 
covariates (e.g., gender and weight) (97).  Such correlations can mask covariate 
relationships, and lead to difficulties interpreting the effects of two correlated covariates.  
Stepwise backward deletion was conducted once the full model was established. 
 
Relationships between continuous covariates and PK parameters were modeled 
using linear proportional (Eq. 3-1) and power (nonlinear) models (Eq. 3-2) with the 
covariate (COV) normalized to the population median for the dataset.  Categorical 
covariates were modeled as shown in Eq. 3-3: 
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where the θ’s are the parameters to be estimated, and θ1 represents the typical value of a 
PK parameter (P) in an individual with the median value for the covariate. 
 
 
Model Qualification 
 
The ability of the final population PK model to adequately describe the observed 
data in the model building dataset was evaluated using a predictive check.  Cetuximab 
peak and trough concentrations at week 4 of therapy served as the metrics of interest.  
The final population PK model and parameter point estimates were used to perform 
Monte Carlo (parametric) simulations of the metrics of interest.  The model evaluation 
dataset with concentration data beyond week 8 was used to evaluate the ability of the 
final population PK model to predict cetuximab concentrations in an independent dataset.  
Nonparametric bootstrap analysis was used to evaluate the precision and stability of the 
final model parameter estimates.  Patients were randomly sampled with replacement from 
the model building dataset used for building the population PK model to create bootstrap 
datasets with the same sample size as the original.  A stratified sampling approach was 
used in that the ratio of patients from the two studies was kept constant. 
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Results 
 
 
Data 
 
A total of 143 patients provided evaluable PK data for the population analysis, 47 
from study A and 96 from study B.  Table 3-1 summarizes the demographics for these 
patients.  The majority of patients (138/143) had EGFR expressing tumors determined by 
immunohistochemical evaluation. The presence of human anti-chimeric antibodies was 
not detected in any of the patients participating in the two studies. 
 
The initial cetuximab dataset consisted of 1,142 concentration measurements.  
There were 86 baseline observations prior to the first cetuximab administration, which 
were defined as zero and removed from the dataset before log transformation.  After 
splitting the database into a model building and a model evaluation dataset, 912 
concentrations remained for building the population PK model, 530 from study A and 
382 from study B.  Due to the unbalanced sampling schedule between the two studies, 
study A patients contributed a median of 13 data points per individual, while study B 
patients contributed a median of 4 data points per individual. 
 
 
Structural Model 
 
Cetuximab serum concentrations were best described by a two-compartment 
model with nonlinear elimination, based on AIC values and goodness-of-fit plots. 
Compared to a one- or two-compartment model with linear elimination, the 
corresponding model with nonlinear elimination resulted in further reduction of the AIC 
value.  The goodness-of-fit plots indicated that the nonlinear model provided a better fit 
to lower concentrations (<75 µg/mL) than the linear model.  In addition, the results from 
prior PK studies supported the use of a nonlinear elimination model (80, 81, 123).  
Addition of a second, linear elimination pathway to the nonlinear model resulted in no 
change in the OFV.  The goodness-of-fit plots between the nonlinear model and parallel 
elimination model were very similar.  This lack of improvement in fit to the data with the 
parallel elimination model led to selection of the more parsimonious nonlinear model as 
the structural base model.  Regardless of the elimination pathways, a two-compartment 
model always provided a better fit to the data than a one-compartment model based on 
AIC values and goodness-of-fit plots.  The two-compartment nonlinear elimination 
model was parameterized in terms of Vmax, Km , V1, V2, and Q. 
 
The initial structural model was unable to account for between-subject variability 
in both Vmax and Km, even after addition of a covariance term for both parameters.  Based 
on the hypothesis that physiologically there should be more variability among individuals 
with regard to Vmax than Km, the Km parameter was treated as a fixed value across all 
subjects, which resulted in an OFV increase of only 0.3 points and improvement of the 
precision for the estimate of between-subject variability in Vmax.
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Table 3-1. Patient characteristics. 
 
Characteristics N Median Range 
Gender (male/female) 120/23   
Ethnicity (caucasian/unknown) 131/12   
Study (A/B) 47/96   
Concomitant 5FUa (yes/no) 47/96   
Concomitant platinuma (yes/no) 89/54   
Age  56 23-77 
Duration of cetuximab therapy (week)  6 1-54 
Weight (kg)  60 34-113 
BSA (m2)  1.7 1.2-2.2 
IBW (kg)  64.2 43.3-81.3 
White blood cell count (109/L)  6.8 1.7-41.8 
Blood urea nitrogen (mg/dl)  23 4-106 
Serum creatinine (mg/dl)  0.9 0.4-1.9 
Creatinine clearance (ml/min)  74 22-167 
Total bilirubin (mg/dl)  0.5 0.2-1.4 
Albumin (g/dl)  3.9 1.3-4.8 
Aspartate aminotransferase (U/L)  18 5-150 
Alanine aminotransferase (U/L)  14 1-64 
Karnofsky function score  80 60-100 
 
a. Patient received concomitant 5-fluorouracil (5-FU) or platinum chemotherapy at some 
point during the trial. 
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Once the base model was determined, data from study A and B were pooled 
together for the covariate modeling.  Separate residual error models were used for each 
study, which added stability to the minimization procedure and resulted in a change in 
objective function value (∆OFV) of -32.8, as well as a decrease in between-subject 
variability estimates for all parameters. 
 
 
Covariate Model 
 
The effect of covariates on cetuximab PK was first investigated for size measures 
with the purpose of identifying which, if any, are the most influential.  The ∆OFV 
indicated that linearly related IBW (∆OFV -29) was the most important size covariate for 
Vmax versus BSA (∆OFV -14) and WGT (∆OFV -9).  Inclusion of IBW reduced the 
between-subject variability in Vmax from 23.6% to 17.9% (%CV).  Based on ∆OFV, 
linearly related WGT was found to be the most important size covariate on both V1 and 
V2.  Inclusion of WGT on V1 resulted in a ∆OFV of -22.7, and a decrease in between-
subject variability for V1 from 21% to 18.3%.  Adding WGT as a covariate on V2 resulted 
in a ∆OFV of -9.7, and a decrease in between-subject variability for V2 from 54.1% to 
46.6%.  No effect of size covariates was identified for Q or Km. 
 
The remaining covariates were screened using general additive modeling (130) 
and plots of individual empirical Bayes estimates of the parameters versus each of the 
covariates.  The general additive modeling only identified WBC as a covariate on Vmax, 
while graphical analysis identified the same relationship as well as a potential effect of 
gender on Vmax, V1, and V2.  Modeling Vmax as a linear function of WBC resulted in a 
∆OFV of -37.0 and decreased the between-subject variability for Vmax further to 15.3%.  
No effect of gender was identified for Vmax (∆OFV -0.3) or V2 (∆OFV -2.4).  Adding 
gender as a covariate for V1 resulted in a ∆OFV of -6.4, but reduced the between-subject 
variability only from 18.7% to 17.8%.  The estimated difference in V1 between males and 
females was small (13.5% smaller V1 for females).  Subsequently, the effect of gender on 
V1 did not pass the criterion for backward deletion and was removed from the model.  
The effect of WGT on V2 was also removed during the backward deletion step, but all 
other covariates were retained in the model. The addition of covariance terms between 
Vmax and the volume parameters was investigated with the final model, but did not result 
in any improvement. 
 
The final population PK model and parameter estimates are presented in Table 
3-2.  The NONMEM control stream and run output for the final population PK model are 
included in Appendix A.  Goodness of fit plots for the final model are shown in Figure 
3-1, and model-predicted and measured cetuximab concentration-time profiles for 
representative patients are provided in Figure 3-2.  The estimates for Vmax and Km for a 
typical patient with median covariate values, as defined in the model, were 4.38 mg/hr 
and 74 µg/mL, respectively.  Between-subject variability in the parameters was relatively 
small for Vmax (15.4%) and V1 (18.6%), but was larger for V2 (56.4%) and Q (97.2%).  
IBW and WBC accounted for almost 35% of the total variability in Vmax, while WGT 
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Table 3-2. Final population pharmacokinetic model and its parameter estimates with bootstrap-derived 90% confidence intervals. 
 
Parameter Model  Parameter 
estimate 
Parameter 
90%CI 
BSV 
(%CV)a 
BSV 
90%CI 
Vmax [mg/hr] 
θ1 x (1+θ2 x (IBW-64) 
+θ3 x (WBC-6.8)) θ1 4.38 3.40, 6.64 15.4 12.0, 19.1 
  θ2 0.0108 0.0077, 0.0139   
  θ3 0.0216 0.0169, 0.0296   
Km [µg/mL] θ4 θ4 74 38.2, 163.3 ----b  
V1 [L] θ5 x (1+θ6 x (WGT-60)) θ5 2.83 2.69, 2.96 18.6 12.5, 22.2 
  θ6 0.0083 0.0057, 0.0115   
V2 [L] θ7 θ7 2.43 1.95, 2.85 56.4 18.0, 72.8 
Q [L/hr] θ8 θ8 0.103 0.062, 0.191 97.2 40.2,  133 
       
Residual variability (%CV)a [90%CI]:   Study A:  14.6  [12.3, 16.8] 
                                                                Study B:  21.2  [18.8, 23.7] 
 
CI = confidence interval; BSV = between-subject variability; IBW = ideal body weight (kg); WBC = white 
blood cell count (109/L); WGT = body weight (kg). 
a. Approximate %CV calculated as 1002   where ω2 is the between-subject variance estimate. 
b. BSV not estimated for Km. 
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Figure 3-1. Goodness-of-fit plots for the final model.  Plot of population and individual predicted versus observed cetuximab 
concentrations and plot of conditional weighted residuals versus population predicted concentrations and time (days). 
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Figure 3-2. Cetuximab serum concentration-time profile in six representative patients (patient ID indicated) over a period of 28 
days after initiation of therapy with a dose of 400 mg/m2, followed by weekly doses of 250 mg/m2.  Measured serum concentrations 
are indicated by open circles, model-based population and individual predicted concentration-time profiles by dashed and solid lines, 
respectively. 
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accounted for approximately 10% of the variability in V1.  The estimate of the 
proportional residual variance for study A (14.6%) was less than that for study B 
(21.2%), which may be attributed to the highly unbalanced sampling designs of the two 
studies. 
 
 
Model Qualification 
 
The precision of model parameter estimates was assessed by 500 nonparametric 
bootstrap replicates.  As shown in Table 3-2, the 90% confidence intervals were 
relatively tight and indicated good precision of most parameter estimates.  The median 
population estimates obtained from the nonparametric bootstrap were generally within 
5% of the estimates from the final model (data not shown), indicating that the final 
population model was stable. Furthermore, the 95% confidence intervals for the covariate 
effects did not overlap with zero, indicating the statistical significance of the covariates 
included in the final model. 
 
The model was further evaluated using a predictive check for the model building 
dataset and simulation of concentrations in the model evaluation data set.  For both model 
qualification methods, 500 Monte-Carlo simulated datasets were created and compared to 
the observed peak and trough concentrations at week 4 for the model building dataset 
(Figures 3-3 and 3-4) and beyond week 8 for the model evaluation dataset (Figure 3-5), 
respectively.  The model adequately described general tendencies of peak and trough 
concentrations and the between-subject variability of peaks at week 4 in the model 
building data set (Figures 3-3 and 3-4) and beyond week 8 of therapy in the model 
evaluation data set (Figure 3-5).  Figure 3-3, however, indicates that the model 
overpredicted the between-subject variability in trough concentrations at week 4 at the 
lower concentrations, suggesting that one or more of the variance components of the 
model were over-estimated.  This is reflected in Figures 3-4 and 3-5 where less than 10% 
of the trough observations fell outside the simulated 90% prediction interval. 
 
For the model evaluation dataset, the median prediction error and median absolute 
prediction error were calculated using the individually predicted and observed 
concentrations beyond week 8.  The median prediction error was -0.1% and 0.3% and the 
median absolute prediction error was 2.9% and 6.8% for peak and trough concentrations, 
respectively, indicating that the predictions were generally unbiased and relatively 
precise. 
 
 
Discussion 
 
Therapeutic mAbs often exhibit nonlinear PK presumably attributable to target-
mediated elimination pathways via interaction with their antigen (6).  The binding of 
cetuximab to the membrane receptor EGFR presents a specific, saturable elimination 
mechanism by which the cetuximab/EGFR complex is internalized and either degraded 
or recycled with recurrence of the receptor at the cell surface (109).  This receptor-  
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Figure 3-3. Results of the predictive check for peak and trough concentrations at week 
4 of therapy.  The histogram plot shows the distribution of peak (top panel) and trough 
(bottom panel) quartiles (Q1: 25th percentile; Q2: median; Q3: 75th percentile) for 500 
simulated datasets, and the vertical lines indicate the quartiles for the observed data.  The 
z-value represents the fraction of the quartiles of the simulated data that are larger than 
the corresponding observed quartile. 
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Figure 3-4. Scatterplot of the results from the predictive check of peak and trough 
concentrations at week 4 of therapy in the model building dataset.  The solid lines 
indicate the peak and trough 5th, 50th, and 95th percentiles determined from all 500 
simulated datasets.  Observed data is plotted as individual points. 
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Figure 3-5. Results of the simulation of concentrations in the model evaluation dataset 
beyond week 8 of therapy.  The solid lines indicate the peak and trough 5th, 50th, and 95th 
percentiles determined from all 500 simulated datasets.  Observed data is plotted as 
individual points. 
 
Beyond Week 8 Trough Beyond Week 8 Peak 
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mediated endocytosis likely contributes a significant portion to the total clearance of 
cetuximab, given that EGFR is widely expressed in a variety of tissues.  Panitumumab, 
another mAb targeted towards EGFR, also exhibits nonlinear PK attributed to saturation 
of EGFR-mediated clearance (131).  The effect of target-mediated clearance on 
therapeutic mAbs has also been observed for other membrane targets (8, 30). 
 
The saturable, nonlinear PK of cetuximab has been well characterized in phase I 
studies (80, 81, 123), where cetuximab clearance was shown to decrease with increasing 
doses in the range of 20 to 200 mg/m2.  Likewise, in the current population analysis, I 
found that a two-compartment model with nonlinear elimination provided the best fit to 
the data.  Phase I studies also showed that at doses of 200 mg/m2 and greater (up to 500 
mg/m2), the estimated clearance for cetuximab levels off (80, 81, 109).  The biphasic 
nature of cetuximab clearance versus dose suggests the presence of a nonsaturable first-
order process in parallel to the EGFR-mediated elimination described above (109).  This 
nonspecific linear elimination process is common for all antibodies, and is likely due to 
slow proteolytic degradation from interaction between the Fc region of the antibody and 
Fc-receptors on hepatic cells or cells of the reticuloendothelial system (8, 109).  An 
attempt was made to model this parallel elimination process by building a model with 
both linear and nonlinear elimination pathways as it has previously been used in the PK 
analysis of other therapeutic mAbs, including sibrotuzumab and panitumumab (45, 131).  
The parallel elimination model did not offer a significant improvement in describing the 
data over the simpler nonlinear model likely because the data did not support the more 
complex model.  Certainly, a limitation to this analysis was that dose escalation data was 
not available as all patients included in the analysis were treated at the same clinically 
approved dose level.  Such data might have supported the more complex parallel 
elimination model, and even helped further define the population estimates and between-
subject variability for Vmax and Km. 
 
Based on the final population PK model, cetuximab distributes into a central 
compartment volume (V1) of 2.83 L for a patient weighing 60 kg, which is approximately 
equal to the plasma volume.  The volume of distribution at steady-state (Vss=V1+V2) of 
5.26 L for a 60 kg patient suggests an apparently limited distribution outside the vascular 
space, which is in line with the results from cetuximab phase I studies (80, 81, 109), and 
consistent with the behavior of endogenous IgG and other therapeutic mAbs (6, 132).  
Nevertheless, cetuximab is able to distribute to its target as evidenced by 
immunohistochemistry studies and EGFR tyrosine kinase assays, which showed almost 
complete EGFR saturation in tumor tissue samples obtained from patients with SCCHN 
receiving the approved doses of cetuximab (133). 
 
The results of the predictive check and simulations revealed that the population 
PK model adequately described the central tendencies of peak and trough concentrations 
at week 4 in the model building data set and beyond week 8 in the model evaluation 
dataset.  The model was able to adequately account for the between-subject variability in 
peak concentrations, but the variability in trough concentrations was overpredicted 
towards lower concentrations as indicated by the disparity between the 25th percentiles 
(Q1) for observed and simulated trough concentration data in Figure 3-3.  Given that Vmax 
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significantly influences trough concentrations, overestimation of the between-subject 
variability in Vmax may be the cause for this deviation. 
 
Binding of cetuximab to EGFR induces internalization of the receptor, which is 
believed to lead to EGFR down-regulation (109).  Given the role EGFR plays in the 
elimination of cetuximab, one might hypothesize that with down-regulation of EGFR, 
there may also be a decrease in cetuximab clearance over time.  Based on the Monte 
Carlo simulations for the model evaluation dataset, however, the population PK model 
was able to adequately describe cetuximab peak and trough concentrations beyond 8 
weeks of therapy.  This finding suggests that the elimination PK of cetuximab remains 
relatively stable over time during prolonged therapy.  It is further supported by findings 
from a phase I study, where no statistically significant change in clearance values was 
found between the first and fourth weekly dose of cetuximab (81). 
 
An interesting and unexpected covariate relationship identified in my analysis is 
the influence of WBC count on Vmax.  There is evidence in the literature, however, that 
lymphocytes, monocytes, macrophages, and neutrophils do express EGFR (134-136).  
This suggests that these cells may be involved in the receptor-mediated clearance of 
cetuximab.  The final population PK model predicted a 2.2% change in Vmax per unit 
(109/L) change in WBC from the median WBC (6.8 109/L).  Over the normal range of 
WBC (~4-11 109/L), the typical value for Vmax would vary from 4.1 to 4.8 mg/hr, 
representing a -6.4% and +9.6% change from the population mean Vmax, respectively.  
The modest change in Vmax over the range of normal WBC would not likely necessitate a 
change in dosing, even in patients who develop leukopenia due to concomitant 
chemotherapy. 
 
Size covariates are probably the most frequently identified covariates in 
population PK analyses, and are well established as predictors of systemic exposure for 
small molecule drugs as well as therapeutic mAbs (13).  In this study, three different size 
covariates (IBW, WGT, and BSA) were evaluated.  IBW was found to be a better 
predictor of Vmax than BSA and WGT.  As interactions with EGF- as well as Fc-receptors 
resulting in receptor-mediated endocytosis are assumed to be the major elimination 
pathways of cetuximab (137), my results suggest that the number of these receptors in its 
distribution space is better reflected by IBW than any of the other body size measures.  
This observation is not unexpected as the elimination capacity of at least the liver and the 
reticuloendothelial system as major sites of Fc-receptor-mediated elimination of mAbs 
are only marginally affected by deviations of weight from IBW. The final model 
predicted a 1.1% change in Vmax per kg IBW deviation from the median IBW of 64 kg.  
The estimated changes from the typical population Vmax (4.38 mg/hr) for patients with 
IBW varying from the observed minimum (43.3 kg) to the maximum IBW (81.3 kg) were 
-22.4% (3.4 mg/hr) and +18.7% (5.2 mg/hr), respectively. 
 
Although Vmax as a direct determinant of cetuximab clearance is best predicted by 
IBW, clinical dosing of cetuximab is currently performed based on BSA following the 
traditional standard practice of dosing in oncology (109).  To visualize the impact of 
dosing based on BSA rather than IBW, consider a 6 foot tall male patient whose body 
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weight is 77.6 kg, which is also his IBW.  Based on BSA calculated according to DuBois 
(138), his cetuximab maintenance dose would be 498 mg (250 mg/m2).  Now suppose the 
above patient has lost 20% weight (62 kg body weight; 80% of IBW) or even 35% body 
weight (50.4 kg body weight; 65% of IBW).  His BSA-based cetuximab maintenance 
dose would be 453 mg (at 62 kg) or 415 mg (at 50.4 kg), i.e. 9.1% or 16.7% lower, but 
my population PK model would predict the same Vmax for both situations, leading to a 
reduced systemic exposure of cetuximab in the underweight patient.  The modest impact 
of this effect, however, indicates that the approved BSA-based dosing regimen for 
cetuximab provides consistent systemic exposure in clinical use even in subjects with 
substantial deviation between their actual body weight and IBW.  Only in very extreme 
cases of severe underweight, standard dosing might need to be adjusted to avoid 
underdosing of the patient. 
 
The potential clinical relevance of this finding is supported by the prominence of 
underweight in patients with advanced stages of solid tumors, including SCCHN.  In fact, 
in the patient population used for this analysis, almost 25% of the patients weighed less 
than 80% of IBW.  A comparison of the trough concentrations at 4 weeks and beyond in 
these patients with the troughs of the other patients in my analysis indicated that the 
troughs were indeed lower in the underweight group (median 48.2 vs. 62.4 µg/mL, 
p=0.014).  This finding supports the selection of IBW as predictor for cetuximab 
elimination rather than BSA or WGT.  My results are furthermore in agreement with a 
previous report that suggests the dosing based on BSA may have limitations for some 
therapeutic mAbs (45). 
 
Fracasso et al. recently reported a correlation between cetuximab trough levels 
and antitumor response on cetuximab monotherapy (107).  Patients with partial 
response/stable disease tended to have higher average trough levels compared to those 
with progressive disease (mean 60.7 vs. 33.2 µg/mL, p=0.002).  Although these study 
results were based on a small number of patients (n=33) with different cancer types 
(predominantly colorectal, breast and head and neck carcinomas), they highlight the 
potential relevance of adequate systemic exposure, and thus dosing, for achieving 
antitumor response in cetuximab pharmacotherapy. Further studies, however, are needed 
to clearly define an optimal systemic exposure range for cetuximab. 
 
The population estimates for Vmax and Km are in agreement with findings from 
other PK analyses of cetuximab (123, 139).  The PK parameter estimates of my final 
model are also in line with a previous population analysis of cetuximab PK for regulatory 
purposes where a two-compartment model with nonlinear elimination was also used (109, 
140).  This population analysis for regulatory purposes included nineteen clinical studies 
in various cancer types.  The similar results of the two population analyses suggest that 
cetuximab PK are not different in patients with SCCHN compared with other cancer 
types.  My analysis did not identify an effect of concomitant chemotherapy, 
cisplatin/carboplatin and 5-fluorouracil, on cetuximab PK which is in agreement with 
several earlier clinical trials (81, 141).  Furthermore, I could not detect differences in 
cetuximab PK for patients receiving cetuximab as first-line treatment during the 
recurrence or metastatic stage of SCCHN (study A) as compared to patients pretreated 
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with at least one line of chemotherapy during this stage (study B).  Although several of 
the tested covariates were not found to influence the PK of cetuximab (e.g., gender, 
ethnicity, renal and hepatic function), it should be noted that the majority of the studied 
patients were male, Caucasian, and had adequate hepatic and renal function.  Therefore 
the impact of these covariates on the PK of cetuximab remains to be elucidated. 
 
In summary, I developed a population PK model for cetuximab that characterized 
the nonlinear PK of this therapeutic mAb.  IBW and WBC count were identified as 
predictors for cetuximab clearance.  The currently approved BSA-based dosing of 
cetuximab provides adequate exposure in most patients, but may require adjustments in 
cases with extreme deviations of their body weight from their IBW. 
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CHAPTER 4.  COMPARATIVE PERFORMANCE OF BAYESIAN MARKOV 
CHAIN MONTE CARLO AND MAXIMUM LIKELIHOOD POPULATION 
ESTIMATION METHODS WHEN APPLIED TO NONLINEAR 
PHARMACOKINETICS OF MONOCLONAL ANTIBODIES 
 
 
Introduction 
 
 In Chapter 3, a population PK analysis of cetuximab, an anti-EGFR therapeutic 
mAb, was performed in patients with SCCHN.  The final population PK model, which 
incorporated a two-compartment model with nonlinear elimination, was able to 
adequately describe the nonlinear PK of cetuximab at the currently approved dosage 
regimen.  During the population PK analysis, various issues were encountered which 
were likely the result of an attempt to describe this nonlinearity.  During evaluation of the 
different structural PK models, the one- and two-compartment models with nonlinear or 
parallel linear and nonlinear elimination pathways exhibited convergence difficulties and 
prolonged run times.  The convergence of these PK models was stabilized and run times 
reduced by log transforming the data and using separate residual error models per clinical 
study.  Limitations with the final population PK model included the inability to quantify 
between-subject variability simultaneously in Vmax and Km, the relatively low precision in 
Km compared to other model parameters in the bootstrap analysis (Table 3-2), and the 
predictive check showed that the model overpredicted the between-subject variability in 
trough concentrations at week 4 at the lower concentrations (Figure 3-3).  Since trough 
concentrations are largely influenced by Vmax, the deviation in the predictive check may 
have been due to an overestimation of the between-subject variability in Vmax. 
 
 The difficulty characterizing the nonlinear elimination of cetuximab and the 
apparent bias in one or more of the parameter estimates were likely due to limitations of 
the clinical study designs and possibly the population estimation method used.  One 
drawback of the two clinical studies included in the analysis was that dose escalation data 
was not available as all patients were treated at the same dose level.  Another drawback 
was the unbalanced sampling design of the two studies, as the majority of patients (96 of 
143) provided only peak and trough concentrations while the remaining patients provided 
a full concentration-time profile in addition to peak and trough concentrations.  The 
FOCE method in NONMEM was used throughout the model-building process, and it is 
known that the first-order approximation methods can be inaccurate when dealing with 
highly nonlinear models such as the PK model with nonlinear elimination used to 
describe the PK of cetuximab (112).  Therefore, it was questioned whether or not the use 
of another population estimation method in the cetuximab analysis would have led to 
more accurate parameter estimates and better characterization of the nonlinear PK of 
cetuximab (e.g., allowed between-subject variability in Km to be estimated). 
 
 Nonlinear elimination is a common characteristic of the PK of therapeutic mAbs 
(6, 8), and accordingly, PK models with nonlinear elimination were used in almost half of 
the population PK analyses of therapeutic mAbs published in the scientific literature 
(Table 1-1).  The question of how well other population estimation methods would have 
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performed in evaluating the nonlinear elimination of cetuximab is therefore relevant for 
other therapeutic mAbs.  This question is also relevant for other therapeutic mAbs, 
because similar difficulties encountered during the cetuximab analysis were also reported 
in population PK analyses of other therapeutic mAbs.  These difficulties included 
challenges in detecting and characterizing nonlinear elimination due to study design 
limitations, convergence difficulties with PK models with nonlinear elimination, and the 
inability to estimate between-subject variability in Km (Chapter 1, Table 1-4).  It is 
estimated that half of all current projects in new drug development are biologics, with 
mAbs being the predominant class of biologics under clinical study (1).  According to a 
report by Reichert, in 2008 there were over 200 mAbs undergoing clinical study (2).  
With the growing number of therapeutic mAbs in drug development and reaching FDA 
approval, the challenges with population PK modeling of therapeutic mAbs with 
nonlinear PK will continue to remain an issue. 
 
 A number of studies have evaluated the performance of different estimation 
methods for population PK modeling, and in most of these studies a one-compartment 
model with IV bolus or first-order input and first-order (linear) elimination was used for 
comparison (142-147).  Studies by Hashimoto et al. (148) and Sheiner and Beal (149) 
evaluated estimation methods in NONMEM for population PK modeling of nonlinear PK 
data at steady-state.  However, both studies used PK models that have not been used in 
population PK analyses of therapeutic mAbs.  Sheiner and Beal used only the Michaelis-
Menten model where the dosage rate was assumed to be equal to the elimination rate and 
concentrations were at steady-state.  A one-compartment model with nonlinear 
elimination was used in the analysis by Hashimoto et al.  Although Hashimoto et al. used 
a PK model with nonlinear elimination, in most of the therapeutic mAb population PK 
analyses a two-compartment model was used (Table 1-1).  Bauer et al. recently evaluated 
various population estimation methods and software when applied to different PK/PD 
models (150).  One of the PK models included in the study was a one-compartment 
model with parallel linear and nonlinear elimination pathways.  While this clearance 
model has been used in several therapeutic mAb population PK analyses, again in most 
cases a two-compartment model was used.  Also, only one data set was simulated for 
each PK/PD model in the analysis by Bauer et al., so the population estimation methods 
could not be systematically evaluated.  Therefore, little work has been done evaluating 
population estimation methods using PK models that are representative of the typical 
disposition characteristics of therapeutic mAbs. 
 
 In the current chapter, a simulation study was conducted to compare the 
parameter estimation performance of the approximate maximum likelihood methods in 
NONMEM and a full Bayesian MCMC method in WinBUGS for population PK 
modeling of therapeutic mAbs with nonlinear PK.  A review of the literature in Chapter 1 
showed that the population PK of different therapeutic mAbs are quite similar.  The 
findings from published therapeutic mAb population PK analyses were used in the 
present study to define aspects of the candidate population PK simulation model in order 
to simulate PK data for a representative therapeutic mAb.  The software NONMEM was 
included in this study as it is the most widely used software for population PK/PD 
modeling (151).  WinBUGS was chosen as the Bayesian MCMC method provides a 
 67
different approach compared to the estimation methods in NONMEM to solving the 
population PK problem (152), and there is a growing interest in applying full Bayesian 
methods in population PK modeling.  In addition, the Bayesian MCMC method allowed 
investigation of the utility of including prior information in a population PK analysis.  
The Bayesian MCMC method was evaluated with both uninformative and informative 
priors, which were obtained from population PK analyses of therapeutic mAbs in the 
literature.  The performance of the different population estimation methods was evaluated 
under different clinical study designs commonly encountered during drug development, 
and the sensitivity of estimation error to parameter uncertainty was also explored. 
 
 
Methods 
 
 
Overview of Methodology Steps 
 
 The methodology for this study can be divided into two main steps: simulation 
and estimation.  An overview of the simulation and estimation steps is illustrated in 
Figure 4-1.  Simulation of replicate data sets was performed with uncertainty included 
simultaneously on all parameters in the population PK model.  The software program R 
(Version 2.7.2; http://www.r-project.org/) (153) was used to randomly sample 1000 
values for each parameter from their respective uncertainty distributions, which were then 
combined to create 1000 full sets of simulation parameter values for the population PK 
model.  Each full set of simulation parameter values was used to simulate one replicate 
data set under a given study design template, therefore, 1000 replicate data sets were 
created per study design.  Parameter estimates were then obtained for each replicate using 
the estimation methods of interest which included three methods in NONMEM (FO, 
FOCE-I, LAP-I) and a Bayesian MCMC method in WinBUGS.  The estimation 
performance of the methods was evaluated under five different study design scenarios.  
NONMEM was used to simulate the concentration data sets, and the R package MIfuns 
(Metrum Institute, Augusta, Maine) (154) was used to automate the creation of replicate 
NONMEM simulation control streams by systematically substituting in a set of 
simulation parameter values.  The population PK model, study designs, and parameter 
uncertainty distributions used for performing the simulations are described in the 
following sections.  Example computer codes used for the simulation and estimation 
steps are provided in Appendix B. 
 
 
Population Pharmacokinetic Model 
 
 The published findings from population PK analyses of therapeutic mAbs and 
their general PK behavior (Chapter 1) were used to define the population PK model for 
this study in terms of model structure and fixed and random effect parameters.  For 
purposes of this study it was assumed that the administered drug was a therapeutic human 
IgG1 mAb indicated in the area of oncology that targets a cell membrane receptor 
primarily expressed in tissue.  Therapeutic mAbs often exhibit two distinct elimination  
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Figure 4-1. Overview of the methodology of the simulation and estimation steps. 
Sampled 1000 values from each simulation 
parameter uncertainty distribution 
Combined sampled values to create 1000 full sets of 
simulation parameter values for the population PK model 
Each row represents 1 full set of simulation parameter values 
Each set of simulation parameter values was used to simulate 1 replicate data 
set under a given study design template (n=number of replicates simulated) 
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Study Design 
n=1000 
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Study Design 
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Study Design 
(600 mg dose level) 
n=1000 
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(800 mg dose level) 
n=1000 
Obtained parameter estimates for each replicate data set using the following 
estimation methods: FO, FOCE-I, LAP-I, and Bayesian MCMC with 
informative and uninformative priors 
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pathways which includes a linear (first-order) clearance pathway mediated by interaction 
with Fc-receptors and a nonlinear clearance pathway attributable to saturable target-
mediated mechanisms (e.g., receptor-mediated endocytosis) (Chapter 1).  Therefore, it 
was believed that the theoretical mAb for this study was also eliminated via these two 
pathways.  A commonly used PK model in population PK analyses of therapeutic mAbs 
that can be related to the two distinct physiologic elimination pathways is a two-
compartment model with parallel linear and nonlinear elimination from the central 
compartment (Table 1-1, Figure 1-2A).  Accordingly, the same structural PK model was 
used for the simulation/estimation steps in this study.  The use of a two-compartment 
model was further supported by the fact that a two-compartment model was used in the 
majority of therapeutic mAb population PK analyses (Table 1-1).  The PK model was 
parameterized in terms of Vmax, Km, CLL, V1, V2, and Q.  Under the condition that the 
absolute bioavailability of the administered dose is known, the parameters for the 
aforementioned PK model have been shown to be globally identifiable (83).  The 
therapeutic mAb in this study was administered as an IV infusion so bioavailability was 
assumed to be 1.  This route of administration was chosen as most therapeutic mAbs that 
are approved or in development are administered IV (Chapter 1).  The parallel 
elimination PK model was defined in terms of the differential equations below: 
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where X1 and X2 represent the mAb amount in the central and peripheral compartments, 
respectively. 
 
 The population PK model included between-subject variability for all model 
parameters except Km and Q.  Between-subject variability in the parameters Vmax, CLL, 
V1, and V2, was assumed to follow a lognormal distribution and was modeled using an 
exponential error model.  The exclusion of between-subject variability for Km and Q in 
the population PK model is in line with the literature, as between-subject variability in 
both parameters was often not estimated in population PK analyses of therapeutic mAbs 
(Tables 1-3 and 1-4).  Given that Km is related to the affinity of the mAb to its target, it is 
a reasonable approach to hypothesize that physiologically there is negligible variability in 
Km among individuals.  Although between-subject variability in Q was not modeled, 
variability in Q can be considered to be intrinsically included in the between-subject 
variability for V1 and V2 since the volume parameters can be defined in terms of Q (e.g., 
V1 = Q/K12). 
 
 Body weight (kg) was included in the population PK model as a predictor of Vmax, 
CLL, V1, and V2.  The choice of body weight as a covariate was supported by the 
observation that body weight was the most commonly identified covariate in therapeutic 
mAb population PK analyses, and it was often found to be a predictor of the 
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aforementioned parameters (Table 1-5).  The inclusion of a covariate in the model also 
allowed for evaluating the performance of the estimation methods in estimating a 
covariate effect.  Correlation among the between-subject random effects was modeled 
using a fixed effect (i.e., weight as a predictor of Vmax, CLL, V1, and V2) rather than a 
random effect.  Any remaining variability after accounting for the covariate effect was 
assumed to be uncorrelated.  This approach to handling the correlation between the 
random effects was in part based on the findings from the population PK analyses of 
sibrotuzumab (45) and matuzumab (40).  In the sibrotuzumab analysis, weight was 
included in the population PK model as a covariate for Vmax, CLL, V1, and V2.  No 
correlation was modeled between the random effects for these parameters, although a 
shared variance term was included in the model between V1 and V2.  In the matuzumab 
analysis, weight was included in the population PK model as a covariate for CLL and V1.  
Correlation between the random effects was modeled for V1 and V2, Vmax and V2, and 
Vmax and V1, but no correlation was modeled between CLL and V1.  The relationship 
between body weight and the PK parameters was modeled using a power model with the 
individual patient weight normalized to a weight of 72 kg as shown in the following 
equation: 
 
2θ
kg 72
(kg)Weight *1θP 


  
 
where the θs are the parameters to be estimated, and θ1 represents the typical value of a 
PK parameter (P) in an individual with a body weight of 72 kg.  In most population PK 
analyses of therapeutic mAbs, the effect of body size (including weight) on a PK 
parameter was modeled using a power function (Table 1-5). 
 
 Residual variability was modeled using an exponential error model.  An 
exponential error model was used to prevent simulation of negative concentrations.  
Residual variability in most of the therapeutic mAb population PK studies was modeled 
using either a proportional or a combined additive and proportional error model (Chapter 
1).  Although an exponential error model was used in this study, the simulation 
uncertainty distribution for the standard deviation of residual variability (see next section) 
encompassed a low to moderate range of variability (~10-20 %CV), and within this 
range, an exponential error model closely approximates a proportional error model.  
There were a total of 15 parameters in the population PK model, and the same model was 
used for both simulation and estimation steps. 
 
 
Simulation Parameter Uncertainty Distributions 
 
Simulation of the replicate data sets was performed with uncertainty included 
simultaneously on all parameters in the population PK model.  A review of the literature 
in Chapter 1 showed that the population PK of different therapeutic mAbs are quite 
similar.  In order to simulate concentration data for a prototypical mAb, the simulation 
parameter values selected from the uncertainty distributions needed to be realistic and 
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representative of the population PK characteristics of therapeutic mAbs.  Therefore, the 
published findings from over 20 population PK analyses of therapeutic mAbs were used 
to define the simulation parameter uncertainty distributions (Chapter 1, Tables 1-3 
through 1-6).  In general, a two-step approach was taken in specifying the uncertainty 
distributions.  First, the literature reported parameter values were summarized by 
calculating summary statistics and creating plots of the parameter values.  This 
information aided in selecting an appropriate type of statistical distribution to describe the 
parameter uncertainty.  After the type of distribution was selected, the second step was to 
simulate a large number of parameter values from the uncertainty distribution using the 
summary statistics as initial values for the distribution parameters (e.g., mean and 
variance).  Histograms of the simulated parameter values were created and compared 
against the literature reported values.  The distribution parameters were then adjusted as 
needed so that the uncertainty distribution adequately reflected the parameter estimates 
reported in the literature.  The approach to specifying the simulation parameter 
uncertainty distributions was generally to use parameter values reported from population 
PK analyses of therapeutic mAbs that used a two-compartment model with parallel linear 
and nonlinear elimination or only nonlinear elimination from the central compartment.  
However, the final parameter uncertainty distributions were checked visually to make 
sure that they were representative of parameter values reported from all therapeutic mAb 
population PK analyses that used a two-compartment PK model regardless of the 
clearance model.  The findings published from population PK analyses that used a one-
compartment PK model were not taken into account in specifying the uncertainty 
distributions. 
 
 The approach to specifying the simulation uncertainty distributions for Vmax and 
Km differed from the methodology described above.  Population estimates for Vmax and 
Km varied considerably between different therapeutic mAbs (Table 1-4), which can be 
expected as Vmax and Km will be specific for a given mAb and its pharmacologic target.  
Therefore, it was not reasonable to use all reported population estimates for Vmax and Km 
to specify their respective simulation uncertainty distributions.  Instead, the geometric 
means of the lognormal uncertainty distributions for Vmax (18 mg/day) and Km (5.0 mg/L) 
were selected based on reported values from the population PK analysis of matuzumab 
where a two-compartment model with parallel linear and nonlinear elimination was used 
(40) (Table 1-4).  The population estimates of Vmax and Km for matuzumab were 10.9 
mg/day and 4.0 mg/L, respectively.  The variances selected for the uncertainty 
distributions for Vmax and Km allowed for a small but reasonable amount of variability in 
the simulation parameter values, since these parameters are specific for the theoretical 
mAb and its target.  The expected CLint for the theoretical mAb based on the geometric 
means of the simulation uncertainty distributions for Vmax and Km was 3.6 L/day, which 
is in line with other therapeutic mAbs that target cell membrane antigens primarily 
expressed in tissue (Table 1-4).  As discussed in Chapter 1, therapeutic mAbs with cell 
membrane targets primarily expressed in tissue had similar CLint values that were also 
much smaller compared to mAbs whose cell membrane target was largely expressed on 
blood cells. 
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 A lognormal uncertainty distribution was used for most of the parameters in the 
population PK model since PK parameters often follow this type of distribution.  The 
population values for Vmax and Km, between-subject standard deviations for V1 and V2, 
and the standard deviation of residual variability were all randomly sampled from 
lognormal distributions.  The population values for CLL, V1, V2, and Q were drawn from 
a multivariate lognormal distribution.  The decision to use a multivariate distribution for 
CLL, V1, V2, and Q, and not univariate distributions was based on observed correlations 
between estimates for these parameters reported in population PK analyses of mAbs 
where a two-compartment parallel elimination model was used (Tables 1-3 and 1-4).  The 
between-subject standard deviations for Vmax and CLL and the coefficients for the weight 
effect were sampled from uniform distributions.  A uniform distribution was used for the 
weight effect on Vmax, CLL, V1, and V2, because this type of distribution appeared to 
describe the estimates reported in the literature for the effect of weight on these 
parameters better than a lognormal distribution.  While a lognormal distribution was 
considered for the between-subject standard deviations for Vmax and CLL, a uniform 
distribution was used because there was interest in evaluating the performance of the 
estimation methods in cases of low and high between-subject variability in Vmax and CLL.  
By using a uniform distribution, this ensured that a larger number of parameter values 
would be sampled from the extremes of the range specified for the simulation uncertainty 
distribution.  The range of the uncertainty distributions used for the Vmax and CLL 
between-subject standard deviations were based on the minimum and maximum values 
observed in the literature for the parameters (Table 1-4). 
 
 Although the same uncertainty distributions were defined for some parameters 
(e.g., Vmax and CLL between-subject standard deviations), the parameter values were 
sampled from independent distributions.  The exception to this was the coefficient value 
for the magnitude of the weight effect, which was assumed to be the same for the volume 
related parameters (V1 and V2) and the same for the clearance related parameters (Vmax 
and CLL).  The simulation parameter uncertainty distributions are defined below, where 
~N(μ,σ2) denotes that the parameter follows a normal distribution with a mean (μ) and 
variance (σ2), and ~U(a,b) refers to a uniform distribution with lower (a) and upper (b) 
limits.  In the case of the multivariate normal distribution, the term   refers to a vector 
of means and Σ is the variance-covariance matrix. 
 
Fixed Effects 
    0.01 mg/day), ln(18.0  N~Vln max      0.01 ,mg/L 5.0ln  N~Kln m  
 
    ,N~Q ,V ,V ,CLln 21L   
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  1.0 0.4,U~CL and Von effect Weight Lmax  
  1.0 0.4,U~V and Von effect Weight 21  
 
Between-Subject Variability 
(Distributions defined for standard deviation) 
  0.65 0.15,U~ Vmax    0.65 0.15,U~ CLL   
     0.04 ,0.25ln  N~ Vln 1       0.04 ,0.25ln  N~ Vln 2   
 
Residual Variability 
(Distribution defined for standard deviation) 
     0.04 ,0.15ln  N~ln   
 
 Individual patient weights were simulated simultaneously with concentration data 
for each replicate data set, since weight was included in the population PK model as a 
covariate.  Given that the mAb in this study was assumed to be for therapeutic use in the 
area of oncology, the goal was to simulate patient weights that were representative of a 
population of adult cancer patients.  Patient weights were assumed to follow a lognormal 
distribution with a variance of 0.04 and a mean weight that was randomly sampled from 
the following uncertainty distribution: 
 
ln(population mean weight)   4-6.25E ,kg 72ln  N~  
 
 Therefore, the mean patient weight was different for each replicate data set, but 
the variability in patient weights remained the same.  Specification of the uncertainty 
distribution for the mean patient weight was based on median weights reported in 
population PK analyses of therapeutic mAbs in cancer patients (Table 1-1).  The decision 
to use 0.04 as the between-subject variance for patient weight was based on the 
variability of patient weights in the cetuximab population PK analysis (Chapter 3).  In 
addition, patient weights were available from a study by Sparreboom et al. (personal 
communication) where the PK of different anticancer drugs was evaluated in over 1,200 
adult cancer patients (155).  This data was also taken into account when specifying the 
variability for patient weights and the uncertainty distribution for the mean patient 
weight. 
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Study Designs 
 
 Replicate data sets were simulated under two different study designs typically 
encountered during drug development: a dose-ranging design (‘informative design’) and 
a single dose level design (‘uninformative design’).  The study templates were designed 
to be representative of what one might see in typical phase I/II studies of therapeutic 
mAbs in drug development.  The study designs used herein were similar in nature to a 
number of clinical studies included in the population PK analyses of various therapeutic 
mAbs (21, 23, 29, 30, 40, 45). 
 
 In the informative design there were six dose groups with six patients per group.  
The therapeutic mAb was administered weekly for 4 weeks as a 1 hr IV infusion at doses 
of 50, 100, 200, 400, 800, or 1600 mg.  Peak and trough mAb concentrations were 
obtained at weeks 2 and 3, and on weeks 1 and 4 a full PK concentration-time profile was 
obtained with concentrations sampled at 1, 3, 6, 10, 24, 48, 72, 96, and 168 hours after 
the start of the infusion.  This sampling schedule resulted in 22 data points per patient.  
The selection of the dose levels was based on simulations of concentrations at the 
sampling time points using the means and midpoints of the simulation uncertainty 
distributions.  The dose levels for the informative study design were selected because 
they resulted in concentration ranges that were below and above the Km.  The software 
program PopED (Version 2.06; http://poped.sourceforge.net/) (156) was also used to aid 
in the selection of dose levels for the informative design.  Attempts were made to 
simultaneously optimize dose levels and sampling times using PopED, but this was not 
feasible due to prolonged run times, so only the dose levels were optimized.  Given the 
similarities in population PK between the theoretical mAb for this study and matuzumab 
(including population estimates for Vmax and Km), the sampling times reported for three 
phase I trials included in the population PK analysis of matuzumab (40) were taken into 
account in selecting the sampling times for the informative (and uninformative) study 
design. 
 
 In the uninformative design there were 36 patients and all were treated at the same 
dose level.  There were 4 different versions of the uninformative design with patients 
treated at different dose levels of 200, 500, 600, or 800 mg.  Just as with the informative 
design, simulations were used to help select dose levels for the uninformative design.  
The dose levels were selected so that the concentration ranges would either be 
below/around (200 mg) or above (500, 600, and 800 mg) the Km, thereby making it more 
difficult to detect and characterize the nonlinear elimination of the mAb.  The dosing and 
sampling schedules were the same as in the informative design except for the full PK 
concentration-time profile at week 1 which was removed, resulting in 13 data points per 
patient. 
 
 
Estimation Methods 
 
 The estimation methods evaluated in this study included approximate maximum 
likelihood methods available in NONMEM and a Bayesian MCMC method with two 
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different sets of priors (informative and uninformative).  The estimation methods 
evaluated in NONMEM (Version VI, level 2.0; Icon Development Solutions, Ellicott 
City, Maryland) (20) were FO, FOCE-I, and LAP-I.  Computer resources included a 
computer grid, with each node running NetBSD 3.1 (64bit) on AMD64 processors, and 
the GNU Fortran compiler GCC-3.3.3 (GNU Project; http://www.gnu.org/).  NMQual 6.3 
(Metrum Institute, Augusta, Maine; http://code.google.com/p/nmqual/) was used to track 
all code patches/options and install the NONMEM software.  Simulation of the replicate 
data sets was also carried out using NONMEM and the computer grid.  The two-
compartment parallel elimination PK model was implemented in NONMEM using the 
subroutine ADVAN6 TRANS1 TOL=8.  The default boundary test in NONMEM was 
disabled for all parameters in the population PK model by specifying the 
NOTHETABOUNDTEST, NOOMEGABOUNDTEST, and NOSIGMABOUNDTEST 
options in the $ESTIMATION record.  If an estimation run crashed or minimization 
terminated, up to four restarts were allowed in which the TOL or initial estimates were 
adjusted according to a predefined protocol.  All runs that reported parameter estimates, 
including those where minimization terminated, were used in the analysis.  The initial 
estimates used for NONMEM are shown below, and for most parameters the initial 
estimates were within 20-100% of the mean or the midpoint of their respective simulation 
parameter uncertainty distribution: 
 
Fixed Effects 
 
 Vmax = 28.8 mg/day Km = 10.0 mg/L 
 
 CLL = 0.72 L/day V1 = 3.0 L 
 
 V2 = 2.0 L Q = 1.8 L/day 
 
 Weight~Vmax = 0.8 Weight~CLL = 0.8 
 
 Weight~V1 = 0.8 Weight~V2 = 0.8 
 
Between-Subject Variability 
(Initial estimates shown for standard deviation) 
 
 Vmax ω = 0.4 CLL ω = 0.4 
 
 V1 ω = 0.4 V2 ω = 0.4 
 
Residual Variability 
(Initial estimate shown for standard deviation) 
 
σ = 0.4 
 
 The population PK model was also implemented in WinBUGS (version 1.4.3; 
http://www.mrc-bsu.cam.ac.uk/bugs/) (114) using BUGSModelLibrary (version 1.1; 
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Metrum Institute, Augusta, Maine; http://code.google.com/p/bugsmodellibrary/) (157), a 
prototype PK/PD model library developed for use with WinBUGS.  The use of 
BUGSModelLibrary also required the installation of WBDev (http://www.winbugs-
development.org.uk/wbdev.html) (158) and the BlackBox Component Builder (version 
1.5; Oberon Microsystems, Zurich, Switzerland; http://www.oberon.ch/blackbox.html).  
Data management, launching WinBUGS, and analysis of the MCMC samples was done 
using R with the R packages coda (159) and a modified version of R2WinBUGS (160) 
contributed by W.R. Gillespie (Metrum Research Group, Tariffville, CT).  WinBUGS 
was run on a Thinkmate VSX i20S4-T with 2 Intel quad-core Xeon 5345 2.33GHz 
processors and 16 GB RAM. The operating system was Microsoft Windows Server 2003. 
 
 The Bayesian MCMC method was evaluated with uninformative (vague) priors.  
The rationale behind specifying the uninformative priors is as follows.  For Vmax, Km, 
CLL, V1, V2, and Q, the geometric means of their respective uninformative priors were 
set to the initial estimates used for NONMEM.  By assuming a lognormal prior 
distribution for these parameters and using a variance of 10,000 (SD=100), the priors can 
be considered vague since the 95% confidence interval would be approximately 0 and +∞ 
on the linear scale.  Uniform priors were specified for the weight effects, which is the 
same type of distribution used for their simulation parameter values, but the range of the 
uniform priors was increased to 0 to 5.  The range in the case was constrained to be 
positive, as one would not expect weight to be a negative predictor of clearance and 
volume parameters.  Although some informativeness was imparted in the priors by doing 
this, the range of the uniform distributions was large enough to be considered weakly 
informative.  Uniform priors with a large range of 1.0E-4 to 1.0E4 were specified for the 
standard deviations of between-subject variability and residual variability.  The 
uninformative priors for the random effects were chosen based on recommendations from 
a paper by A. Gelman in which various uninformative prior distributions for variance 
parameters in hierarchical models are discussed (161). 
 
 The Bayesian MCMC method was also evaluated with informative priors.  A 
review of the literature in Chapter 1 indicated that many characteristics of the population 
PK of currently used therapeutic mAbs are quite similar.  Therefore, the idea was that the 
published findings from the population PK analyses of therapeutic mAbs could be used 
as prior information for the population model parameters.  The rationale and 
methodology used to specify the informative priors was similar to that used for the 
simulation parameter uncertainty distributions.  Although the literature was used in 
specifying both the informative priors and simulation parameter uncertainty distributions, 
the distribution parameter values for the informative priors differed somewhat from the 
simulation uncertainty distributions, as the priors were updated with additional 
therapeutic mAb population PK studies that were published or found in the literature 
from the time the simulation uncertainty distributions were specified.  The types of 
distributions used for the model parameters were the same for the informative priors and 
the simulation uncertainty distributions.  The exception to this was the between-subject 
standard deviation for Vmax and CLL, where lognormal priors were used since the 
reasoning behind using a uniform distribution for the simulation uncertainty distributions 
no longer applied for the estimation step.  Although a Wishart distribution is commonly 
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used in Bayesian modeling as a prior for the variance-covariance matrix of the between-
subject random effects, in this case, lognormal distributions were used since it was 
assumed that between-subject variability was uncorrelated to keep consistent with the 
assumptions made for the simulation model. 
 
 As previously mentioned, the population estimates for Vmax and Km varied 
considerably between different therapeutic mAbs (Table 1-4).  This can be expected as 
Vmax and Km will be specific for a given mAb and its pharmacologic target.  Therefore, it 
was not plausible to use reported population estimates for Vmax and Km as prior 
information.  However, in Chapter 1 it was observed that therapeutic mAbs with cell 
membrane targets primarily expressed in tissue had similar CLint values that were also 
much smaller compared to mAbs whose cell membrane target was largely expressed on 
blood cells.  In the current study, it was assumed that the theoretical mAb targets a cell 
membrane receptor primarily expressed in tissue.  Thus, the CLint values (Table 1-4) for 
other therapeutic mAbs (e.g., sibrotuzumab, matuzumab, cetuximab, and CP-751,871) 
that also bind to cell membrane antigens primarily expressed in the tissue were used as 
prior information for the CLint of the theoretical mAb.  In addition to CLint, an 
informative prior was specified for Km, and then Vmax was determined as a secondary 
parameter as CLint * Km.  In order to specify an informative prior for Km, an assumption 
had to be made that prior information was available during drug development of the 
theoretical mAb.  It was assumed that a single dose, dose escalation, first-in-man study of 
the theoretical mAb had been conducted, and Km was estimated from a standard two-
stage PK analysis of the concentration data (a population PK analysis could have been 
conducted as well).  In addition, Km may have been estimated in pre-clinical PK studies 
in animals, and this information could be used in the prior for Km.  During drug 
development, in vitro binding studies are commonly performed for the mAb and its 
pharmacologic target, and this could be used as prior information for Km although the Kd 
and Km are often not similar.  A lognormal prior was used for Km with a geometric mean 
of 10 mg/L and a variance of 1.38, which resulted in a 95% confidence interval of 
approximately 1 and 100 mg/L on the linear scale.  This seemed like a reasonable degree 
of informativeness for Km given the realistic availability of prior information from the 
previously mentioned scenarios. 
 
 In WinBUGS, the variability of a normal distribution is defined in terms of 
precision (inverse of variance), or in the case of a multivariate normal distribution a 
precision matrix (inverse of covariance matrix) is used.  However, for the uninformative 
and informative prior distributions described below, the uncertainty is defined in terms of 
variance or a covariance matrix so that comparisons can be easily made with the 
simulation parameter uncertainty distributions.  The notations used for the simulation 
uncertainty distributions also apply for the prior distributions. 
 
Uninformative Priors 
 
Fixed Effects 
    10000 mg/day), ln(28.8  N~Vln max      10000 ,mg/L 10.0ln  N~Kln m  
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   10000 L/day), ln(0.72  N~CLln L     10000 L), ln(3.0  N~Vln 1  
    10000 L), ln(2.0  N~Vln 2     10000 L/day), ln(1.8  N~Qln  
  5.0 0,U~Von effect Weight max   5.0 0,U~CLon effect Weight L  
  5.0 0,U~Von effect Weight 1   5.0 0,U~Von effect Weight 2  
 
Between-Subject Variability 
(Distributions defined for standard deviation) 
  4-4max 1.0E ,1.0EU~ V    4-4L 1.0E ,1.0EU~ CL   
  4-41 1.0E ,1.0EU~ V    4-42 1.0E ,1.0EU~ V   
 
Residual Variability 
(Distribution defined for standard deviation) 
  4-4 1.0E ,1.0EU~  
 
Informative Priors 
 
Fixed Effects 
    0.25 L/day), ln(2.4  N~CLln int      1.38 ,mg/L 10.0ln  N~Kln m  
 
    ,N~Q ,V ,V ,CLln 21L   
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  1.25 0.25,U~Von effect Weight max   1.25 0.25,U~CLon effect Weight L  
  1.25 0.25,U~Von effect Weight 1   1.25 0.25,U~Von effect Weight 2  
 
 
 
 
 
 79
Between-Subject Variability 
(Distributions defined for standard deviation) 
     0.16 ,0.35ln  N~ Vln max       0.16 ,0.35ln  N~ CLln L   
     0.16 ,0.25ln  N~ Vln 1       0.16 ,0.25ln  N~ Vln 2   
 
Residual Variability 
(Distribution defined for standard deviation) 
     0.16 ,0.20ln  N~ln   
 
 Due to prolonged run times, WinBUGS was only evaluated under the informative 
and uninformative 600 mg dose level study designs, and the number of estimation runs 
was limited to 100 replicate data sets.  WinBUGS was run with three MCMC chains for 
250,000 iterations with a burn-in phase of 25,000 and every 25th sample was retained.  
Therefore, a total of 27,000 MCMC samples were retained for analysis.  The length of the 
burn-in phase was determined by performing a number of trial runs (n=15) with different 
simulated replicate data sets (under both the informative and uninformative 600 mg study 
designs), and convergence was monitored by visualization of the MCMC chain histories 
and the use of Gelman-Rubin-Brooks plots (162).  The trial runs were also performed 
with both uninformative and informative priors.  Since the data sets were different for 
each Bayesian MCMC run, a conservative number was chosen for the burn-in phase to 
increase the likelihood that convergence had been reached in all runs.  The trial runs were 
also used to determine an adequate number of iterations for sampling after the burn-in 
phase.  For purposes of this study, it was believed that 250,000 iterations for each MCMC 
chain would be an adequate number to sufficiently characterize the posterior median, 
which was chosen as the summary statistic of interest to calculate the parameter bias and 
precision.  For example, had the 2.5 and 97.5 percentiles of the posterior distribution been 
of interest, then it is likely that more MCMC samples would be needed to characterize the 
tails of the posterior distribution.  An adequate number of MCMC samples after the burn-
in phase was also assessed by using the Monte Carlo error, which is similar to the 
standard error of the mean but adjusted for autocorrelation between the parameters.  A 
Monte Carlo error of less than 5% of the standard deviation of the MCMC samples was 
considered to be sufficient for this study. 
 
 The BUGSModelLibrary offers a choice of two different ordinary differential 
equation solvers, and the Runge-Kutta 4th/5th order method was used for this analysis.  
Initial estimates for the three MCMC chains were interdispersed by 25%.  When 
uninformative priors were used, the initial estimates for one of the MCMC chains were 
set equal to those used for NONMEM.  When informative priors were used, the initial 
estimates for one of the MCMC chains were set equal to the means and midpoints of the 
informative prior distributions, which were comparable to the initial estimates used for 
NONMEM. 
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Evaluation of Estimation Performance 
 
 The estimation results from NONMEM differ from WinBUGS, as NONMEM 
provides maximum likelihood estimates while WinBUGS provides full posterior 
probability distributions of the parameters.  In order to make comparisons between 
NONMEM and WinBUGS with regards to estimation performance, the median of the 
posterior distributions was chosen as the point estimate.  The parameter values used to 
simulate each replicate data set were considered to be the true parameter values.  The 
difference between the parameter estimate and true value was calculated as the percent 
estimation error: 
  
100
Parameter
Parameter-Parameter
Error EstimationPercent 
True
TrueEstimate   
 
 The percent estimation errors were summarized for each estimation method under 
a given study design by calculating bias and precision.  Bias was calculated as the median 
percent estimation error (MPE), and precision was calculated as the median absolute 
percent estimation error (MAPE): 
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 A global sensitivity analysis was performed to evaluate the dependence of 
simulation conclusions on parameter uncertainty.  The sensitivity analysis was visualized 
by plotting the percent estimation error vs. the specific value of simulation model 
parameters for each trial replicate.  The plots were then viewed for trends in the 
estimation error when viewed across the range of parameter uncertainty employed for the 
simulations.  These sensitivity plots were created for each simulation model parameter. 
 
 Predictive checks were performed to assess whether the observed parameter 
biases would result in predictions that deviate significantly from the “true model”.  For 
purposes of the predictive check, the means and midpoints of the simulation parameter 
uncertainty distributions were assumed to be the true parameter values.  The true 
parameter values were then altered based on the parameter biases observed in the 
analysis.  Monte Carlo simulations were performed with both the true and biased 
parameter values using a template data set from one of the study designs.  The median 
and 90% prediction interval of simulated concentrations during the week 4 full 
concentration-time profile served as the metrics by which the true model predictions and 
analysis-derived predictions were compared. 
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Results 
 
 Under all study designs, the FO method generally produced larger bias and lower 
precision for the model parameters compared to the other estimation methods.  Therefore, 
the following discussion of the results is based on the findings for the FOCE-I, LAP-I, 
and Bayesian MCMC methods.  The discussion is also focused on the results from the 
informative and uninformative 600 mg dose level study designs, as these were the two 
designs under which both NONMEM and WinBUGS were evaluated and could be 
compared.  Results for the NONMEM estimation methods under the uninformative 200, 
500, and 800 mg dose level study designs can be found in Appendix C (Tables C-1 and 
C-2).  MCMC chain histories, probability densities of the posterior distributions of the 
model parameters, and Gelman-Rubin-Brooks plots for representative estimation runs 
using both sets of Bayesian priors under the informative and uninformative 600 mg dose 
designs are also presented in Appendix C (Figures C-1 through C-3). 
 
 
Informative Study Design 
 
 Bias and precision of the population PK model parameters under the informative 
study design are summarized in Tables 4-1 and 4-2, and boxplots of percent estimation 
errors of the model parameters are shown in Figure 4-2.  It should be noted that for the 
random effect parameters (i.e., between-subject variability and residual variability) bias 
and precision was calculated with respect to the variance term.  No appreciable bias was 
observed for the estimation methods, as the MPE was less than ±25% (ranged from -24% 
to 21%) for all parameters.  Bias was comparable across the estimation methods for a 
given parameter, with the most noticeable difference being the smaller bias for the V2 
between-subject variance when uninformative or informative Bayesian priors were used 
compared to FOCE-I and LAP-I.  For each estimation method, parameter bias tended to 
be larger for the between-subject variances compared to other model parameters. 
 
 Good precision was observed for the estimation methods, as the MAPE was less 
than 52% (ranged from 3% to 52%) for all model parameters.  Under each estimation 
method, the degree of precision varied among the parameters as a lower precision (i.e., 
larger MAPE) was observed for the covariate effects and between-subject variances 
compared to other parameters in the model.  Precision was similar across the estimation 
methods for a given parameter, but Bayesian MCMC (particularly with informative 
priors) produced noticeably better precision in the covariate effects and the V2 between-
subject variance compared to FOCE-I and LAP-I.  The differences in parameter precision 
between the estimation methods were also evident in the boxplots in Figure 4-2 for the 
aforementioned parameters. 
 
 Bias and precision of the PK parameter estimates for Bayesian MCMC with 
uninformative priors were comparable to that when informative priors were used, which 
can be expected given the informativeness of the data under the dose escalation study 
design. 
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Table 4-1. Bias (median percent estimation error) in the population pharmacokinetic model parameters under the informative 
study design. 
 
Parameter FO FOCE-I LAP-I B-MCMC B-MCMC
    [UP] [IP] 
Vmax -3.6 4.5 0.67 -5.6 -3.0 
Km 17 2.9 1.3 -1.1 1.2 
CLL 0.12 -0.61 -2.2 0.46 -0.062 
V1 -2.8 -0.83 -1.2 0.32 0.062 
V2 21 -0.46 -1.3 3.2 2.3 
Q 17 -1.5 -0.79 -0.25 -0.50 
WGT~Vmax -0.59 -0.32 -0.037 8.7 1.4 
WGT~CLL -3.8 0.47 -0.024 1.5 6.9 
WGT~V1 0.027 1.5 1.4 4.3 3.5 
WGT~V2 -0.77 -1.3 -1.3 11 5.4 
Vmax BSV (ω2) -30 -8.1 -8.4 21 1.4 
CLL BSV (ω2) 18 -13 -12 4.3 -9.5 
V1 BSV (ω2) -4.6 -8.6 -7.8 1.5 -2.3 
V2 BSV (ω2) 121 -18 -24 2.8 -0.59 
Residual variance (σ2) 16 -0.65 -0.76 0.82 1.3 
 
B-MCMC = Bayesian Markov Chain Monte Carlo; BSV = between-subject variance; IP = informative priors; UP = uninformative 
priors; WGT = weight. 
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Table 4-2. Precision (median absolute percent estimation error) in the population pharmacokinetic model parameters under the 
informative study design. 
 
Parameter FO FOCE-I LAP-I B-MCMC B-MCMC
    [UP] [IP] 
Vmax 19 11 11 11 9.5 
Km 32 11 11 9.4 8.8 
CLL 11 7.9 8.6 9.5 7.8 
V1 3.7 2.9 3.1 3.2 2.7 
V2 22 5.7 6.0 7.2 6.4 
Q 17 5.2 5.5 5.0 4.7 
WGT~Vmax 88 47 49 28 14 
WGT~CLL 77 51 52 40 20 
WGT~V1 26 21 21 21 16 
WGT~V2 61 37 39 30 15 
Vmax BSV (ω2) 43 25 25 37 25 
CLL BSV (ω2) 39 27 26 30 23 
V1 BSV (ω2) 19 17 18 19 17 
V2 BSV (ω2) 121 48 49 43 28 
Residual variance (σ2) 16 4.0 4.0 3.8 3.3 
 
B-MCMC = Bayesian Markov Chain Monte Carlo; BSV = between-subject variance; IP = informative priors; UP = uninformative 
priors; WGT = weight.
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Figure 4-2. Boxplots of percent estimation errors for the population pharmacokinetic 
model parameters under the informative study design.  Outliers are not shown for 
visualization purposes and made up <10% of the data for each parameter-estimation 
method combination.  The median percent estimation error corresponds to the calculated 
parameter bias.  Note that the y-axis scale differs from one boxplot to another.  B-
MCMC = Bayesian Markov Chain Monte Carlo; IP = informative priors; UP = 
uninformative priors. 
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Figure 4-2 continued. 
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Figure 4-2 continued.
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 Select plots from the global sensitivity analysis under the informative study 
design are shown in Figure 4-3 for the covariate effects and between-subject variances.  
Similar results were observed in the global sensitivity analysis for FOCE-I and LAP-I, 
therefore plots for FOCE-I are only shown.  For each estimation method, with the 
exception of when informative Bayesian priors were used, the sensitivity plots showed 
that for all parameters the percent estimation errors were insensitive to uncertainty in the 
values of the simulation parameters.  In other words, no trends were observed in the 
parameter estimation errors when viewed across the range of parameter uncertainty 
employed for simulating the replicate data sets.  In the case of informative priors, the 
sensitivity plots for the weight effect and the between-subject variance for Vmax, CLL, and 
V2 showed an increase in bias as simulation parameter values were selected further away 
from the mean or midpoint of their respective informative prior distribution.  For 
reference, the geometric means of the informative priors for the between-subject 
variability in Vmax, CLL, and V2 in terms of variance were 0.1225, 0.1225, and 0.0625, 
respectively.  The midpoints of the informative priors for the covariate weight effect were 
each 0.75. 
 
 Predictive checks showed that the parameter biases observed under the 
informative study design for FOCE-I, LAP-I, and Bayesian MCMC with informative and 
uninformative priors would not result in predictions that differed significantly from the 
true model.  This was expected given the relatively small parameter biases seen in Table 
4-1.  For the true and biased parameter values, 1000 data sets were simulated using an 
informative study design template data set, and the simulated concentrations during the 
full concentration-time profile at week 4 of therapy were then compared.  As seen in 
Figures 4-4 and 4-5 for FOCE-I and Bayesian MCMC with uninformative priors, the 
analysis-derived median and 90% prediction interval for concentrations during week 4 
were almost identical to the true model predicitons across all dose levels in the 
informative study design.  Similar plots were observed for LAP-I and Bayesian MCMC 
with informative priors (not shown). 
 
 
Uninformative 600 mg Dose Level Study Design 
 
 Bias and precision of the population PK model parameters under the 
uninformative 600 mg dose level study design are summarized in Tables 4-3 and 4-4, and 
boxplots of percent estimation errors for the model parameters are shown in Figure 4-6.  
The bias for most parameters under FOCE-I and LAP-I was less than ±20%.  Parameter 
biases were comparable between FOCE-I and LAP-I, although LAP-I produced a 
noticeably smaller bias for Vmax and the between-subject variance for Vmax and V2 
compared to FOCE-I.  The largest parameter biases (MPE) observed under FOCE-I were 
for Vmax (42%), Km (129%), Vmax between-subject variance (-40%), and V2 between-
subject variance (-100%), while the largest biases observed under LAP-I were for Km 
(143%) and V2 between-subject variance (-53%).  When informative Bayesian priors 
were used, the bias for all parameters was less than ±10%, with the only exception being 
Km which had an MPE of 34%.  The use of informative priors produced smaller biases 
for most of the model parameters compared to FOCE-I and/or LAP-I, and this was 
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Figure 4-3. Global sensitivity analysis results from the informative study design.  Plots are shown for selected parameters where 
the percent estimation error is plotted relative to the specific value of the simulation model parameter for each replicate.  The red line 
indicates a LOESS smoothing curve.  Panels A-D show sensitivity plots for the between-subject variances for Vmax, CLL, V1, and V2, 
respectively.  Panels E-H show sensitivity plots for the weight effect on Vmax, CLL, V1, and V2, respectively.  Note that the y-axis scale 
differs from one plot to another.  BSV = between-subject variance; IP = informative priors; %PE = percent estimation error; UP = 
uninformative priors. 
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Figure 4-3 continued. 
C 
D 
 92
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
2
0
0
0
2
0
0
4
0
0
FOCE-I
WGT~Vmax
W
G
T
~
V
m
a
x
 
%
P
E
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
5
0
0
5
0
1
0
0
2
0
0
Bayesian MCMC [UP]
WGT~Vmax
W
G
T
~
V
m
a
x
 
%
P
E
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
5
0
0
5
0
1
0
0
Bayesian MCMC [IP]
WGT~Vmax
W
G
T
~
V
m
a
x
 
%
P
E
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
4
0
0
-
2
0
0
0
2
0
0
4
0
0
FOCE-I
WGT~CLL
W
G
T
~
C
L
L
 
%
P
E
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
5
0
0
5
0
1
0
0
2
0
0
Bayesian MCMC [UP]
WGT~CLL
W
G
T
~
C
L
L
 
%
P
E
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
5
0
0
5
0
1
0
0
Bayesian MCMC [IP]
WGT~CLL
W
G
T
~
C
L
L
 
%
P
E
 
 
Figure 4-3 continued. 
E 
F 
 93
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
1
5
0
-
5
0
0
5
0
1
5
0
FOCE-I
WGT~V1
W
G
T
~
V
1
 
%
P
E
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
5
0
0
5
0
Bayesian MCMC [UP]
WGT~V1
W
G
T
~
V
1
 
%
P
E
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
4
0
-
2
0
0
2
0
4
0
6
0
8
0
Bayesian MCMC [IP]
WGT~V1
W
G
T
~
V
1
 
%
P
E
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
6
0
0
-
4
0
0
-
2
0
0
0
2
0
0
4
0
0
FOCE-I
WGT~V2
W
G
T
~
V
2
 
%
P
E
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
5
0
0
5
0
1
0
0
2
0
0
Bayesian MCMC [UP]
WGT~V2
W
G
T
~
V
2
 
%
P
E
0.4 0.5 0.6 0.7 0.8 0.9 1.0
-
5
0
0
5
0
1
0
0
Bayesian MCMC [IP]
WGT~V2
W
G
T
~
V
2
 
%
P
E
 
 
Figure 4-3 continued.
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Figure 4-4. Simulated prediction intervals for concentrations during week 4 of therapy 
based on the true parameter values and biased parameter values derived from the FOCE-I 
results under the informative study design.  The true model and analysis-derived 
predictions are indicated by the solid black lines and dashed red lines, respectively.  The 
three lines represent the 5th, 50th, and 95th percentiles determined from 1000 simulated 
data sets.  The simulations were carried out using an informative study design template 
data set.  Simulated prediction intervals are shown separately for each dose group. 
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Figure 4-5. Simulated prediction intervals for concentrations during week 4 of therapy 
based on the true parameter values and biased parameter values derived from the 
Bayesian MCMC (with uninformative priors) results under the informative study design.  
The true model and analysis-derived predictions are indicated by the solid black lines and 
dashed red lines, respectively.  The three lines represent the 5th, 50th, and 95th 
percentiles determined from 1000 simulated data sets.  The simulations were carried out 
using an informative study design template data set.  Simulated prediction intervals are 
shown separately for each dose group.
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Table 4-3. Bias (median percent estimation error) in the population pharmacokinetic model parameters under the uninformative 
600 mg dose level study design. 
 
Parameter FO FOCE-I LAP-I B-MCMC 
    [IP] 
Vmax 75 42 12 7.4 
Km 446 129 173 34 
CLL -21 -12 -6.5 -5.9 
V1 -4.0 -1.4 -1.3 -0.43 
V2 23 0.23 -2.0 4.7 
Q 20 3.4 2.2 2.6 
WGT~Vmax -18 3.8 5.2 9.6 
WGT~CLL -17 -18 -11 4.7 
WGT~V1 -1.9 -0.28 -0.23 0.63 
WGT~V2 46 21 18 3.1 
Vmax BSV (ω2) -75 -40 5.9 -8.4 
CLL BSV (ω2) -1.9 -0.92 -4.9 0.77 
V1 BSV (ω2) -6.0 -7.1 -5.9 -8.7 
V2 BSV (ω2) 57 -100 -53 -2.4 
Residual variance (σ2) 6.9 -2.6 -2.3 0.40 
 
B-MCMC = Bayesian Markov Chain Monte Carlo; BSV = between-subject variance; IP = informative priors; WGT = weight. 
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Table 4-4. Precision (median absolute percent estimation error) in the population pharmacokinetic model parameters under the 
uninformative 600 mg dose level study design. 
 
Parameter FO FOCE-I LAP-I B-MCMC 
    [IP] 
Vmax 100 54 53 25 
Km 446 129 173 38 
CLL 26 17 16 9.5 
V1 4.5 3.3 3.3 2.9 
V2 29 16 17 9.8 
Q 24 16 17 12 
WGT~Vmax 119 99 97 18 
WGT~CLL 101 83 73 16 
WGT~V1 27 23 24 17 
WGT~V2 120 102 112 19 
Vmax BSV (ω2) 100 81 79 43 
CLL BSV (ω2) 61 32 28 17 
V1 BSV (ω2) 22 20 19 19 
V2 BSV (ω2) 100 100 100 30 
Residual variance (σ2) 8.3 5.2 5.7 4.6 
 
B-MCMC = Bayesian Markov Chain Monte Carlo; BSV = between-subject variance; IP = informative priors; WGT = weight. 
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Figure 4-6. Boxplots of percent estimation errors for the population pharmacokinetic 
model parameters under the uninformative 600 mg dose level study design.  Outliers are 
not shown for visualization purposes and made up <10% of the data for each parameter-
estimation method combination.  The median percent estimation error corresponds to the 
calculated parameter bias.  Note that the y-axis scale differs from one boxplot to another.  
B-MCMC = Bayesian Markov Chain Monte Carlo; IP = informative priors. 
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Figure 4-6 continued. 
 101
-5
0
0
50
V1 Between-Subject Variance
%
 E
st
im
at
io
n 
Er
ro
r
FOCE-I LAP-I B-MCMC 
 [IP]
0
20
0
40
0
60
0
80
0
10
00
V2 Between-Subject Variance
%
 E
st
im
at
io
n 
Er
ro
r
FOCE-I LAP-I B-MCMC 
 [IP]
-2
0
-1
0
0
10
20
Residual Variance
%
 E
st
im
at
io
n 
Er
ro
r
FOCE-I LAP-I B-MCMC 
 [IP]
 
 
Figure 4-6 continued. 
 
 102
particularly evident for Vmax, Km, the weight effect on CLL and V2, and the between-
subject variance for Vmax and V2 (Table 4-3 and Figure 4-6). 
 
 FOCE-I and LAP-I produced similar results with regards to parameter precision, 
but both estimation methods exhibited low precision as almost half of the model 
parameters had a MAPE greater than 50%.  These parameters included Vmax, Km, the 
weight effect on Vmax, CLL, V2, and the between-subject variance for Vmax and V2.  When 
informative Bayesian priors were used, the MAPE was less than 30% for all parameters 
with the exception of Km (38%) and Vmax between-subject variance (43%).  Compared to 
FOCE-I and LAP-I, the use of informative priors resulted in greater parameter precision 
and smaller MAPEs for all model parameters.  This was most apparent for Vmax, Km, the 
weight effect on Vmax, CLL, V2, and the between-subject variance for Vmax and V2 (Table 
4-4).  The differences in parameter precision between the estimation methods were also 
evident in the boxplots in Figure 4-6, as the variability in the percent estimation errors for 
the aforementioned parameters was dramatically smaller when informative priors were 
used compared to FOCE-I and LAP-I. 
 
 The results for the estimation methods were also compared between the 
informative and uninformative 600 mg dose level study designs to evaluate the 
performance of the methods as the amount of information in the dataset decreased and the 
nature of the study design made it more difficult to detect and characterize the nonlinear 
elimination of the therapeutic mAb.  The estimation performance of the methods was 
adequate and comparable under the informative study design, considering that the bias 
and precision for all model parameters was less than ±25% and 52%, respectively.  Under 
the uninformative 600 mg dose level study design, the performance of FOCE-I and LAP-
I decreased as the bias and precision for many of the parameters significantly increased to 
±40-173% and 53-173%, respectively, while Bayesian MCMC with informative priors 
produced results that were comparable to those under the informative study design. 
 
 Select global sensitivity analysis plots are shown in Figure 4-7 for the between-
subject variance and weight effect parameters.  For FOCE-I, LAP-I, and Bayesian 
MCMC with informative priors, the sensitivity plots showed that for most parameters the 
percent estimation errors were insensitive to uncertainty in the values of the simulation 
parameters.  However, for each estimation method, trends were observed in the 
sensitivity plots for certain parameters.  For FOCE-I and LAP-I, an increasing trend 
towards underpredicting the V2 between-subject variance was observed as smaller 
simulation parameter values were selected for the V2 between-subject variance.  A 
similar observation was made for the Vmax between-subject variance under FOCE-I, 
where an increasing trend towards underpredicting the variance was observed as smaller 
between-subject variances for Vmax were selected from the simulation uncertainty 
distribution.  When informative Bayesian priors were used, the sensitivity plots for the 
weight effect and the between-subject variance for Vmax, CLL, and V2 showed an increase 
in bias as simulation parameter values were selected far away from the mean or midpoint 
of their respective informative prior distribution.  Similar plots were observed for these 
parameters in the global sensitivity analysis under the informative study design when 
informative Bayesian priors were used (Figure 4-3).
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Figure 4-7. Global sensitivity analysis results from the uninformative 600 mg dose level study design.  Plots are shown for selected 
parameters where the percent estimation error is plotted relative to the specific value of the simulation model parameter for each 
replicate.  The red line indicates a LOESS smoothing curve.  Panels A-D show sensitivity plots for the between-subject variances for 
Vmax, CLL, V1, and V2, respectively.  Panels E-H show sensitivity plots for the weight effect on Vmax, CLL, V1, and V2, respectively.  
Note that the y-axis scale differs from one plot to another.  BSV = between-subject variance; IP = informative priors; %PE = percent 
estimation error. 
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 Predictive checks showed that the parameter biases observed under the 
uninformative 600 mg dose level study design for FOCE-I, LAP-I, and Bayesian MCMC 
with informative priors (Table 4-3) can result in predictions that differ significantly from 
the true model depending on the doses (concentrations) at which the predictions are made 
(Figures 4-8 through 4-10).  For the true and biased parameter values, 1000 data sets 
were simulated using an uninformative study design template with different dose levels 
of 50, 100, 200, 400, 600, or 800 mg, and the simulated concentrations during the full 
concentration-time profile at week 4 of therapy were then compared.  Although the 
parameter values used for the simulations were based on the biases observed under the 
uninformative 600 mg dose level study design, the predictive checks were carried out at 
other doses in addition to 600 mg to investigate how the analysis-derived predictions 
would perform when extrapolated to other dose levels.  For FOCE-I, LAP-I, and 
Bayesian MCMC with informative priors, the analysis-derived median and 90% 
prediction interval for concentrations during week 4 were quite similar to the predictions 
based on the true model at dose levels of 400 mg and greater.  At the lower dose levels 
(50, 100, and 200 mg), the analysis-derived median and 90% prediction interval under 
each estimation method for the peak concentration at week 4 were very similar to the true 
model prediction.  This can be expected given that the peak concentrations are largely 
determined by V1, and the estimation methods produced negligible bias in both V1 and 
the between-subject variance for V1.  At the lower dose levels, the FOCE-I and LAP-I 
derived predictions for concentrations later in week 4 (e.g., the trough concentration) 
began to deviate from the true model, while the predictions based on Bayesian MCMC 
with informative priors remained closer to the true model.  The trough concentrations are 
largely determined by the total clearance of the mAb, which in the parallel elimination 
PK model, is determined by the clearance from the nonlinear pathway (CLNL) plus that of 
the linear pathway (CLL).  A large bias was observed for Km under FOCE-I and LAP-I of 
129% and 173%, respectively, while the use of informative priors resulted in a much 
smaller bias of 34%.  These differences in the bias for Km were likely the main reason for 
the predictive check observations, given that for each estimation method much smaller 
biases were observed for parameters related to Vmax and CLL compared to Km.  An 
overprediction of Km would cause a decrease in CLint, and consequently the CLNL and 
total clearance would decrease over the range of concentrations in which the nonlinear 
pathway is not saturated.  This decrease in total clearance would result in overprediction 
of trough concentrations which is what was observed in Figures 4-8 and 4-9 for the 
FOCE-I and LAP-I derived predictions. 
 
 The Bayesian MCMC method with uninformative priors was not investigated 
under the uninformative 600 mg dose level study design, because all of the initial 
estimation runs under this scenario failed to run to completion.  This could be expected, 
as the uninformative nature of the data sets simulated under the 600 mg dose level study 
design may not have supported the use of the vague priors specified in this study.  
However, if the originally specified vague priors were constrained to more biologically 
plausible values, but enough uncertainty retained so the priors could still be considered 
weakly informative, then the estimation runs would run to completion.  The use of the 
biologically plausible but weakly informative priors was not further investigated in the  
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Figure 4-8. Simulated prediction intervals for concentrations during week 4 of therapy 
based on the true parameter values and biased parameter values derived from the FOCE-I 
results under the uninformative 600 mg dose level study design.  The true model and 
analysis-derived predictions are indicated by the solid black lines and dashed red lines, 
respectively.  The three lines represent the 5th, 50th, and 95th percentiles determined 
from 1000 simulated data sets.  The simulations were carried out at different dose levels 
using an uninformative study design template data set. 
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Figure 4-9. Simulated prediction intervals for concentrations during week 4 of therapy 
based on the true parameter values and biased parameter values derived from the LAP-I 
results under the uninformative 600 mg dose level study design.  The true model and 
analysis-derived predictions are indicated by the solid black lines and dashed red lines, 
respectively.  The three lines represent the 5th, 50th, and 95th percentiles determined 
from 1000 simulated data sets.  The simulations were carried out at different dose levels 
using an uninformative study design template data set. 
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Figure 4-10. Simulated prediction intervals for concentrations during week 4 of therapy 
based on the true parameter values and biased parameter values derived from the 
Bayesian MCMC (with informative priors) results under the uninformative 600 mg dose 
level study design.  The true model and analysis-derived predictions are indicated by the 
solid black lines and dashed red lines, respectively.  The three lines represent the 5th, 
50th, and 95th percentiles determined from 1000 simulated data sets.  The simulations 
were carried out at different dose levels using an uninformative study design template 
data set. 
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study in order to maintain consistency in the methodology, since these priors would have 
differed from the vague priors used under the informative study design. 
 
 
Discussion 
 
 Nonlinear elimination is a common characteristic of the PK of therapeutic mAbs 
(6, 8), and accordingly, PK models with nonlinear elimination were used in almost half of 
the population PK analyses of therapeutic mAbs reported in the literature (Table 1-1).  It 
was also common in the population PK analyses to use a two-compartment model to 
describe the distribution of the therapeutic mAb.  It is estimated that half of all current 
projects in new drug development are biologics, with mAbs being the predominant class 
of biologics under clinical study (1).  As the number of therapeutic mAbs undergoing 
drug development and gaining FDA approval continue to increase, it is important that 
currently available estimation methods used for population PK modeling be evaluated 
when applied to therapeutic mAbs with nonlinear PK.  The challenge with detecting and 
characterizing nonlinear PK is not only dependent on the study design, but also on the 
estimation method used for the population PK analysis (163).  However, little work has 
been done evaluating population estimation methods using PK models that are 
representative of the typical disposition characteristics of therapeutic mAbs, as most 
method comparison studies used a one-compartment model with linear elimination for 
comparison (142-147).  In the current study, I evaluated the FO, FOCE-I, and LAP-I 
methods in NONMEM and a full Bayesian MCMC method in WinBUGS with both 
uninformative and informative priors in population PK modeling of therapeutic mAbs 
with nonlinear PK.  The structural PK model used for the simulation of trial replicates 
was a two-compartment model with parallel linear and nonlinear elimination pathways, 
which was also used in the population PK analyses of several therapeutic mAbs (Table 
1-1).  Furthermore, to my knowledge this is the first study to have systematically 
evaluated the formal inclusion of prior information with Bayesian MCMC methods when 
used for population PK modeling. 
 
 Given the similar population PK characteristics of therapeutic mAbs (Chapter 1), 
the idea was that the published findings from the population PK studies could not only be 
used to define the parameter uncertainty distributions for simulation of the trial replicates, 
but could also be used as prior information in a Bayesian analysis.  With regards to the 
simulation parameter uncertainty distributions, it was important that the values sampled 
from the distributions were realistic and representative of the population PK parameters 
observed for therapeutic mAbs in order to simulate concentration data for a prototypical 
mAb.  As shown in Figure 4-11, the probability density plots for the parameter 
uncertainty distributions adequately characterized the parameter estimates reported in 
published population PK analyses of therapeutic mAbs.  Population estimates for Vmax 
and Km are not shown in Figure 4-11 for their respective uncertainty distributions since 
both parameters are specific for a given mAb and pharmacological target, and as 
discussed in Chapter 1, Vmax and Km varied considerably among the different therapeutic 
mAbs.  The probability density plots for the Bayesian informative prior distributions (not 
shown) differed somewhat from those for the simulation uncertainty distributions, as the  
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Figure 4-11. Probability density plots of the parameter uncertainty distributions used 
for simulation of the trial replicates.  The red vertical dashes represent parameter 
estimates reported in published population PK analyses of therapeutic mAbs (see Tables 
1-3 through 1-6).  In some of the plots the red dashes are staggered for visualization 
purposes.  SD = standard deviation. 
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Figure 4-11 continued. 
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Bayesian informative priors were updated with additional population PK studies of 
therapeutic mAbs that were published or found in the literature after the simulation of the 
replicate data sets had been performed.  However, the Bayesian informative priors still 
adequately described the population PK parameter estimates reported in the literature for 
therapeutic mAbs.  Figure 4-12 shows a scatterplot matrix of parameter values drawn 
from the multivariate lognormal simulation uncertainty distribution defined for the 
parameters CLL, V1, V2, and Q, so that the correlations between the parameters can be 
visualized. 
 
 An issue that had to be addressed during this study was how to compare the 
parameter estimation output from NONMEM and WinBUGS.  While NONMEM 
provides maximum likelihood estimates (i.e., point estimates), WinBUGS provides the 
full posterior marginal distributions of the MCMC sampled values of the model 
parameters.  Summary statistics (e.g., mean, median, standard deviation, and 2.5 and 97.5 
percentiles) and probability density plots of the posterior marginal distributions can then 
be obtained.  Consideration was given to using the posterior mean, median, or mode, as 
the point estimate for calculating bias and precision of the parameter estimates for the 
Bayesian MCMC method.  Since the maximum likelihood estimate is the mode of the 
likelihood, the closest analog in a Bayesian analysis to a maximum likelihood estimate 
would be the mode of the posterior distribution.  However, estimating the mode from 
MCMC samples of a continuous variable can be problematic, and is not always reliable 
as this requires the probability density of the posterior distribution to be estimated from 
the MCMC samples and then the mode of the estimated density is used.  For a 
symmetrical posterior distribution, the mean, median, and mode would all be 
approximately equal; however, for many of the model parameters a positively skewed 
posterior distribution was observed.  Given the skewed nature of the posterior 
distributions, the posterior mean was typically larger than the mode and median.  
Therefore, for purposes of comparing the parameter estimation performance of 
WinBUGS and NONMEM, the posterior median was selected as a comparable metric to 
the maximum likelihood estimates provided by NONMEM.  The posterior median was 
also used in a study by Bennett and Wakefield, in which the estimation performance of a 
Bayesian MCMC method in the software package POPKAN was compared to the FOCE 
method in NONMEM and a two-step algorithm within another software package 
PPHARM (142). 
 
 Another issue that had to be addressed in this study was that due to prolonged run 
times it was not feasible to evaluate the estimation performance of WinBUGS under each 
of the dose levels used for the uninformative study design.  For this reason, WinBUGS 
was evaluated only under the 600 mg dose level uninformative design.  This dose level 
was selected for the reason that if the theoretical mAb in this study was undergoing drug 
development, a similar dose might be selected for entering phase II studies.  The 
approach to selecting the 600 mg dose level was to first simulate one replicate data set 
under the informative study design using the means and midpoints of the simulation 
parameter uncertainty distributions.  A noncompartmental analysis was then performed 
on the simulated concentration-time data.  As shown in Figure 4-13, there is a dose-
dependent decrease in clearance, which can be expected given the nonlinear PK of the  
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Figure 4-12. Scatterplot matrix of parameter values drawn from the multivariate 
lognormal uncertainty distribution defined for the parameters CLL, V1, V2, and Q, for 
simulating the trial replicates.  1000 values were drawn for each parameter. 
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Figure 4-13. Plot of clearance versus dose based on a noncompartmental analysis of a 
simulated replicate dataset under the informative study design.  There were six patients 
per dose level, and for each dose level the mean ±SD clearance is shown. 
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theoretical mAb.  Assuming that the theoretical mAb is eliminated via a saturable target-
mediated mechanism (i.e., receptor-mediated endocytosis), then theoretically, the 
asymptotic decrease of the clearance of the mAb would be the result of saturating the 
pharmacologic target.  Looking at Figure 4-13, the clearance of the mAb begins to level 
off somewhere around the 600 mg dose level.  These findings could be used as the basis 
for recommending a dose of around 600 mg for future phase II studies.  This rationale 
was similar to that used in a phase I study of cetuximab, where the maintenance dose 
recommendation for future phase II studies was based on the results of a 
noncompartmental analysis of cetuximab concentration-time data from patients treated at 
different dose levels (81).  In the cetuximab phase I study, a maintenance dose of around 
200 mg/m2 was recommended based on an observed dose-dependent decrease of 
cetuximab clearance over a range of 20-400 mg/m2, where saturation of the clearance 
began to occur around the 200 mg/m2 dose level (81).  The 600 mg dose level was also 
selected, because at larger doses the two-compartment parallel linear and nonlinear 
elimination model essentially collapses to a two-compartment linear model.  At these 
higher doses it would be difficult for any estimation method to detect the nonlinear PK.  
This was indicated by the increasing bias in the population estimate for Km for the 
NONMEM estimation methods as the dose levels increased under the uninformative 
design (Tables 4-1, 4-3, C-1). 
 
 Under all study designs, the FO method generally produced larger bias and lower 
precision for the model parameters compared to the other estimation methods evaluated.  
This was expected since FO is generally considered to be a less accurate estimation 
method compared to FOCE and LAP (13).  All three methods in NONMEM (FO, FOCE, 
LAP) linearize the nonlinear mixed effects model (e.g., population PK model) around the 
between-subject random effects (112, 113).  The FO method takes a first-order 
approximation around the expected value of the between-subject random effects which is 
0 (i.e., η = 0).  On the other hand, FOCE takes a first-order approximation around the 
conditional estimate of the between-subject random effects.  The LAP method is similar 
to FOCE, but takes a second-order approximation.  Despite the more accurate 
approximation of the nonlinear mixed effects model used by LAP, the estimation 
performance of LAP and FOCE were very similar under the informative and 
uninformative 600 mg study designs (Tables 4-1 through 4-4), although the LAP method 
did show improvement over FOCE under the uninformative 600 mg study design for the 
bias in Vmax and the between-subject variance for Vmax and V2.  A detailed discussion of 
the theory behind the approximate maximum likelihood methods in NONMEM (FO, 
FOCE, LAP) and Bayesian MCMC methods, such as that used by WinBUGS, is not 
within the scope of this text but are discussed elsewhere (112, 113, 115, 116, 150, 152).  
Although, it is worth noting that Bayesian MCMC methods do not rely on analytical 
approximations of the nonlinear mixed effects model like with FO, FOCE, and LAP, but 
instead use Monte Carlo integration techniques to obtain parameter estimates for the 
exact model (115, 116).  The extent to which the theoretical differences in the methods in 
NONMEM and WinBUGS translated into differences in their estimation performance is 
unknown and was not evaluated per se in this study. 
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 There are a number of practical advantages and disadvantages with NONMEM 
and WinBUGS.  One advantage with Bayesian MCMC methods is the ability to include 
prior information in the population PK analysis by using informative priors.  This 
advantage was demonstrated by the superior performance of Bayesian MCMC with 
informative priors over the NONMEM estimation methods under the uninformative 600 
mg design.  Another advantage with Bayesian MCMC is that full posterior distributions 
of the PK model parameters are provided from which inferences can made using the 
entire distribution.  Depending on the computing resources available, a potential 
disadvantage with WinBUGS is prolonged run times.  As observed in this study, run 
times with WinBUGS were considerably longer compared to when the NONMEM 
estimation methods were used.  Average run times for FOCE-I and LAP-I under the 
informative study design were 7 minutes and 30 minutes, respectively, while run times 
for Bayesian MCMC with uninformative priors and informative priors averaged around 
19 hours and 25 hours, respectively.  Under the uninformative 600 mg study design, 
average run times for FOCE-I, LAP-I, and Bayesian MCMC with informative priors were 
8 minutes, 45 minutes, and 19 hours, respectively.  In the past, another drawback to 
Bayesian MCMC methods was the lack of accessibility to such methods and software 
without having to do additional custom programming to implement the population PK 
model and to input and manage data.  However, accessibility to Bayesian MCMC 
methods for population PK modeling is improving.  For example, the 
BUGSModelLibrary (157), a recently developed WinBUGS PK/PD model library, was 
used in this study to implement the population PK model.  In addition, a Bayesian 
MCMC method was incorporated in the recent release of NONMEM version VII (164).  
A benefit to using NONMEM is that it is the most widely used software for population 
PK/PD modeling (151), and since it has been available for more than 30 years, there is a 
wealth of studies and experience with using NONMEM in the literature.  For 
pharmacometricians that have primarily used NONMEM for population PK/PD 
modeling, switching to WinBUGS may require additional training and education in 
Bayesian analysis and MCMC methods. 
 
 The NONMEM user’s guide points out that the FO, FOCE, and LAP estimation 
methods can be inaccurate when dealing with highly nonlinear models (112).  However, 
when evaluating the performance of any estimation method, one should always take into 
consideration the nature of the data and study design under which the method was 
evaluated.  As shown in this study, the FOCE and LAP methods performed reasonably 
well and on par with the Bayesian MCMC method under the conditions used for the 
informative study design.  FOCE and LAP also performed relatively well under the 
uninformative 200 mg study design, as the bias and precision for many of the parameters 
were comparable to those under the informative study design, although a noticeably 
larger bias and/or lower precision was observed for some of the parameters (e.g., V2 and 
weight effect on V2) under the uninformative 200 mg design (Tables 4-1, 4-2, C-1, C-2). 
 
 The estimation performance of FOCE-I and LAP-I decreased as the dose levels 
used for the uninformative study design (200, 500, 600, and 800 mg) were increased 
(Tables 4-3, 4-4, C-1, C-2).  This decrease in performance was particularly evident for 
the model parameters related to nonlinear elimination.  This was not a surprise, since the 
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larger doses resulted in concentrations well above the Km, thereby leading to saturation of 
the nonlinear elimination pathway and making it more difficult to detect and characterize 
the nonlinear PK.  For this reason, I was interested in whether or not the nonlinearity 
could be detected with FOCE-I and LAP-I at the dose levels used for the uninformative 
design.  In other words, would a two-compartment model with parallel nonlinear and 
linear elimination be selected over a more parsimonious two-compartment model with 
linear elimination at these dose levels?  This question was investigated by fitting both PK 
models to 50 replicate data sets simulated under the uninformative study design for the 
200, 500, 600, and 800 mg dose levels.  This was only done for the FOCE-I method, 
since it was believed that similar results would be achieved using LAP-I.  Model 
selection was based on the likelihood ratio test.  Since, the PK models are not strictly 
hierarchical, a p value of 0.01 was used which corresponds to a change in the OFV of 
13.28 at 4 degrees of freedom.  In more than 70% of the runs under the 200, 500, and 600 
mg dose levels, the two-compartment parallel elimination model would have been 
selected over the two-compartment linear model.  Under the 800 mg dose level, this 
would have been the case in less than 30% of the runs.  The significance of this finding is 
that while FOCE-I in NONMEM was able to detect nonlinearity at the 600 mg dose level, 
and that it is plausible that a two-compartment parallel elimination model would have 
been selected over a simpler PK model, the results in Tables 4-3 and 4-4 show that 
FOCE-I at the 600 mg dose level resulted in biased and imprecise estimates for many of 
the model parameters.  This scenario is also relevant, because it represents a situation 
often encountered in population PK modeling where a more complex and 
mechanistically-plausible PK model is not fully supported by available concentration data 
due to study design limitations, and consideration must be given to using a more 
parsimonious PK model. 
 
 The global sensitivity analysis produced some interesting findings.  Under the 
different study designs, the global sensitivity plots for the evaluated estimation methods 
showed that for most of the model parameters the percent estimation errors were 
insensitive to uncertainty in the values of the simulation parameters.  However, FOCE-I, 
LAP-I, and Bayesian MCMC with uninformative priors tended to be more robust to 
uncertainty in the simulation values for select parameters (weight effect and the between-
subject variance for Vmax, CLL, and V2) compared to when informative Bayesian priors 
were used.  The global sensitivity analysis results are conditional on the degree of 
uncertainty in the simulation parameter values employed in this study.  Perhaps the 
FOCE-I and LAP-I methods would have been less robust had broader simulation 
uncertainty distributions been used for some of the parameters such as the between-
subject variances.  However, the uncertainty distributions were defined so that the 
sampled parameter values were realistic and representative of those reported in published 
population PK analyses of therapeutic mAbs.  Looking at the global sensitivity analysis 
plots under the informative study design for the weight effect and the between-subject 
variance for Vmax, CLL, and V2 (Figure 4-3), there were no trends in the estimation errors 
when uninformative priors were used, but there were when informative priors were used.  
This observation suggests that the formal inclusion of prior information influenced the 
estimates for these parameters, and it also illustrates the importance of investigating the 
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sensitivity of parameter estimates to different prior distributions when performing a 
Bayesian analysis of population PK data. 
 
 The findings from this simulation study may be of value to pharmacometricians 
performing population PK analyses of therapeutic mAbs.  The acceptable performance of 
the FOCE-I, LAP-I, and Bayesian MCMC estimation methods under the informative 
study design suggests that if sufficient concentration-time data is available to adequately 
characterize the nonlinear elimination of the mAb, then any one of these estimation 
methods would be suitable for the population PK analysis.  The choice then of one 
estimation method over another would depend on other factors such as available 
computing resources and familiarity with the methods.  However, as often encountered in 
drug development, concentration-time data may only be available from clinical studies 
where limitations in the study design make it difficult to detect and characterize the 
nonlinear elimination of the therapeutic mAb.  As discussed in Chapter 1, these clinical 
study design limitations are often due to the doses (concentrations) studied, because the 
doses (which may be clinically relevant) result in concentrations that are high enough to 
saturate the nonlinear target-mediated elimination of the therapeutic mAb.  For example, 
nonlinear elimination has been observed for efalizumab and trastuzumab and attributed to 
saturable target-mediated elimination (33, 35, 79, 82), but population PK analyses of the 
two mAbs were able to adequately describe their PK using a compartmental model with 
linear elimination (33, 46).  Based on PK data from dose escalation studies of efalizumab 
(35) and trastuzumab (82), the doses of these mAbs investigated in the aforementioned 
population PK analyses may have resulted in steady-state concentrations where target-
mediated clearance was saturated, and thus the use of a PK model with linear elimination 
was warranted.  In this study, the estimation methods were evaluated under similar 
conditions with the uninformative study designs where concentration data was only 
available from a single dose level, and the dose levels selected resulted in concentrations 
that were generally above the Km.  Under a less-than-optimal study design, such as the 
uninformative 600 mg dose design, consideration should first be given to what the 
population PK model is to be used for.  If the model is to be used for 
describing/predicting concentrations at doses where the nonlinear elimination pathway is 
at or near saturation, then using a PK model with linear elimination would be a 
reasonable approach as the nonsaturable Fc-mediated elimination pathway becomes the 
major determinant of the mAb clearance (Chapter 1, Figure 1-2B).  In this case, the use 
of the FOCE or LAP estimation methods in NONMEM would likely be sufficient.  
However, if for example the population PK model is to be used to predict concentrations 
at lower doses, then the findings under the uninformative 600 mg study design would 
suggest that one may want to consider the use of a Bayesian MCMC method with 
informative priors given its improved performance over the NONMEM estimation 
methods.  As shown in Figures 4-8 through 4-10, the analysis-derived predictions for 
FOCE-I, LAP-I, and Bayesian MCMC with informative priors were quite similar to the 
predictions based on the true model at the 600 mg dose level.  However, at lower doses, 
the analysis-derived predictions for FOCE-I and LAP-I deviated further from the true 
model than the analysis-derived predictions for Bayesian MCMC with informative priors.  
As discussed in Chapter 1 and implemented in this study, the findings from published 
population PK analyses of therapeutic mAbs could be used as prior information given 
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their similar population PK characteristics.  Prior information on the PK of the 
therapeutic mAb of interest could also be available and used in defining the priors. 
 
 The population PK analysis of cetuximab in Chapter 3 found that the PK of 
cetuximab was best described using a two-compartment model with nonlinear 
elimination.  The final population PK model was able to adequately describe the 
nonlinear PK of cetuximab at the clinically approved dosage regimen, and the PK 
parameter estimates were in line with a previous population PK analysis of cetuximab 
conducted for regulatory purposes which also used the same structural model as in my 
study (109, 140).  The population estimates for Vmax and Km were also in agreement with 
findings from other PK analyses of cetuximab (123, 139).  Concentration data from 
multiple dose groups was available in the cetuximab population PK analysis conducted 
for regulatory purposes (109, 140) and in the aforementioned cetuximab PK studies (123, 
139).  Various issues were encountered during the cetuximab analysis which were likely 
the result of attempting to describe its nonlinear elimination.  This difficulty was likely 
due in part to limitations of the clinical study designs, which included the lack of dose 
escalation concentration data and that the majority of patients provided only peak and 
trough concentrations.  Given the relative uninformativeness of the data that was 
available for the cetuximab population PK analysis (particularly the single dose level 
study designs), the results from the current study suggest that the inclusion of prior 
information within the context of a full Bayesian analysis may have benefited the 
cetuximab analysis.  Prior information was available from a number of sources that could 
have been used in the cetuximab population PK analysis.  For example, the results from 
the previously conducted population PK analysis of cetuximab could have been used 
(109, 140), and parameter estimates for Vmax and/or Km had also been reported in other 
PK studies of cetuximab (80, 123, 139).  In addition, it would have been a reasonable 
approach to have also used the published results from population PK analyses of other 
therapeutic mAbs as prior information in the cetuximab analysis. 
 
 In summary, I conducted a simulation study to compare the parameter estimation 
performance of the FO, FOCE-I, and LAP-I methods in NONMEM and a full Bayesian 
MCMC method in WinBUGS when applied to population PK modeling of therapeutic 
mAbs with nonlinear PK.  The Bayesian MCMC method was evaluated with both 
uninformative and informative priors.  The estimation methods were evaluated under a 
dose-ranging design and four different single dose level designs at different dose levels.  
When sufficient data was available to characterize the nonlinear PK of the therapeutic 
mAb, as in the case of the dose-ranging design, the estimation performance of the FOCE-
I, LAP-I, and Bayesian MCMC (with both sets of priors) methods were comparable and 
demonstrated acceptable bias and precision of the parameter estimates.  Under a less-
than-optimal study design, the formal inclusion of prior information with the Bayesian 
MCMC method provided a clear performance advantage over the other methods. 
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CHAPTER 5.  SUMMARY OF DISSERTATION RESEARCH 
 
 
 Over the past two decades, there has been an increase in the research and 
development and therapeutic application of mAbs.  Currently, there are over 20 mAb 
products (i.e. antibodies, antibody fragments, or antibody-conjugates) approved by the 
FDA for therapeutic use in areas such as oncology, immunology, ophthalmology, 
cardiovascular disease, and infectious disease.  It is estimated that half of all current 
projects in new drug development are biologics, with mAbs being the predominant class 
of biologics under clinical study (1).  In 2008, it was reported that there were over 200 
mAbs undergoing clinical study (2).  One likely reason for the continued success of the 
clinical development of mAbs is the application and integration of PK and PD concepts 
in all stages of pre-clinical and clinical drug development (3, 4).  One application of 
PK/PD concepts in drug development is population PK, which attempts to quantify the 
typical disposition characteristics and sources of PK variability (such as between-subject, 
within-subject, and inter-occasion variability) within study populations.  Population PK 
also attempts to identify and quantify the impact of covariates on systemic drug exposure, 
and assess their potential implications for clinical dosing.  The general theme of my 
dissertation research was population PK modeling of therapeutic mAbs, which focused 
on the population PK modeling of cetuximab (Chapter 3), and the evaluation of different 
estimation methods for population PK modeling of therapeutic mAbs with nonlinear PK 
characteristics (Chapter 4). 
 
 A large number of population PK analyses of therapeutic mAbs have been 
published in the scientific literature.  In Chapter 1, I summarized the findings from these 
population PK studies and related the findings to the general PK and structural 
characteristics of therapeutic mAbs.  A two-compartment model was used in the majority 
of the population analyses to describe the disposition of the mAb.  Population estimates 
for V1 and V2 were typically small with a median (range) of 3.1 L (2.4-5.5) and 2.8 L 
(1.3-6.8), respectively.  The estimated between-subject variability in V1 was usually 
moderate with a median (range) of 28 %CV (12-84).  Between-subject variability in other 
distribution related parameters such as V2 and Q were often not estimated. Although the 
most frequent PK models used in the population analyses were models with linear 
elimination, other models with nonlinear or parallel linear and nonlinear elimination 
pathways were also applied as many therapeutic mAbs are eliminated via saturable 
target-mediated mechanisms.  Population estimates of Vmax and Km, the parameters 
characterizing Michaelis-Menten type saturable clearance pathways, varied considerably 
among the different therapeutic mAbs.  However, estimates for CLT in mAbs with linear 
elimination characteristics and for CLL in mAbs with parallel linear and nonlinear 
elimination were quite similar among the different mAbs, and typically ranged from 
around 0.2-0.5 L/day, which is relatively close to the estimated CL of endogenous IgG of 
0.21 L/day.  The between-subject variability in Vmax, CLT, and CLL was moderate to 
large with estimates ranging from 15-65 %CV.  Measures of body size were the most 
commonly identified covariates found to influence the PK of therapeutic mAbs.  My 
literature review found that many characteristics of the population PK of currently used 
therapeutic mAbs are quite similar despite differences in their pharmacologic targets and 
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studied patient populations.  These similarities are likely in part due to general structural 
features that are shared among most therapeutic mAbs as IgG molecules such as a 
functional human Fc region.  One could hypothesize that target-binding specific PK 
parameters such as Vmax and Km are likely to be influenced by the interaction between a 
given therapeutic mAb and its target, and thus show high variability among different 
mAbs, while the differences among parameters such as CLL, V1, V2, and Q that are 
thought to be largely affected by the general structural features of mAbs are minimal.   
Given the similar population PK characteristics of therapeutic mAbs, I proposed in this 
review that the results from the population PK analyses could serve a practical purpose 
and be used to construct informative priors for a Bayesian data analysis or for 
constructing parameter uncertainty distributions to simulate PK data for a prototypical 
therapeutic mAb.  These ideas were put into practice in Chapter 4 where the estimation 
methods in NONMEM and WinBUGS were evaluated. 
 
 A therapeutic mAb that was of particular interest in my dissertation research was 
cetuximab, which is directed against EGFR and is indicated in the treatment of SCCHN.  
In Chapter 3, I performed a population PK analysis of cetuximab using nonlinear mixed 
effects modeling and the software NONMEM (version V).  I hypothesized that nonlinear 
mixed effects modeling could be used to develop a population PK model that could 
adequately predict the systemic exposure of cetuximab in patients with SCCHN.  
Furthermore, I hypothesized that covariates could be identified that are significant 
predictors for cetuximab systemic exposure.  A total of 912 cetuximab concentrations 
were available from 143 patients with recurrent and/or metastatic SCCHN enrolled in two 
phase I/II studies.  The PK of cetuximab was best described by a two-compartment model 
with Michaelis-Menten type saturable elimination.  Mean population estimates (between-
subject variability, %CV) of the PK parameters were: Vmax 4.38 mg/hr (15.4%), Km 74 
μg/ml, V1 2.83 L (18.6%), V2 2.43 L (56.4%), and Q 0.103 L/hr (97.2%).  Covariates that 
were identified included IBW and WBC count as predictors of Vmax, and WGT as a 
predictor of V1.  The findings of the population PK analysis suggest that clinical dose 
adjustments beyond the approved BSA-based dosing of cetuximab may be warranted in 
patients with extreme deviations of their actual body weight from IBW.  Agreement 
between simulated and measured concentrations for up to 43 weeks of therapy indicated 
that the final population PK model was able to adequately describe the nonlinear PK of 
cetuximab in patients with SCCHN at the currently approved dosage regimen, and that 
the cetuximab PK parameters remained constant during prolonged therapy. 
 
 During the cetuximab population PK analysis, a number of issues and challenges 
were encountered which were likely the result of an attempt to describe the nonlinear 
elimination of cetuximab.  The difficulty characterizing the nonlinear PK of cetuximab 
was likely due to limitations of the clinical study designs, which included the lack of dose 
escalation data and the majority of patients provided only peak and trough 
concentrations.  However, the difficulty may also have been due to the use of the FOCE 
estimation method throughout the analysis.  It is known that FOCE, in addition to the FO 
and LAP estimation methods in NONMEM, can be inaccurate when dealing with highly 
nonlinear models such as the model with nonlinear elimination used to describe the PK of 
cetuximab (112).  Therefore, it was questioned whether or not the use of another 
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population estimation method in the cetuximab analysis would have led to more accurate 
parameter estimates and better characterization of the nonlinear PK of cetuximab.  I was 
particularly interested in how a full Bayesian analysis using MCMC methods such as that 
implemented in the software WinBUGS would have performed.  Unlike the 
aforementioned estimation methods in NONMEM, Bayesian MCMC methods do not rely 
on analytical approximations of the nonlinear mixed effects model, but instead use Monte 
Carlo integration techniques to obtain parameter estimates for the exact model (115, 116).  
Bayesian MCMC methods also allow one to include prior information about the model 
parameters in the Bayesian hierarchical model by using informative priors.   
 
 The question of how well other population estimation methods would have 
performed in evaluating the nonlinear elimination of cetuximab is also relevant for other 
therapeutic mAbs.  Nonlinear elimination is a common characteristic of the PK of 
therapeutic mAbs (6, 8), and accordingly, PK models with nonlinear elimination were 
used in almost half of the population PK analyses of therapeutic mAbs published in the 
scientific literature (Chapter 1).  In addition, similar difficulties encountered during the 
cetuximab analysis were also reported in population PK analyses of other therapeutic 
mAbs (Chapter 1).  The challenge with detecting and characterizing nonlinear PK is not 
only dependent on the study design, but also on the estimation method used for the 
population PK analysis (163).  However, little work has been done so far evaluating 
population estimation methods using PK models that are representative of the typical 
disposition characteristics of therapeutic mAbs, as most method comparison studies used 
a one-compartment model with linear elimination for comparison (142-147). 
 
 I hypothesized that compared to the FO, FOCE-I, and LAP-I methods in 
NONMEM, other parameter estimation methods that avoid linearization of the nonlinear 
mixed effects model such as Bayesian MCMC, would lead to more accurate parameter 
estimates and better characterization of the nonlinear PK encountered with therapeutic 
mAbs such as cetuximab.  I conducted a simulation study to compare the parameter 
estimation performance of the FO, FOCE-I, and LAP-I methods in NONMEM and a 
Bayesian MCMC method in WinBUGS when applied to population PK modeling of 
therapeutic mAbs with nonlinear PK.  The Bayesian MCMC method was evaluated with 
uninformative and informative priors, which were obtained from the literature.  To my 
knowledge, this was the first study to have systematically evaluated the formal inclusion 
of prior information with Bayesian MCMC methods when applied to population PK 
modeling.  The uncertainty distributions for the population PK model parameters were 
also obtained from the literature in order to simulate concentration data for a prototypical 
therapeutic mAb.  The estimation methods were evaluated under a dose-ranging design 
(informative study design) and four different single dose level designs at different dose 
levels (uninformative study designs).  In my analysis, I addressed the following three 
subhypotheses: 1) under all study designs the FO method would be less accurate and 
precise compared to the other estimation methods; 2) when sufficient data is available to 
characterize the nonlinear PK of the therapeutic mAb, as in the case of the informative 
design, the estimation performance of FOCE-I, LAP-I, and Bayesian MCMC (with both 
sets of priors) would be adequate and comparable; and 3) under the less-than-optimal 
(uninformative) study designs there would be a decline in the estimation performance of 
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the FOCE-I and LAP-I methods, while the formal inclusion of prior information with the 
Bayesian MCMC method would provide a clear performance advantage over the other 
methods.   
 
 Under all study designs, the FO method generally produced larger bias and lower 
precision for the model parameters compared to the other estimation methods.  
Comparison of the estimation performance of the methods in NONMEM and WinBUGS 
was limited to the informative and uninformative 600 mg dose level study designs due to 
prolonged run times with WinBUGS.  Under the informative study design, bias and 
precision for all model parameters was less than ±25% and 52%, respectively, for FOCE-
I, LAP-I, and Bayesian MCMC with both sets of priors.  Under the uninformative 600 mg 
dose level study design, the estimation performance of FOCE-I and LAP-I decreased as 
bias and precision for many of the model parameters, in particular those related to 
nonlinear elimination, significantly increased to ±40-173% and 53-173%, respectively, 
while Bayesian MCMC with informative priors produced results that were comparable to 
those under the informative study design. 
 
 Given the relative uninformativeness of the data that was available for the 
cetuximab population PK analysis, the results from the estimation method comparison 
study suggested that the inclusion of prior information within the context of a full 
Bayesian analysis may have benefited the cetuximab analysis.  Prior information was 
available from a number of sources that could have been used in the cetuximab 
population PK analysis.  For example, the results from a previously conducted population 
PK analysis of cetuximab could have been used (109, 140), and parameter estimates for 
Vmax and/or Km had also been reported in prior PK studies of cetuximab (80, 123, 139).  
In addition, it would have been a reasonable approach to have also used the published 
results from population PK analyses of other therapeutic mAbs as prior information given 
their similar population PK characteristics. 
 
 To visualize the potential application of the results from the estimation method 
comparison study, consider a population PK analysis of a prototypical therapeutic mAb 
that exhibits nonlinear PK due to saturable target-mediated elimination mechanisms.  If 
sufficient concentration data is available to adequately characterize the nonlinear 
elimination of the mAb, then the adequate performance of the FOCE-I, LAP-I, and 
Bayesian MCMC estimation methods under the informative study design would suggest 
that any one of these estimation methods would be suitable for the population PK 
analysis.  The choice then of one estimation method over another would depend on other 
factors such as available computing resources and familiarity with the methods.  
However, as frequently encountered in drug development, consider that concentration 
data is only available from a less-than-optimal study design such as the uninformative 
600 mg dose level design used in the method comparison study, where the dose results in 
concentrations that are high enough to saturate the nonlinear target-mediated elimination 
of the mAb.  In this case, consideration should first be given to what the population PK 
model is to be used for.  If the model is to be used for describing/predicting 
concentrations at doses where the nonlinear elimination pathway is at or near saturation, 
then using a PK model with linear elimination would be a reasonable approach as the 
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nonsaturable Fc-mediated elimination pathway becomes the major determinant of the 
mAb clearance.  In this case, the use of the FOCE or LAP estimation methods in 
NONMEM would likely be sufficient.  However, if for example, the population PK 
model is to be used to predict concentrations at lower doses, then the findings under the 
uninformative 600 mg study design would suggest that one may want to consider the use 
of a Bayesian MCMC method with informative priors given the superior estimation 
performance over the NONMEM estimation methods. 
 
 In summary, the general theme of my dissertation research was population PK 
modeling of therapeutic mAbs.  My research work began with a population PK analysis 
of cetuximab in patients with SCCHN.  The challenges and issues encountered during the 
analysis led me to investigate the estimation performance of the FO, FOCE-I, and LAP-I 
methods in NONMEM and a Bayesian MCMC method (with both uninformative and 
informative priors) in WinBUGS when applied to population PK modeling of therapeutic 
mAbs with nonlinear PK, and to delineate scenarios in which one estimation method may 
be superior to the others.  The findings from this work should be of value to 
pharmacometricians who are involved in population PK modeling of therapeutic mAbs. 
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APPENDIX A: 
NONMEM CONTROL STREAM AND OUTPUT FOR THE FINAL 
CETUXIMAB POPULATION PK MODEL 
 142
A-1. NONMEM control stream for the final cetuximab population pharmacokinetic 
model. 
 
 
$PROBLEM **FINAL MODEL** 
 
$INPUT C PTID=DROP ID DAT1=DROP TIME AMT RATE DV MDV VIS=DROP 
WEEK=DROP STDY SITE=DROP SEX AGE=DROP ETHN=DROP HGT=DROP 
WGT IBW BSA=DROP CBSA=DROP BUN=DROP SRCR=DROP CRCL=DROP 
ADJC=DROP RENL=DROP TBIL=DROP ALB=DROP AST=DROP ALT=DROP 
KSKY=DROP EF=DROP EFNA=DROP EGFR=DROP HACA=DROP FU=DROP 
FUD=DROP PLTM=DROP PLTD=DROP CHEM=DROP WBC MONO=DROP 
BUNM=DROP CRCM=DROP TBLM=DROP ALBM=DROP ALTM=DROP 
WBCM=DROP 
 
$DATA 8WK_LN_CTXDTB_medians.CSV IGNORE=C 
$ABB COMRES=6 
 
$SUBROUTINE ADVAN6 TRANS1 TOL=6 INFN=MYINFN.FOR 
 
$MODEL NPAR=5 NCOMP=2 COMP=(CENTRAL DEFOBSERVATION DEFDOSE) 
COMP=(PERIPH) 
 
$PK 
  TVVMAX=THETA(1)*(1+THETA(6)*(IBW-64)+THETA(8)*(WBC-6.8)) 
  VMAX=TVVMAX*EXP(ETA(1)) 
  KM=THETA(2) 
  TVV1=THETA(3)*(1+THETA(7)*(WGT-60)) 
  V1=TVV1*EXP(ETA(2)) 
  TVV2=THETA(4) 
  V2=TVV2*EXP(ETA(3)) 
  Q=THETA(5)*EXP(ETA(4)) 
  S1=V1 
 
$DES 
 C1=A(1)/V1 
 C2=A(2)/V2 
 DADT(1)=-VMAX*C1/(KM+C1)-(Q*C1)+(Q*C2) 
 DADT(2)=(Q*C1)-(Q*C2) 
 
$ERROR 
  CALLFL=0 
  IF (F.LE.0) THEN 
  IPRED=-5 
  ELSE 
  IPRED=LOG(F) 
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  ENDIF 
  IRES=DV-IPRED 
  IWRES=IRES/IPRED 
  IF (STDY.EQ.8) THEN 
  Y=IPRED+ERR(1) 
  ELSE 
  Y=IPRED+ERR(2) 
  ENDIF 
 
"LAST 
"COM(1)=G(1,1) 
"COM(2)=G(2,1) 
"COM(3)=G(3,1) 
"COM(4)=G(4,1) 
"COM(5)=HH(1,1) 
"COM(6)=HH(2,1) 
 
$THETA 
(1.5, 4.22, 7.5)  ;VMAX (mg/hr) 
(35, 71.6, 150)  ;KM (μg/mL) 
(1.3, 2.72, 5)   ;V1 (L) 
(1.1, 2.43, 5)   ;V2 (L) 
(0.001, 0.095, 0.15)  ;Q (L/hr) 
(0.001, 0.0115, 0.05)  ;IBW(l)~Vmax 
(0.001, 0.0080, 0.05)  ;WGT(l)~V1 
(0.001, 0.0240, 0.075) ;WBC(l)~Vmax 
 
$OMEGA .025   ;VMAX 
$OMEGA .032   ;V1 
$OMEGA .29    ;V2 
$OMEGA .975   ;Q 
 
$SIGMA 
0.030     ;STUDY 08 
0.050     ;STUDY 16 
 
$ESTIMATION NOABORT MAXEVAL=9999 PRINT=5 METHOD=1 
$COVARIANCE PRINT=E 
 
$TABLE ID TIME IPRED IWRES NOPRINT ONEHEADER FILE=sdtab1077 
$TABLE ID VMAX KM V1 V2 Q NOPRINT ONEHEADER FILE=patab1077 
$TABLE ID IBW WGT WBC NOPRINT ONEHEADER FILE=cotab1077 
$TABLE ID SEX NOPRINT ONEHEADER FILE=catab1077 
$TABLE ID COM(1)=G11 COM(2)=G21 COM(3)=G31 COM(4)=G41 COM(5)=H11 
COM(6)=H21 IPRED MDV NOPRINT ONEHEADER FILE=cwtab1077 
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A-2. NONMEM run output for the final cetuximab population pharmacokinetic model. 
 
 
1NONLINEAR MIXED EFFECTS MODEL PROGRAM (NONMEM) 
DOUBLE PRECISION NONMEM    VERSION V LEVEL 1.1   
DEVELOPED AND PROGRAMMED BY STUART BEAL AND LEWIS SHEINER 
  
 PROBLEM NO.:         1 
 **FINAL MODEL**                                                          
0DATA CHECKOUT RUN:               NO  
  DATA SET LOCATED ON UNIT NO.:  2 
  THIS UNIT TO BE REWOUND:         NO  
  NO. OF DATA RECS IN DATA SET:  1849 
  NO. OF DATA ITEMS IN DATA SET:   13 
  ID DATA ITEM IS DATA ITEM NO.:    2 
  DEP VARIABLE IS DATA ITEM NO.:    6 
  MDV DATA ITEM IS DATA ITEM NO.:   7 
0INDICES PASSED TO SUBROUTINE PRED: 
 13  3  4  5  0  0  0  0  0 
   0  0 
0LABELS FOR DATA ITEMS: 
        C         ID    TIME     AMT    RATE      DV     MDV    STDY     SEX 
  WGT     IBW     WBC    EVID 
0(NONBLANK) LABELS FOR PRED-DEFINED ITEMS: 
 G11   G21      G31       G41     H11     H21    VMAX      KM      V1 
   V2       Q    IPRE    IWRE 
0FORMAT FOR DATA: 
 (E2.0,E4.0,E8.0,2E7.0,E12.0,E2.0,E3.0,E2.0,E6.0,E7.0,E5.0,1F2.0)                 
  
 TOT. NO. OF OBS RECS:         912 
 TOT. NO. OF INDIVIDUALS:  143 
0LENGTH OF THETA:  8 
0OMEGA HAS SIMPLE DIAGONAL FORM WITH DIMENSION:  4 
0SIGMA HAS SIMPLE DIAGONAL FORM WITH DIMENSION:    2 
0INITIAL ESTIMATE OF THETA: 
 LOWER BOUND    INITIAL EST    UPPER BOUND 
   0.1500E+01     0.4220E+01     0.7500E+01 
   0.3500E+02     0.7160E+02     0.1500E+03 
  0.1300E+01     0.2720E+01     0.5000E+01 
   0.1100E+01     0.2430E+01     0.5000E+01 
   0.1000E-02      0.9500E-01      0.1500E+00 
   0.1000E-02      0.1150E-01      0.5000E-01 
   0.1000E-02      0.8000E-02      0.5000E-01 
   0.1000E-02      0.2400E-01      0.7500E-01 
 
 
 145
0INITIAL ESTIMATE OF OMEGA: 
 0.2500E-01 
 0.0000E+00   0.3200E-01 
 0.0000E+00   0.0000E+00   0.2900E+00 
 0.0000E+00   0.0000E+00   0.0000E+00   0.9750E+00 
0INITIAL ESTIMATE OF SIGMA: 
 0.3000E-01 
 0.0000E+00   0.5000E-01 
0ESTIMATION STEP OMITTED:            NO  
 CONDITIONAL ESTIMATES USED:        YES  
 CENTERED ETA:                       NO  
 EPS-ETA INTERACTION:                NO  
 LAPLACIAN OBJ. FUNC.:               NO  
 NO. OF FUNCT. EVALS. ALLOWED:     9999 
 NO. OF SIG. FIGURES REQUIRED:        3 
 INTERMEDIATE PRINTOUT:             YES  
 ESTIMATE OUTPUT TO MSF:             NO  
 ABORT WITH PRED EXIT CODE 1:        NO  
0COVARIANCE STEP OMITTED:    NO  
 EIGENVLS. PRINTED:    YES  
 SPECIAL COMPUTATION:   NO  
 COMPRESSED FORMAT:      NO  
0TABLES STEP OMITTED:        NO  
 NO. OF TABLES:            5 
0-- TABLE  1 -- 
 PRINTED:                 NO  
 HEADERS:                ONE 
 FILE TO BE FORWARDED:    NO  
0USER-CHOSEN ITEMS  
 IN THE ORDER THEY WILL APPEAR IN THE TABLE: 
   ID    TIME    IPRE    IWRE 
0-- TABLE  2 -- 
 PRINTED:                 NO  
 HEADERS:                ONE 
 FILE TO BE FORWARDED:    NO  
0USER-CHOSEN ITEMS  
 IN THE ORDER THEY WILL APPEAR IN THE TABLE: 
   ID    VMAX      KM      V1      V2       Q 
0-- TABLE  3 -- 
 PRINTED:                 NO  
 HEADERS:                ONE 
 FILE TO BE FORWARDED:    NO  
0USER-CHOSEN ITEMS  
 IN THE ORDER THEY WILL APPEAR IN THE TABLE: 
   ID     IBW     WGT     WBC 
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0-- TABLE  4 -- 
 PRINTED:                 NO  
 HEADERS:                ONE 
 FILE TO BE FORWARDED:   NO  
0USER-CHOSEN ITEMS  
 IN THE ORDER THEY WILL APPEAR IN THE TABLE: 
   ID     SEX 
0-- TABLE  5 -- 
 PRINTED:                 NO  
 HEADERS:                ONE 
 FILE TO BE FORWARDED:    NO  
0USER-CHOSEN ITEMS  
 IN THE ORDER THEY WILL APPEAR IN THE TABLE: 
   ID     G11     G21     G31     G41     H11     H21    IPRE     MDV 
1DOUBLE PRECISION PREDPP VERSION IV LEVEL 1.1   
  
 GENERAL NONLINEAR KINETICS MODEL (ADVAN6) 
0MODEL SUBROUTINE USER-SUPPLIED - ID NO. 9999 
0MAXIMUM NO. OF BASIC PK PARAMETERS:   5 
0COMPARTMENT ATTRIBUTES  
COMPT. NO. FUNCTION  INITIAL  ON/OFF      DOSE          DEFAULT   DEFAULT 
                                             STATUS ALLOWED ALLOWED  FOR DOSE  FOR OBS. 
    1                  CENTRAL      ON          YES            YES                 YES           YES 
    2                  PERIPH           ON          YES            YES                 NO             NO  
    3                  OUTPUT         OFF        YES             NO                  NO             NO  
0NRD VALUE FROM SUBROUTINE TOL:   6 
1 
 ADDITIONAL PK PARAMETERS - ASSIGNMENT OF ROWS IN GG 
 COMPT. NO.                                                  INDICES 
                        SCALE      BIOAVAIL.   ZERO-ORDER  ZERO-ORDER  ABSORB 
                                          FRACTION    RATE                 DURATION      LAG   
    1                       6                   *                      *                          *                       * 
    2                       *                   *                      *                          *                       * 
    3                       *                   -                       -                           -                       - 
             - PARAMETER IS NOT ALLOWED FOR THIS MODEL 
             * PARAMETER IS NOT SUPPLIED BY PK SUBROUTINE; 
               WILL DEFAULT TO ONE IF APPLICABLE 
0DATA ITEM INDICES USED BY PRED ARE: 
   EVENT ID DATA ITEM IS DATA ITEM NO.:      13 
   TIME DATA ITEM IS DATA ITEM NO.:           3 
   DOSE AMOUNT DATA ITEM IS DATA ITEM NO.:    4 
   DOSE RATE DATA ITEM IS DATA ITEM NO.:      5 
  
0PK SUBROUTINE CALLED WITH EVERY EVENT RECORD. 
 PK SUBROUTINE NOT CALLED AT NONEVENT (ADDITIONAL OR LAGGED) 
DOSE TIMES. 
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0DURING SIMULATION, ERROR SUBROUTINE CALLED WITH EVERY EVENT 
RECORD.     
 OTHERWISE, ERROR SUBROUTINE CALLED ONLY WITH OBSERVATION 
EVENTS. 
0DES SUBROUTINE USES COMPACT STORAGE MODE 
1 
 MONITORING OF SEARCH: 
 
0ITERATION NO.: 0  OBJECTIVE VALUE: -0.1720E+04  NO. OF FUNC. EVALS.:12 
 CUMULATIVE NO. OF FUNC. EVALS.:   12 
 PARAMETER:  0.1000E+00  0.1000E+00  0.1000E+00  0.1000E+00  0.1000E+00                              
                            0.1000E+00  0.1000E+00  0.1000E+00  0.1000E+00  0.1000E+00 
                            0.1000E+00  0.1000E+00  0.1000E+00  0.1000E+00 
 GRADIENT:  -0.1987E+04  0.7020E+03 -0.1821E+04 -0.7369E+02 -0.1583E+03   
                          0.1211E+03 -0.3783E+02  0.6401E+02  0.1225E+03  0.6147E+02 
                          0.3547E+02  0.5211E+02  0.2233E+04  0.3586E+03 
0ITERATION NO.: 5   OBJECTIVE VALUE: -0.1734E+04 NO. OF FUNC. EVALS.:16 
 CUMULATIVE NO. OF FUNC. EVALS.:   95 
 PARAMETER:  0.1022E+00  0.1018E+00  0.1111E+00  0.1004E+00  0.1054E+00   
                            0.9592E-01  0.1017E+00  0.9341E-01  0.9685E-01  0.1023E+00 
                            0.9986E-01  0.9828E-01  0.7662E-01  0.9383E-01 
 GRADIENT:  -0.2774E+03  0.1573E+03  0.2254E+04  0.5423E+02  0.1088E+03 – 
                          0.1481E+02 -0.5559E+01  0.2991E+02 -0.5791E+02 -0.2172E+03 
                        -0.5601E+02 -0.2452E+02 -0.2079E+04 -0.1212E+03 
0ITERATION NO.:10 OBJECTIVE VALUE: -0.1734E+04  NO. OF FUNC. EVALS.:28 
 CUMULATIVE NO. OF FUNC. EVALS.:  193 
 PARAMETER:  0.1023E+00  0.1018E+00  0.1107E+00  0.1021E+00  0.1135E+00   
                            0.9619E-01  0.1030E+00  0.9554E-01  0.9668E-01  0.1037E+00 
                            0.1026E+00  0.9905E-01  0.7667E-01  0.9333E-01 
 GRADIENT:  -0.3024E+03  0.1401E+03  0.2190E+04  0.6069E+02  0.1494E+03 – 
                          0.2381E+01  0.9320E+01  0.9397E+02 -0.5406E+02 -0.1898E+03 
                        -0.4180E+02 -0.3083E+02 -0.2064E+04 -0.1451E+03 
0ITERATION NO.: 15 OBJECTIVE VALUE: -0.1735E+04 NO. OF FUNC. EVALS.:24 
 CUMULATIVE NO. OF FUNC. EVALS.:  329 
 PARAMETER:  0.1107E+00  0.1230E+00  0.1108E+00  0.9981E-01  0.1108E+00   
                            0.9788E-01  0.9636E-01  0.9667E-01  0.1018E+00  0.1054E+00 
                            0.1069E+00  0.1026E+00  0.7697E-01  0.9319E-01 
 GRADIENT:  -0.3194E+03  0.1718E+03  0.2123E+04  0.4061E+02  0.1482E+03   
                          0.1371E+02 -0.6102E+02  0.9505E+02 -0.3377E+02 -0.1517E+03 
                        -0.2690E+02 -0.1610E+02 -0.1952E+04 -0.1347E+03 
0ITERATION NO.: 20 OBJECTIVE VALUE: -0.1749E+04 NO. OF FUNC. EVALS.:23 
 CUMULATIVE NO. OF FUNC. EVALS.:  445 
 PARAMETER:  0.1035E+00  0.1037E+00  0.1044E+00  0.1001E+00  0.1064E+00   
                            0.9633E-01  0.1022E+00  0.9394E-01  0.9712E-01  0.1039E+00 
                            0.1045E+00  0.9996E-01  0.8401E-01  0.9484E-01 
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GRADIENT:  -0.5994E+01  0.8684E+00 -0.1413E+02  0.7832E+00 -0.1302E+01 – 
                         0.1207E+01 -0.7490E+00 -0.9671E-01  0.5682E+00 -0.2083E+01 
                       -0.2933E+00  0.1312E+02  0.4625E+01 -0.1651E+01 
0ITERATION NO.:25 OBJECTIVE VALUE: -0.1749E+04 NO. OF FUNC. EVALS.:23 
 CUMULATIVE NO. OF FUNC. EVALS.:  561 
 PARAMETER:  0.1035E+00  0.1038E+00  0.1045E+00  0.1002E+00  0.1063E+00   
                            0.9638E-01  0.1023E+00  0.9393E-01  0.9711E-01  0.1040E+00 
                            0.1046E+00  0.9842E-01  0.8402E-01  0.9488E-01 
 GRADIENT:  -0.1407E+00  0.2594E+00 -0.1476E+00  0.5952E-01  0.1299E+00   
                          0.9197E-01  0.1468E+00 -0.4645E-01  0.8486E-01 -0.3774E-01 
                        -0.2707E-01  0.9374E-01  0.6367E-02 -0.1270E+00 
0ITERATION NO.:  26 OBJECTIVE VALUE: -0.1749E+04 NO. OF FUNC. EVALS.: 0 
 CUMULATIVE NO. OF FUNC. EVALS.:  561 
 PARAMETER:  0.1035E+00  0.1038E+00  0.1045E+00  0.1002E+00  0.1063E+00   
                            0.9638E-01  0.1023E+00  0.9393E-01  0.9711E-01  0.1040E+00 
                            0.1046E+00  0.9842E-01  0.8402E-01  0.9488E-01 
 GRADIENT:  -0.1407E+00  0.2594E+00 -0.1476E+00  0.5952E-01  0.1299E+00   
                          0.9197E-01  0.1468E+00 -0.4645E-01  0.8486E-01 -0.3774E-01 
                        -0.2707E-01  0.9374E-01  0.6367E-02 -0.1270E+00 
0MINIMIZATION SUCCESSFUL 
 NO. OF FUNCTION EVALUATIONS USED:  561 
 NO. OF SIG. DIGITS IN FINAL EST.:               3.4 
 
 ETABAR IS THE ARITHMETIC MEAN OF THE ETA-ESTIMATES, 
 AND THE P-VALUE IS GIVEN FOR THE NULL HYPOTHESIS THAT THE TRUE    
 MEAN IS 0. 
 
 ETABAR:   0.13E-02      -0.11E-01     -0.29E-01       -0.95E-02 
 
 P VAL.:      0.90E+00       0.34E+00     0.22E+00       0.82E+00 
0R MATRIX ALGORITHMICALLY NON-POSITIVE-SEMIDEFINITE 
 BUT NONSINGULAR 
0COVARIANCE STEP ABORTED 
 
 
 
 
************************************************************************ 
MINIMUM VALUE OF OBJECTIVE FUNCTION 
************************************************************************ 
-1749.176 
 
************************************************************************ 
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************************************************************************ 
FINAL PARAMETER ESTIMATE 
************************************************************************ 
 
 THETA - VECTOR OF FIXED EFFECTS PARAMETERS   ********* 
 
 
     TH 1           TH 2          TH 3          TH 4          TH 5          TH 6         TH 7         TH 8 
  
4.38E+00   7.40E+01   2.83E+00   2.43E+00   1.03E-01   1.08E-02   8.30E-03   2.16E-02 
  
 
 OMEGA - COV MATRIX FOR RANDOM EFFECTS - ETAS  ******** 
 
 
            ETA1         ETA2         ETA3         ETA4 
  
 ETA1 
+       2.36E-02 
  
 ETA2 
+       0.00E+00    3.46E-02 
  
 ETA3 
+       0.00E+00    0.00E+00    3.18E-01 
  
 ETA4 
+       0.00E+00    0.00E+00    0.00E+00    9.44E-01 
  
 
 SIGMA - COV MATRIX FOR RANDOM EFFECTS - EPSILONS  **** 
 
 
            EPS1            EPS2 
  
 EPS1 
+        2.12E-02 
  
 EPS2 
+        0.00E+00     4.50E-02 
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APPENDIX B: 
EXAMPLE COMPUTER CODES USED FOR THE SIMULATION AND 
ESTIMATION STEPS IN CHAPTER 4 
 151
B-1. R script used to sample parameter values from their specified simulation prior 
(uncertainty) distributions. 
 
 
#Set seed for reproducibility 
set.seed(48215) 
rnorm(5) 
#[1]  0.5228567 -2.2998926  0.6365216 -0.5349108  0.6051626 
 
#Simulate Vmax (mg/hr) thetas from a lognormal distribution 
 
vmax.theta.vct<-rlnorm(n=1000, meanlog=log(0.75), sdlog=0.1) 
head(vmax.theta.vct) 
 
#Convert vector of simulated Vmax thetas to dataframe; assign column name 
vmax.theta<-data.frame(vmax.theta.vct) 
dim(vmax.theta) 
names(vmax.theta)<-"VMAX_TH" 
head(vmax.theta) 
#***#***#***#***#***#***#***# 
 
#Simulate Km (mg/L) thetas from a lognormal distribution 
 
km.theta.vct<-rlnorm(n=1000, meanlog=log(5.0), sdlog=0.1) 
head(km.theta.vct) 
 
#Convert vector of simulated Km thetas to dataframe; assign column name 
km.theta<-data.frame(km.theta.vct) 
dim(km.theta) 
names(km.theta)<-"KM_TH" 
head(km.theta) 
#***#***#***#***#***#***#***# 
 
#Read in Ln values of CLL, V1, V2, and Q thetas from 4 poppk studies 
 
ln.cll.v1.v2.q.4mabs<-read.table("cll_v1_v2_q_ln theta_4 mabs.csv", header=T, sep=",", 
as.is=T, skip=0) 
ln.cll.v1.v2.q.4mabs 
 
#Calculate correlation and covariance matrices for CLL, V1, V2, and Q 
 
correlation<-cor(ln.cll.v1.v2.q.4mabs) 
correlation 
 
covariance<-cov(ln.cll.v1.v2.q.4mabs) 
covariance 
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#Export correlation and covariance matrices as .csv files 
 
write.table(correlation, file="cll_v1_v2_q_correlation.csv", sep=",", col.names=T, 
row.names=F) 
write.table(covariance, file="cll_v1_v2_q_covariance.csv", sep=",", col.names=T, 
row.names=F) 
 
#Load MASS package for mvrnorm function 
 
library(MASS) 
 
#Create vector of means of Ln CLL, V1, V2, and Q thetas from 4 poppk studies 
#Order is CLL, V1, V2, Q 
 
mu<-c(-3.926715, 1.468283, 1.003866, -3.212994) 
mu 
 
#Simulate CLL (L/hr), V1 (L), V2 (L), and Q (L/hr) (Ln values) from multivariate 
#normal distribution 
 
multivariate.ln.vct<-mvrnorm(n=1000, mu=mu, Sigma=covariance) 
head(multivariate.ln.vct) 
 
#Convert vector of CLL, V1, V2, and Q (Ln values) thetas to dataframe; 
#and assign column names 
 
multivariate.ln<-data.frame(multivariate.ln.vct) 
dim(multivariate.ln) 
names(multivariate.ln)<-c("CLL_TH","V1_TH","V2_TH","Q_TH") 
head(multivariate.ln) 
 
#Convert CLL, V1, V2, and Q Ln values to normal scale 
 
multivariate.theta<-exp(multivariate.ln) 
head(multivariate.theta) 
#***#***#***#***#***#***#***# 
 
#Simulate thetas for body weight effect on Vmax, CLL, V1, and V2 
#from uniform distributions; assign column names; and combine into  
#one dataframe 
 
wt.vmax.cll.vct<-runif(n=1000, min=0.4, max=1.0) 
head(wt.vmax.cll.vct) 
 
wt.vmax<-data.frame(wt.vmax.cll.vct) 
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dim(wt.vmax) 
names(wt.vmax)<-"WGT_VMAX" 
head(wt.vmax) 
 
wt.cll<-data.frame(wt.vmax.cll.vct) 
dim(wt.cll) 
names(wt.cll)<-"WGT_CLL" 
head(wt.cll) 
 
wt.v1.v2.vct<-runif(n=1000, min=0.4, max=1.0) 
head(wt.v1.v2.vct) 
 
wt.v1<-data.frame(wt.v1.v2.vct) 
dim(wt.v1) 
names(wt.v1)<-"WGT_V1" 
head(wt.v1) 
 
wt.v2<-data.frame(wt.v1.v2.vct) 
dim(wt.v2) 
names(wt.v2)<-"WGT_V2" 
head(wt.v2) 
 
wt.cov.theta<-cbind(wt.vmax, wt.cll, wt.v1, wt.v2) 
dim(wt.cov.theta) 
head(wt.cov.theta) 
#***#***#***#***#***#***#***# 
 
#Simulate population mean weights (kg) from lognormal distribution 
 
wt.pop.vct<-rlnorm(n=1000, meanlog=log(72), sdlog=0.025) 
head(wt.pop.vct) 
 
#Convert vector of population mean weights to dataframe; assign column names 
 
wt.pop.theta<-data.frame(wt.pop.vct) 
dim(wt.pop.theta) 
names(wt.pop.theta)<-"WT_POP" 
head(wt.pop.theta) 
#***#***#***#***#***#***#***# 
 
#Simulate intersubject variances (omega^2) for Vmax and CLL from a uniform 
#distribution; convert vector to dataframe and assign column names 
 
vmax.om.vct<-runif(n=1000, min=0.0225, max=0.4225) 
head(vmax.om.vct) 
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vmax.om<-data.frame(vmax.om.vct) 
dim(vmax.om) 
names(vmax.om)<-"VMAX_OM" 
head(vmax.om) 
#***#***#***#***#***#***#***# 
 
cll.om.vct<-runif(n=1000, min=0.0225, max=0.4225) 
head(cll.om.vct) 
 
cll.om<-data.frame(cll.om.vct) 
dim(cll.om) 
names(cll.om)<-"CLL_OM" 
head(cll.om) 
#***#***#***#***#***#***#***# 
 
#Simulate intersubject variances (omega^2) for V1 and V2 from a lognormal 
#distribution; convert vector to dataframe and assign column names 
 
v1.om.vct<-rlnorm(n=1000, meanlog=log(0.0625), sdlog=0.4) 
head(v1.om.vct) 
 
v1.om<-data.frame(v1.om.vct) 
dim(v1.om) 
names(v1.om)<-"V1_OM" 
head(v1.om) 
#***#***#***#***#***#***#***# 
 
v2.om.vct<-rlnorm(n=1000, meanlog=log(0.0625), sdlog=0.4) 
head(v2.om.vct) 
 
v2.om<-data.frame(v2.om.vct) 
dim(v2.om) 
names(v2.om)<-"V2_OM" 
head(v2.om) 
#***#***#***#***#***#***#***# 
 
#Create vector of 1000 intersubject variances (omega^2) for weight; fix 
#at a variance of 0.04, convert vector to dataframe and assign column name 
 
wtpop.om.vct<-rep(0.04,1000) 
head(wtpop.om.vct) 
 
wtpop.om<-data.frame(wtpop.om.vct) 
dim(wtpop.om) 
names(wtpop.om)<-"WTPOP_OM" 
head(wtpop.om) 
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#***#***#***#***#***#***#***# 
 
#Simulate residual error variance (sigma^2) from a lognormal distribution; 
#convert vector to dataframe and assign column names 
 
sigma.vct<-rlnorm(n=1000, meanlog=log(0.0225), sdlog=0.4) 
head(sigma.vct) 
 
sigma<-data.frame(sigma.vct) 
dim(sigma) 
names(sigma)<-"SIGMA" 
head(sigma) 
#***#***#***#***#***#***#***# 
 
#Pull together dataframes into one large dataframe and export to .csv file 
#Each row will contain one set of parameters to be used for each simulation 
#of the data 
 
ls() 
 
sim<-cbind(wt.pop.theta, vmax.theta, km.theta, multivariate.theta, 
wt.cov.theta, wtpop.om, vmax.om, cll.om, v1.om, v2.om, sigma) 
dim(sim) 
head(sim) 
 
#Change number of sig digits in the output 
simparam<-signif(sim, digits=4) 
dim(simparam) 
head(simparam) 
 
write.table(simparam, file="simparam.csv", col.names=T, row.names=F, sep=",") 
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B-2. Example R script (“trialsimulation.R”) used to automate creation of replicate 
NONMEM control streams for simulation of the replicate data sets. 
 
 
#Load MItools 
library(MItools) 
 
#setup control streams for simulation 
DirName<-"/center/comp/home/nated/FOCE-I/sim/" 
setwd(paste(DirName)) 
simparam<-read.table("simparam.csv", sep=",", header=T, skip=0, as.is=T) 
dim(simparam) 
head(simparam) 
 
metaSub( 
 as.filename(paste(DirName,"simtemp2cnll.ctl",sep="")), 
 names=1:1000, 
 pattern=list("\\$PROBLEM[^$]*", 
   "\\$THETA[^$]*", 
   "\\$OMEGA[^$]*", 
   "\\$SIGMA[^$]*", 
   "\\$SIMULATION[^$]*", 
   "\\$TABLE.*"), 
 replacement=list(expression(paste("$PROBLEM RUN ",as.numeric(name)," 
SIM","\n", sep="")), 
 expression(paste("$THETA 
\n",paste(simparam[rownames(simparam)==name,c(1:11)],collapse="\n"),"\n",sep="")), 
 expression(paste("$OMEGA 
\n",paste(simparam[rownames(simparam)==name,c(12:16)],collapse="\n"),"\n",sep="")), 
 expression(paste("$SIGMA 
\n",paste(simparam[rownames(simparam)==name,17],collapse="\n"),"\n",sep="")), 
 expression(paste("$SIMULATION (",as.numeric(name)+12345,") 
(",as.numeric(name)+6789," UNIFORM) ONLYSIMULATION","\n",sep="")), 
 expression(paste("$TABLE ID TIME AMT RATE DV EVID PKTR GRP WGTI 
WGTP","\n","NOPRINT NOHEADER NOAPPEND 
FILE=../trialdata.tmp/sim",(name),".TAB","\n",sep="")) 
 ), 
 fixed=FALSE, 
 out=".", 
 suffix=".ctl" 
 ) 
 
#Perform Simulations 
NONR(ProjectDir=DirName, NMcom="nm6amd64e.pl", b=c(1:1000), 
checkrunno=F, diag=F, boot=1) 
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B-3. Example NONMEM control stream template (“simtemp2cnll.ctl”) used for 
simulation of the replicate data sets.  The R script in B-2 was executed using this control 
stream. 
 
 
$PROBLEM Control stream template for simulation of study replicates 
;This will serve as the input for metaSUB, which will replace the 
;thetas, omegas, sigmas, etc., with simulated parameter values. 
;The substituted control stream will then be used to simulate data 
;for one study (nrep=1) 
$INPUT C ID TIME AMT RATE DV EVID PKTR GRP 
$DATA ../studytemplate.csv IGNORE=C 
$SUBROUTINE ADVAN6 TRANS1 TOL=8 
$MODEL NPAR=11 NCOMP=2 COMP=(CENTRAL DEFOBSERVATION 
DEFDOSE) COMP=(PERIPH) 
 
$PK 
 
WGTP=THETA(1) 
WGTI=WGTP*EXP(ETA(1)) 
 
TVVMAX=THETA(2)*(WGTI/72)**THETA(8) 
VMAX=TVVMAX*EXP(ETA(2)) 
 
KM=THETA(3) 
 
TVCLL=THETA(4)*(WGTI/72)**THETA(9) 
CLL=TVCLL*EXP(ETA(3)) 
 
TVV1=THETA(5)*(WGTI/72)**THETA(10) 
V1=TVV1*EXP(ETA(4)) 
 
TVV2=THETA(6)*(WGTI/72)**THETA(11) 
V2=TVV2*EXP(ETA(5)) 
 
Q=THETA(7) 
 
S1=V1 
$DES 
  C1=A(1)/V1 
  C2=A(2)/V2 
  DADT(1)=-VMAX*C1/(KM+C1)-(CLL*C1)-(Q*C1)+(Q*C2) 
  DADT(2)=(Q*C1)-(Q*C2) 
 
$ERROR 
Y=F*EXP(EPS(1)) 
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$THETA 
72.0 ;WTPOP (KG) 
0.75 ;VMAX (MG/HR) 
5.0  ;KM (MG/L) 
0.02 ;CLL (L/HR) 
4.5  ;V1 (L) 
3.0  ;V2 (L) 
0.05 ;Q (L/HR) 
0.7 ;WGT~VMAX 
0.7 ;WGT~CLL 
0.7 ;WGT~V1 
0.7 ;WGT~V2 
 
$OMEGA 
0.04  ;WTPOP OM 
0.04  ;VMAX OM 
0.04  ;CLL OM 
0.04  ;V1 OM 
0.04  ;V2 OM 
 
$SIGMA 
0.04  ;EXPONENTIAL ERROR 
 
$SIMULATION (12345) (6789 UNIFORM) ONLYSIMULATION 
$TABLE ID TIME AMT RATE DV EVID PKTR GRP WGTI WGTP 
NOPRINT NOHEADER NOAPPEND FILE=sim.TAB 
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B-4. Example R script (“estctl_FOCEI_boot1.R”) for setting up and executing the 
batch estimation runs with NONMEM. 
 
 
#Load MItools 
library(MItools) 
 
#setup control streams for estimation 
 
DirName<-"/center/comp/home/nated/FOCE-I/est/" 
setwd(paste(DirName)) 
 
metaSub( 
 as.filename(paste(DirName,"esttemp2cnll_FOCEI_boot1.ctl",sep="")), 
 names=1:1000, 
 pattern=list("\\$PROBLEM[^$]*", 
   "\\$DATA[^$]*"), 
 
 replacement=list(expression(paste("$PROBLEM ESTIMATION RUN 
",as.numeric(name),"\n", sep="")), 
 expression(paste("$DATA ../../sim/trialdata.tmp/sim", as.numeric(name), ".TAB", 
"\n", sep="")) 
 ), 
 fixed=FALSE, 
 out=".", 
 suffix=".ctl" 
 ) 
 
#Perform Estimations 
NONR(ProjectDir=DirName, NMcom="nm6amd64e.pl", b=c(1:1000), 
checkrunno=F, diag=F, boot=1) 
 
rlog(b=c(1:1000), boot=1, ProjectDir=DirName, runlog=2) 
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B-5. Example NONMEM control stream estimation template for the batch runs 
(“esttemp2cnll_FOCEI_boot1.ctl”).  The R script in B-4 was executed using this control 
stream. 
 
 
$PROBLEM Control stream template for estimation runs 
$INPUT ID TIME AMT RATE DV EVID PKTR GRP WGTI WGTP 
$DATA ../../sim/trialdata.tmp/sim#.TAB 
$SUBROUTINE ADVAN6 TRANS1 TOL=8 INFN=../MItoolsboot.for 
$MODEL NPAR=10 NCOMP=2 COMP=(CENTRAL DEFOBSERVATION 
DEFDOSE) COMP=(PERIPH) 
 
$PK 
 
TVVMAX=THETA(1)*(WGTI/72)**THETA(7) 
VMAX=TVVMAX*EXP(ETA(1)) 
 
KM=THETA(2) 
 
TVCLL=THETA(3)*(WGTI/72)**THETA(8) 
CLL=TVCLL*EXP(ETA(2)) 
 
TVV1=THETA(4)*(WGTI/72)**THETA(9) 
V1=TVV1*EXP(ETA(3)) 
 
TVV2=THETA(5)*(WGTI/72)**THETA(10) 
V2=TVV2*EXP(ETA(4)) 
 
Q=THETA(6) 
 
S1=V1 
$DES 
  C1=A(1)/V1 
  C2=A(2)/V2 
  DADT(1)=-VMAX*C1/(KM+C1)-(CLL*C1)-(Q*C1)+(Q*C2) 
  DADT(2)=(Q*C1)-(Q*C2) 
 
$ERROR 
Y=F*EXP(EPS(1)) 
 
$THETA 
(0, 1.2) ;VMAX (MG/HR) 
(0, 10)  ;KM (MG/L) 
(0, 0.03) ;CLL (L/HR) 
(0, 3)  ;V1 (L) 
(0, 2)  ;V2 (L) 
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(0, 0.075) ;Q (L/HR) 
0.8 ;WGT~VMAX 
0.8 ;WGT~CLL 
0.8 ;WGT~V1 
0.8 ;WGT~V2 
 
$OMEGA 
0.16  ;VMAX OM 
0.16  ;CLL OM 
0.16  ;V1 OM 
0.16  ;V2 OM 
 
$SIGMA 
0.16  ;EXPONENTIAL ERROR 
 
$ESTIMATION METHOD=1 INTERACTION NOABORT MAXEVAL=9999 
PRINT=5 
NOTBT NOOBT NOSBT 
$COVARIANCE 
 
;END 
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B-6. Section of the BUGSModelLibrary model file 
(“TwoCptParallelModelRK45.odc”) specifying the differential equations for the two-
compartment PK model with parallel nonlinear and linear elimination pathways. 
 
 
MODULE PmetricsTwoCptParallelModelRK45; 
  
IMPORT 
  PmetricsPKModels, 
  Math, 
  MathODE, 
  MathRungeKutta45, 
  Vec := LibVectors, 
  Solve := LibSolve; 
 
 TYPE 
  Equations = POINTER TO RECORD(MathODE.Equations) END; 
  ODEModel* = POINTER TO RECORD (PmetricsPKModels.PKModel) 
END; 
  SSFun  =  POINTER  TO  RECORD (Solve.RouteFns) 
   m: PmetricsPKModels.PKModel;  
   p: PmetricsPKModels.ModelParameters; 
   amt, rate, tau: REAL; 
   cmt: INTEGER 
  END; 
 
 CONST tol = 1.0E-7; 
  numEq = 2; 
 
 VAR 
  equations: Equations; 
  solver: MathODE.Solver; 
   
 PROCEDURE UserDerivatives(IN theta, x: ARRAY OF REAL; 
 numEq: INTEGER; t: REAL; OUT dxdt: ARRAY OF REAL) ; 
 VAR 
  Vmax, Km, CLL, V1, V2, Q, C1, C2: REAL; 
 BEGIN 
  Vmax := theta[0]; 
  CLL := theta[1]; 
  V1 := theta[2]; 
  V2 := theta[3];  
  Km := theta[4]; 
  Q := theta[5]; 
  ASSERT((Vmax > 0) & (Km > 0) & (CLL > 0) & (V1 > 0) & (V2 > 0) & 
(Q > 0) , 20); 
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  C1 := x[0]/V1; 
  C2 := x[1]/V2; 
 
  (* Differential equations for the model excluding piecewise constant input 
rates provided in the data set *) 
   
  dxdt[0] := -Vmax*C1/(Km+C1) - CLL*C1 - Q*C1 + Q*C2; 
  dxdt[1] := Q*C1 - Q*C2; 
    
 END UserDerivatives; 
 
 PROCEDURE (equations: Equations) Derivatives* (IN theta, x: ARRAY OF 
REAL; 
 numEq: INTEGER; t: REAL; OUT dxdt: ARRAY OF REAL) ; 
 VAR 
  i, iRate: INTEGER; 
 BEGIN 
  UserDerivatives (theta, x, numEq, t, dxdt); 
  iRate := LEN(theta) - numEq; 
  FOR i := 0 TO numEq-1 DO 
   dxdt[i] := dxdt[i] + theta[iRate+i] 
  END; 
  
 END Derivatives; 
 
 PROCEDURE (equations: Equations) SecondDerivatives* (IN theta, x: ARRAY 
OF REAL; 
  numEq: INTEGER; t: REAL; OUT d2xdt2: ARRAY OF REAL); 
 BEGIN 
 END SecondDerivatives; 
 
 PROCEDURE (equations: Equations) Jacobian* (IN theta, x: ARRAY OF REAL; 
  numEq: INTEGER; t: REAL; OUT jacob: ARRAY OF ARRAY OF REAL); 
 BEGIN 
 END Jacobian; 
  
 PROCEDURE (m: ODEModel) InitModel*; 
 BEGIN 
  m.nParameter := 10; 
  m.F1Index := 6; 
  m.tlag1Index := 8; 
  m.nCmt := 2; 
  MathRungeKutta45.Install; 
  solver := MathRungeKutta45.fact.New(); 
  NEW(equations); 
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  solver.Init(equations, numEq); 
 END InitModel; 
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B-7. Example R script (“1OSD_TwoCptParallelModelUP.R”) used in conjunction with 
the Bayesian model with uninformative priors.  This R script was used for data 
management, launching WinBUGS, and analysis of the MCMC samples. 
 
 
# WinBUGS PKPD Model Library: Two compartment PK model with nonlinear/linear 
elimination pathways and infusion input 
 
if(.Platform$OS.type == "windows") Sys.setenv(HOME = "c:") 
#subdirectory containing the BUGS model file 
#problemDir = file.path(Sys.getenv("HOME"), 
"metrum/Institute/nateDirks/nate02032009")  
problemDir = "C:/BUGSModelLibrary" #  
toolsDir = problemDir 
#toolsDir = file.path(Sys.getenv("HOME"), "bugsTools") 
model.name = "TwoCptParallelModelUP_RK45" # root names of model file 
bugsDir = "C:/Program Files (x86)/BlackBox Component Builder 1.5/" 
#bugsDir = file.path(Sys.getenv("HOME"), "Program Files/BlackBoxWinBUGS/") 
wineBin = "/usr/local/MacPorts/bin" # directory containing wine and winepath programs. 
only relevant on unix or Mac OS X 
 
setwd(problemDir) 
#library(R2WinBUGS) 
library(coda) 
library(lattice) 
source(file.path(toolsDir,"bugs.tools.R")) 
source(file.path(toolsDir,"bgillespie.utilities.R")) 
source(file.path(toolsDir,"myR2WinBUGS.R")) 
set.seed(10271998) # not required but assures repeatable results 
 
options(error = expression(NULL)) # prevents stopping for errors when running in batch 
memory.limit(2048) 
 
# get data files 
datname = "1" 
########################################################################
############################## 
predata = read.table("C:/BUGSModelLibrary/OSD_Replicates/sim1.TAB", header=F, 
as.is=T, skip=0) ##################### 
########################################################################
############################################ 
data = predata[ ,c(1:6,9)] 
names(data) = c("subject","time","amt","rate","dv","evid","weight") 
data$dv[data$evid==1] = "." 
data$dv = as.numeric(data$dv) 
data$addl = rep(0,nrow(data)) 
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data$ii = rep(0,nrow(data)) 
 
nobs = nrow(data) 
start = (1:nobs)[!duplicated(data$subject)] 
 
# create WinBUGS data set 
bugsdata = list( 
 nobs = nobs, 
 nsub = length(unique(data$subject)), 
 start = start, 
 end = c(start[-1]-1,nobs), 
 subject = data$subject, 
 weight = data$weight, 
 time = data$time, 
 amt = data$amt, 
 rate = data$rate, 
 ii = data$ii, 
 evid = data$evid, 
 cmt = rep(1,nrow(data)), 
 addl = data$addl, 
 ss = rep(0,nobs), 
 logCobs = ifelse(data$dv <=0, NA, log(data$dv))) 
 
# create initial estimates 
 
bugsinit = list( 
list(log.Vmax.Hat = log(1.2),         
log.CLL.Hat = log(0.03), 
log.V1.Hat = log(3), 
log.V2.Hat = log(2), 
log.Km.Hat = log(10), 
log.Q.Hat = log(0.075), 
WT.Vmax.Hat = 0.8, 
WT.CLL.Hat = 0.8, 
WT.V1.Hat = 0.8, 
WT.V2.Hat = 0.8, 
omega.Vmax = 0.40, 
omega.CLL = 0.40, 
omega.V1 = 0.40, 
omega.V2 = 0.40, 
sigmaC = 0.40), 
 
list(log.Vmax.Hat = log(1.5),         
log.CLL.Hat = log(0.0375), 
log.V1.Hat = log(3.75), 
log.V2.Hat = log(2.5), 
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log.Km.Hat = log(12.5), 
log.Q.Hat = log(0.094), 
WT.Vmax.Hat = 1.0, 
WT.CLL.Hat = 1.0, 
WT.V1.Hat = 1.0, 
WT.V2.Hat = 1.0, 
omega.Vmax = 0.50, 
omega.CLL = 0.50, 
omega.V1 = 0.50, 
omega.V2 = 0.50, 
sigmaC = 0.50), 
 
list(log.Vmax.Hat = log(0.9),         
log.CLL.Hat = log(0.0225), 
log.V1.Hat = log(2.25), 
log.V2.Hat = log(1.5), 
log.Km.Hat = log(7.5), 
log.Q.Hat = log(0.0562), 
WT.Vmax.Hat = 0.6, 
WT.CLL.Hat = 0.6, 
WT.V1.Hat = 0.6, 
WT.V2.Hat = 0.6, 
omega.Vmax = 0.30, 
omega.CLL = 0.30, 
omega.V1 = 0.30, 
omega.V2 = 0.30, 
sigmaC = 0.30) 
) 
 
# specify what variables to monitor 
parameters = c("Vmax.Hat","CLL.Hat","V1.Hat","V2.Hat","Km.Hat","Q.Hat", 
"WT.Vmax.Hat","WT.CLL.Hat","WT.V1.Hat","WT.V2.Hat","omega.Vmax","omega.C
LL", 
"omega.V1","omega.V2","sigmaC") 
 
# specify the variables for which you want history and density plots 
parameters.to.plot = c("deviance","Vmax.Hat","CLL.Hat","V1.Hat","V2.Hat","Km.Hat", 
"Q.Hat","WT.Vmax.Hat","WT.CLL.Hat","WT.V1.Hat","WT.V2.Hat", 
"omega.Vmax","omega.CLL","omega.V1","omega.V2","sigmaC") 
 
########################################################################
######################## 
# run WinBUGS 
 
n.chains = 3 
n.iter = 250000 
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n.burnin = 25000 
n.thin = 25 
bugs.fit = my.bugs(data=bugsdata,inits=bugsinit,parameters.to.save=parameters, 
 model.file=file.path(getwd(),paste(model.name,".txt",sep="")), 
 n.chains=n.chains,n.iter=n.iter,n.burnin=n.burnin,n.thin=n.thin,clearWD=F, 
 bugs.directory = bugsDir, refresh = 1, 
 useWINE=(.Platform$OS.type == "unix"), WINE=file.path(wineBin,"wine"), 
 newWINE=(.Platform$OS.type == "unix"), 
WINEPATH=file.path(wineBin,"winepath")) 
 
# save scripts, data and results to a directory 
 
####################################################################### 
resultsdir = "C:/BUGSModelLibrary/OSD_UninformativePrior_Results" 
####################################################################### 
 
 
save.model(bugs.fit,paste(datname,"OSD","_",model.name,sep="")) 
################################ 
#load(paste(model.name,"/",model.name,".fit.Rsave",sep="")) 
 
# rename and reformat MCMC results to facilitate later calculations and plots 
 
sims.array = bugs.fit$sims.array 
posterior = 
array(as.vector(sims.array),dim=c(prod(dim(sims.array)[1:2]),dim(sims.array)[3]), 
 dimnames=list(NULL,dimnames(sims.array)[[3]])) 
 
 
########################################################################
######################## 
# posterior distributions of parameters 
 
# open graphics device 
pdf(file = paste(resultsdir,"/",datname,".plots.pdf",sep=""),width=6,height=6) 
################# 
 
# subset of sims.array containing selected variables 
x1 = sims.array[,,unlist(sapply(c(paste("^",parameters.to.plot,"$",sep=""), 
 paste("^",parameters.to.plot,"\\[",sep="")),grep,x=dimnames(sims.array)[[3]]))] 
 
# create history, density and Gelman-Rubin-Brooks plots, and a table of summary stats 
ptable = parameter.plot.table(x1) 
write.csv(signif(ptable,3),paste(resultsdir,"/",datname,".summary.csv",sep="")) 
################ 
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########################################################################
######################## 
 
dev.off() 
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B-8. BUGS language model for fitting the two-compartment parallel elimination PK 
model using uninformative priors (“TwoCptParallelModelUP_RK45.txt”). 
 
 
model 
 
{ 
 
 for(i in 1:nsub){ 
 
  logtheta[i, 1] ~ dnorm(logthetaMean[i, 1], omega.inv.Vmax)  
  #Vmax eta 
 
  logtheta[i, 2] ~ dnorm(logthetaMean[i, 2], omega.inv.CLL)   
#CLL eta 
 
  logtheta[i, 3] ~ dnorm(logthetaMean[i, 3], omega.inv.V1)   
#V1 eta 
 
  logtheta[i, 4] ~ dnorm(logthetaMean[i, 4], omega.inv.V2)   
#V2 eta 
 
  logtheta[i, 5] <- logthetaMean[i, 5]      
#Km fixed 
 
  logtheta[i, 6] <- logthetaMean[i, 6]      
#Q fixed 
 
  logthetaMean[i, 1] <-  
log.Vmax.Hat + WT.Vmax.Hat*log(weight[start[i]]/72)    #Vmax TH 
 
  logthetaMean[i, 2] <-  
log.CLL.Hat + WT.CLL.Hat*log(weight[start[i]]/72)    #CLL TH 
 
  logthetaMean[i, 3] <-  
log.V1.Hat + WT.V1.Hat*log(weight[start[i]]/72)  #V1 TH 
 
  logthetaMean[i, 4] <-  
log.V2.Hat + WT.V2.Hat*log(weight[start[i]]/72)  #V2 TH 
 
  logthetaMean[i, 5] <-  
log.Km.Hat       #KM TH 
 
  logthetaMean[i, 6] <-  
log.Q.Hat            #Q TH 
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  theta[i,7] <- 1 # F1 
 
  theta[i,8] <- 1 # F2 
 
  theta[i,9] <- 0 # tlag1 
 
  theta[i,10] <- 0 # tlag2 
 
  for(j in 1:6){ 
 
   log(theta[i,j]) <- logtheta[i,j] 
 
  } 
 
  xhat[start[i]:end[i],1:2] <-  
TwoCptParallelModelRK45(time[start[i]:end[i]], amt[start[i]:end[i]], rate[start[i]:end[i]], 
ii[start[i]:end[i]], evid[start[i]:end[i]], cmt[start[i]:end[i]], addl[start[i]:end[i]], 
ss[start[i]:end[i]], theta[i,]) 
 
 } 
 
 for(i in 1:nobs){ 
 
  logCobs[i] ~ dnorm(logCHat[i], tauC) 
 
  CHat[i] <- xhat[i,1]/theta[subject[i],3] 
 
  logCHat[i] <- log(CHat[i]) 
 
 } 
 
 log.Vmax.Hat ~ dnorm(0.18, 0.0001)     #(mg/hr) 
 
 log.CLL.Hat ~ dnorm(-3.5, 0.0001)     #(L/hr) 
 
 log.V1.Hat ~ dnorm(1.1, 0.0001)      #(L) 
 
 log.V2.Hat ~ dnorm(0.69, 0.0001)  #(L) 
 
 log.Km.Hat ~ dnorm(2.3, 0.0001)  #(mg/L) 
 
 log.Q.Hat ~ dnorm(-2.6, 0.0001)  #(L/hr) 
 
 WT.Vmax.Hat ~ dunif(0, 5) 
 
 WT.CLL.Hat ~ dunif(0, 5) 
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 WT.V1.Hat ~ dunif(0, 5) 
 
 WT.V2.Hat ~ dunif(0, 5) 
 
 log(Vmax.Hat) <- log.Vmax.Hat 
 
 log(CLL.Hat) <- log.CLL.Hat 
 
 log(V1.Hat) <- log.V1.Hat 
 
 log(V2.Hat) <- log.V2.Hat 
 
 log(Km.Hat) <- log.Km.Hat 
 
 log(Q.Hat) <- log.Q.Hat 
 
 tauC <- 1/(sigmaC*sigmaC) 
 
 sigmaC ~ dunif(1.0E-4,1.0E4) 
 
 omega.inv.Vmax <- 1/(omega.Vmax*omega.Vmax) 
 
 omega.Vmax ~ dunif(1.0E-4,1.0E4) 
 
 omega.inv.CLL <- 1/(omega.CLL*omega.CLL) 
 
 omega.CLL ~ dunif(1.0E-4,1.0E4) 
 
 omega.inv.V1 <- 1/(omega.V1*omega.V1) 
 
 omega.V1 ~ dunif(1.0E-4,1.0E4) 
 
 omega.inv.V2 <- 1/(omega.V2*omega.V2) 
 
 omega.V2 ~ dunif(1.0E-4,1.0E4) 
  
 
} 
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B-9. Example R script (“1OSD_TwoCptParallelModel_IP.R”) used in conjunction 
with the Bayesian model with informative priors.  This R script was used for data 
management, launching WinBUGS, and analysis of the MCMC samples. 
 
 
# WinBUGS PKPD Model Library: Two compartment PK model with nonlinear/linear 
elimination pathways and infusion input 
 
if(.Platform$OS.type == "windows") Sys.setenv(HOME = "c:") 
#subdirectory containing the BUGS model file 
#problemDir = file.path(Sys.getenv("HOME"), 
"metrum/Institute/nateDirks/nate02032009")  
problemDir = "C:/BUGSModelLibrary" #  
toolsDir = problemDir 
#toolsDir = file.path(Sys.getenv("HOME"), "bugsTools") 
model.name = "TwoCptParallelModel_IP_RK45" # root names of model file 
bugsDir = "C:/Program Files (x86)/BlackBox Component Builder 1.5/" 
#bugsDir = file.path(Sys.getenv("HOME"), "Program Files/BlackBoxWinBUGS/") 
wineBin = "/usr/local/MacPorts/bin" # directory containing wine and winepath programs. 
only relevant on unix or Mac OS X 
 
setwd(problemDir) 
#library(R2WinBUGS) 
library(coda) 
library(lattice) 
source(file.path(toolsDir,"bugs.tools.R")) 
source(file.path(toolsDir,"bgillespie.utilities.R")) 
source(file.path(toolsDir,"myR2WinBUGS.R")) 
set.seed(10271998) # not required but assures repeatable results 
 
options(error = expression(NULL)) # prevents stopping for errors when running in batch 
memory.limit(2048) 
 
# get data files 
datname = "1" 
########################################################################
############################## 
predata = read.table("C:/BUGSModelLibrary/OSD_Replicates/sim1.TAB", header=F, 
as.is=T, skip=0) ##################### 
########################################################################
############################################ 
data = predata[ ,c(1:6,9)] 
names(data) = c("subject","time","amt","rate","dv","evid","weight") 
data$dv[data$evid==1] = "." 
data$dv = as.numeric(data$dv) 
data$addl = rep(0,nrow(data)) 
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data$ii = rep(0,nrow(data)) 
 
nobs = nrow(data) 
start = (1:nobs)[!duplicated(data$subject)] 
 
#read in table with Ln values of CLL, V1, V2, and Q from literature 
LNvalues <- read.table("LN_CLL_V1_V2_Q.csv", header=T, sep=",", skip=0, as.is=T) 
 
#calculate covariance matrix for Ln CLL, V1, V2, and Q 
covMatrix <- cov(LNvalues) 
 
# create WinBUGS data set 
bugsdata = list( 
 nobs = nobs, 
 nsub = length(unique(data$subject)), 
 start = start, 
 end = c(start[-1]-1,nobs), 
 subject = data$subject, 
 weight = data$weight, 
 time = data$time, 
 amt = data$amt, 
 rate = data$rate, 
 ii = data$ii, 
 evid = data$evid, 
 cmt = rep(1,nrow(data)), 
 addl = data$addl, 
 ss = rep(0,nobs), 
 logCobs = ifelse(data$dv <=0, NA, log(data$dv)), 
 logThetaHatPriorMean = c(-4.57, 1.29, 0.95, -3.40), 
 logThetaHatPriorPrecision = solve(covMatrix) 
) 
#logThetaHatPriorMean units: [L/hr, L, L, L/hr] 
# create initial estimates 
 
bugsinit = list( 
list(log.CLint.Hat = log(0.1), 
log.Km.Hat = log(10), 
logThetaHat = log(c(0.01, 3.6, 2.6, 0.03)), 
WT.Vmax.Hat = 0.8, 
WT.CLL.Hat = 0.8, 
WT.V1.Hat = 0.8, 
WT.V2.Hat = 0.8, 
log.omega.Vmax = log(0.35), 
log.omega.CLL = log(0.35), 
log.omega.V1 = log(0.25), 
log.omega.V2 = log(0.25), 
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log.sigmaC = log(0.2)), 
 
list(log.CLint.Hat = log(0.125), 
log.Km.Hat = log(12.5), 
logThetaHat = log(c(0.0125, 4.5, 3.25, 0.0375)), 
WT.Vmax.Hat = 1.0, 
WT.CLL.Hat = 1.0, 
WT.V1.Hat = 1.0, 
WT.V2.Hat = 1.0, 
log.omega.Vmax = log(0.4375), 
log.omega.CLL = log(0.4375), 
log.omega.V1 = log(0.3125), 
log.omega.V2 = log(0.3125), 
log.sigmaC = log(0.25)), 
 
list(log.CLint.Hat = log(0.075), 
log.Km.Hat = log(7.5), 
logThetaHat = log(c(0.0075, 2.7, 1.95, 0.0225)), 
WT.Vmax.Hat = 0.6, 
WT.CLL.Hat = 0.6, 
WT.V1.Hat = 0.6, 
WT.V2.Hat = 0.6, 
log.omega.Vmax = log(0.2625), 
log.omega.CLL = log(0.2625), 
log.omega.V1 = log(0.1875), 
log.omega.V2 = log(0.1875), 
log.sigmaC = log(0.15)) 
) 
 
# specify what variables to monitor 
parameters = 
c("Vmax.Hat","CLL.Hat","CLint.Hat","V1.Hat","V2.Hat","Km.Hat","Q.Hat", 
"WT.Vmax.Hat","WT.CLL.Hat","WT.V1.Hat","WT.V2.Hat","omega.Vmax","omega.C
LL", 
"omega.V1","omega.V2","sigmaC") 
 
# specify the variables for which you want history and density plots 
parameters.to.plot = 
c("deviance","Vmax.Hat","CLL.Hat","CLint.Hat","V1.Hat","V2.Hat","Km.Hat", 
"Q.Hat","WT.Vmax.Hat","WT.CLL.Hat","WT.V1.Hat","WT.V2.Hat", 
"omega.Vmax","omega.CLL","omega.V1","omega.V2","sigmaC") 
 
########################################################################
######################## 
# run WinBUGS 
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n.chains = 3 
n.iter = 250000 
n.burnin = 25000 
n.thin = 25 
bugs.fit = my.bugs(data=bugsdata,inits=bugsinit,parameters.to.save=parameters, 
 model.file=file.path(getwd(),paste(model.name,".txt",sep="")), 
 n.chains=n.chains,n.iter=n.iter,n.burnin=n.burnin,n.thin=n.thin,clearWD=F, 
 bugs.directory = bugsDir, refresh = 1, 
 useWINE=(.Platform$OS.type == "unix"), WINE=file.path(wineBin,"wine"), 
 newWINE=(.Platform$OS.type == "unix"), 
WINEPATH=file.path(wineBin,"winepath")) 
 
# save scripts, data and results to a directory 
 
####################################################################### 
resultsdir = "C:/BUGSModelLibrary/OSD_InformativePrior_Results" 
####################################################################### 
 
 
save.model(bugs.fit,paste(datname,"OSD","_",model.name,sep="")) 
################################ 
#load(paste(model.name,"/",model.name,".fit.Rsave",sep="")) 
 
# rename and reformat MCMC results to facilitate later calculations and plots 
 
sims.array = bugs.fit$sims.array 
posterior = 
array(as.vector(sims.array),dim=c(prod(dim(sims.array)[1:2]),dim(sims.array)[3]), 
 dimnames=list(NULL,dimnames(sims.array)[[3]])) 
 
 
########################################################################
######################## 
# posterior distributions of parameters 
 
# open graphics device 
pdf(file = paste(resultsdir,"/",datname,".plots.pdf",sep=""),width=6,height=6) 
################# 
 
# subset of sims.array containing selected variables 
x1 = sims.array[,,unlist(sapply(c(paste("^",parameters.to.plot,"$",sep=""), 
 paste("^",parameters.to.plot,"\\[",sep="")),grep,x=dimnames(sims.array)[[3]]))] 
 
# create history, density and Gelman-Rubin-Brooks plots, and a table of summary stats 
ptable = parameter.plot.table(x1) 
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write.csv(signif(ptable,3),paste(resultsdir,"/",datname,".summary.csv",sep="")) 
################ 
 
########################################################################
######################## 
 
dev.off() 
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B-10. BUGS language model for fitting the two-compartment parallel elimination PK 
model using informative priors (“TwoCptParallelModel_IP_RK45.txt”). 
 
 
model 
 
{ 
 
 for(i in 1:nsub){ 
 
  logtheta[i, 1] ~ dnorm(logthetaMean[i, 1], omega.inv.Vmax)  
  #Vmax eta 
 
  logtheta[i, 2] ~ dnorm(logthetaMean[i, 2], omega.inv.CLL)   
#CLL eta 
 
  logtheta[i, 3] ~ dnorm(logthetaMean[i, 3], omega.inv.V1)   
#V1 eta 
 
  logtheta[i, 4] ~ dnorm(logthetaMean[i, 4], omega.inv.V2)   
#V2 eta 
 
  logtheta[i, 5] <- logthetaMean[i, 5]      
#Km fixed 
 
  logtheta[i, 6] <- logthetaMean[i, 6]      
#Q fixed 
 
  logthetaMean[i, 1] <-  
log.Vmax.Hat + WT.Vmax.Hat*log(weight[start[i]]/72)  #Vmax TH 
 
  logthetaMean[i, 2] <-  
logThetaHat[1] + WT.CLL.Hat*log(weight[start[i]]/72)    #CLL TH 
 
  logthetaMean[i, 3] <- 
 logThetaHat[2] + WT.V1.Hat*log(weight[start[i]]/72) #V1 TH 
 
  logthetaMean[i, 4] <-  
logThetaHat[3] + WT.V2.Hat*log(weight[start[i]]/72) #V2 TH 
 
  logthetaMean[i, 5] <-  
log.Km.Hat         #KM TH 
 
  logthetaMean[i, 6] <-  
logThetaHat[4]      #Q TH 
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  theta[i,7] <- 1 # F1 
 
  theta[i,8] <- 1 # F2 
 
  theta[i,9] <- 0 # tlag1 
 
  theta[i,10] <- 0 # tlag2 
  
  for(j in 1:6){ 
 
   log(theta[i,j]) <- logtheta[i,j] 
 
  } 
 
  xhat[start[i]:end[i],1:2] <- 
TwoCptParallelModelRK45(time[start[i]:end[i]], amt[start[i]:end[i]], rate[start[i]:end[i]], 
ii[start[i]:end[i]], evid[start[i]:end[i]], cmt[start[i]:end[i]], addl[start[i]:end[i]], 
ss[start[i]:end[i]], theta[i,]) 
 
 } 
 for(i in 1:nobs){ 
 
  logCobs[i] ~ dnorm(logCHat[i], tauC) 
 
  CHat[i] <- xhat[i,1]/theta[subject[i],3] 
 
  logCHat[i] <- log(CHat[i]) 
 } 
 
 logThetaHat[1:4] ~  
dmnorm(logThetaHatPriorMean[], logThetaHatPriorPrecision[,]) 
 
 log.CLint.Hat ~ dnorm(-2.30, 4.0)  #(L/hr) 
 
 log.Km.Hat ~ dnorm(2.30, 0.725)  #(mg/L) 
 
 WT.Vmax.Hat ~ dunif(0.25, 1.25) 
 
 WT.CLL.Hat ~ dunif(0.25, 1.25) 
 
 WT.V1.Hat ~ dunif(0.25, 1.25) 
 
 WT.V2.Hat ~ dunif(0.25, 1.25) 
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 log(CLint.Hat) <- log.CLint.Hat 
 
 log(CLL.Hat) <- logThetaHat[1] 
 
 log(V1.Hat) <- logThetaHat[2] 
 
 log(V2.Hat) <- logThetaHat[3] 
 
 log(Km.Hat) <- log.Km.Hat 
 
 log(Q.Hat) <- logThetaHat[4] 
  
 Vmax.Hat <- Km.Hat*CLint.Hat 
 
 log.Vmax.Hat <- log(Vmax.Hat) 
 
 tauC <- 1/(sigmaC*sigmaC) 
 
 log(sigmaC) <- log.sigmaC 
 
 log.sigmaC ~ dnorm(-1.61, 6.25) 
 
 omega.inv.Vmax <- 1/(omega.Vmax*omega.Vmax) 
 
 log(omega.Vmax) <- log.omega.Vmax 
  
 log.omega.Vmax ~ dnorm(-1.05, 6.25) 
 
 omega.inv.CLL <- 1/(omega.CLL*omega.CLL) 
 
 log(omega.CLL) <- log.omega.CLL 
 
 log.omega.CLL ~ dnorm(-1.05, 6.25) 
 
 omega.inv.V1 <- 1/(omega.V1*omega.V1) 
 
 log(omega.V1) <- log.omega.V1 
 
 log.omega.V1 ~ dnorm(-1.39, 6.25) 
 
 omega.inv.V2 <- 1/(omega.V2*omega.V2) 
 
 log(omega.V2) <- log.omega.V2 
 
 log.omega.V2 ~ dnorm(-1.39, 6.25) 
} 
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APPENDIX C: 
CHAPTER 4 SUPPLEMENTAL FIGURES AND TABLES 
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Table C-1. Bias (median percent estimation error) in the population pharmacokinetic model parameters under the uninformative 
200, 500, and 800 mg dose level study designs. 
 
  200 mg dose level   500 mg dose level   800 mg dose level  
Parameter FO FOCE-I LAP-I FO FOCE-I LAP-I FO FOCE-I LAP-I 
Vmax 10 7.4 5.5 59 32 12 121 67 -2.8 
Km 48 5.0 6.5 268 63 86 1028 340 317 
CLL -16 -3.0 -4.3 -20 -9.8 -6.4 -23 -12 -4.8 
V1 -3.2 -1.1 -1.6 -3.8 -1.3 -1.5 -4.1 -1.5 -1.4 
V2 31 -1.3 -4.1 25 0.33 -2.3 24 -1.3 -1.9 
Q 21 -0.10 1.3 20 1.9 2.5 21 2.7 2.2 
WGT~Vmax -26 -4.8 4.2 -21 2.9 3.7 -13 8.8 -6.7 
WGT~CLL 11 -6.1 -9.7 -13 -17 -17 -17 -18 -4.2 
WGT~V1 -2.6 -0.70 -0.57 -2.0 -0.33 -0.71 -2.1 -0.25 -1.0 
WGT~V2 42 5.5 5.5 47 16 18 36 16 18 
Vmax BSV (ω2) -57 -13 -14 -74 -29 -7.7 -89 -61 61 
CLL BSV (ω2) 33 -7.6 1.8 2.4 -1.4 -2.3 -2.8 1.4 -6.9 
V1 BSV (ω2) -4.2 -6.6 -5.0 -5.5 -6.9 -6.2 -6.4 -7.2 -5.9 
V2 BSV (ω2) 240 -98 -83 94 -100 -94 16 -100 2.17 
Residual variance (σ2) 11 -2.6 -2.3 7.3 -2.5 -2.5 6.6 -2.7 -2.3 
 
BSV = between-subject variance; WGT = weight. 
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Table C-2. Precision (median absolute percent estimation error) in the population pharmacokinetic model parameters under the 
uninformative 200, 500, and 800 mg dose level study designs. 
 
  200 mg dose level   500 mg dose level   800 mg dose level  
Parameter FO FOCE-I LAP-I FO FOCE-I LAP-I FO FOCE-I LAP-I 
Vmax 44 19 20 87 42 39 121 78 58 
Km 77 27 30 268 97 100 1028 340 317 
CLL 37 19 21 26 16 15 25 17 14 
V1 4.1 3.0 3.3 4.4 3.2 3.3 4.6 3.2 3.2 
V2 33 10 12 30 15 17 29 17 19 
Q 26 13 14 23 15 17 25 17 17 
WGT~Vmax 94 60 61 107 89 90 125 121 108 
WGT~CLL 136 77 82 102 79 73 105 81 70 
WGT~V1 27 22 23 27 24 24 28 23 24 
WGT~V2 136 68 73 126 98 101 115 105 113 
Vmax BSV (ω2) 73 33 33 100 68 64 100 100 100 
CLL BSV (ω2) 100 41 39 61 32 30 61 31 27 
V1 BSV (ω2) 21 18 19 21 19 20 22 20 20 
V2 BSV (ω2) 240 100 100 100 100 100 100 100 100 
Residual variance (σ2) 12 5.3 5.7 8.6 5.2 5.6 8.1 5.3 5.5 
 
BSV = between-subject variance; WGT = weight. 
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Figure C-1. Markov Chain Monte Carlo chain histories (first set of plots), probability 
densities of the posterior distributions (second set of plots), and Gelman-Rubin-Brooks 
plots (third set of plots) for a representative estimation run using Bayesian informative 
priors under the informative study design. 
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Figure C-1 continued. 
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Figure C-1 continued. 
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Figure C-1 continued. 
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Figure C-1 continued. 
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Figure C-1 continued. 
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Figure C-2. Markov Chain Monte Carlo chain histories (first set of plots), probability 
densities of the posterior distributions (second set of plots), and Gelman-Rubin-Brooks 
plots (third set of plots) for a representative estimation run using Bayesian uninformative 
priors under the informative study design. 
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Figure C-2 continued. 
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Figure C-2 continued. 
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Figure C-2 continued. 
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Figure C-2 continued. 
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Figure C-2 continued. 
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Figure C-3. Markov Chain Monte Carlo chain histories (first set of plots), probability 
densities of the posterior distributions (second set of plots), and Gelman-Rubin-Brooks 
plots (third set of plots) for a representative estimation run using Bayesian informative 
priors under the uninformative 600 mg study design. 
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Figure C-3 continued. 
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Figure C-3 continued. 
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Figure C-3 continued. 
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Figure C-3 continued. 
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Figure C-3 continued. 
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